Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Mar. 31, 2016	May. 02, 2016	Sep. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Prestige Brands Holdings, Inc.
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		52,759,363
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 2,377.1

Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Revenues
Net sales									$ 803,088	$ 710,070	$ 592,454
Other revenues									3,159	4,553	4,927
Total revenues	$ 207,855	$ 200,195	$ 206,065	$ 192,132	$ 190,046	$ 197,606	$ 181,269	$ 145,702	806,247	714,623	597,381
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	89,604	83,411	86,125	79,896	79,976	85,861	78,727	63,836	339,036	308,400	261,830
Gross profit	118,251	116,784	119,940	112,236	110,070	111,745	102,542	81,866	467,211	406,223	335,551
Operating Expenses
Advertising and promotion	26,552	29,935	27,893	26,422	25,367	30,144	25,044	19,096	110,802	99,651	84,968
General and administrative	20,232	18,135	16,462	17,589	17,685	19,454	27,128	17,006	72,418	81,273	48,481
Depreciation and amortization	6,198	6,071	5,687	5,720	5,773	5,154	3,852	2,961	23,676	17,740	13,486
Total operating expenses	52,982	54,141	50,042	49,731	48,825	54,752	56,024	39,063	206,896	198,664	146,935
Operating income	65,269	62,643	69,898	62,505	61,245	56,993	46,518	42,803	260,315	207,559	188,616
Other (income) expense
Interest income									(162)	(92)	(60)
Interest expense									85,322	81,326	68,642
Gain on sale of asset					0	(1,133)	0	0	0	(1,133)	0
Loss on extinguishment of debt	17,519	0	0	451					17,970	0	18,286
Total other expense									103,130	80,101	86,868
Income before income taxes	24,603	43,181	49,231	40,170	37,449	33,534	28,325	28,150	157,185	127,458	101,748
Provision for income taxes	10,667	15,186	17,428	13,997	13,677	12,241	11,862	11,418	57,278	49,198	29,133
Net income	$ 13,936	$ 27,995	$ 31,803	$ 26,173	$ 23,772	$ 21,293	$ 16,463	$ 16,732	$ 99,907	$ 78,260	$ 72,615
Earnings per share:
Basic (in USD per share)	$ 0.26	$ 0.53	$ 0.60	$ 0.50	$ 0.45	$ 0.41	$ 0.32	$ 0.32	$ 1.89	$ 1.50	$ 1.41
Diluted (in USD per share)	$ 0.26	$ 0.53	$ 0.60	$ 0.49	$ 0.45	$ 0.40	$ 0.31	$ 0.32	$ 1.88	$ 1.49	$ 1.39
Weighted average shares outstanding:
Basic (in shares)	52,833	52,824	52,803	52,548	52,356	52,278	52,088	51,956	52,754	52,170	51,641
Diluted (in shares)	53,252	53,203	53,151	52,958	52,821	52,730	52,594	52,533	53,143	52,670	52,349
Comprehensive income, net of tax:
Currency translation adjustments	$ 6,449	$ 4,922	$ (11,079)	$ (405)	$ (7,268)	$ (8,779)	$ (10,830)	$ 2,726	$ (113)	$ (24,151)	$ 843
Total other comprehensive income (loss)	6,449	4,922	(11,079)	(405)	(7,268)	(8,779)	(10,830)	2,726	(113)	(24,151)	843
Comprehensive income	$ 20,385	$ 32,917	$ 20,724	$ 25,768	$ 16,504	$ 12,514	$ 5,633	$ 19,458	$ 99,794	$ 54,109	$ 73,458

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
Current assets
Cash and cash equivalents	$ 27,230	$ 21,318
Accounts receivable, net	95,247	87,858
Inventories	91,263	74,000
Deferred income tax assets	10,108	8,097
Prepaid expenses and other current assets	25,165	10,434
Total current assets	249,013	201,707
Property and equipment, net	15,540	13,744
Goodwill	360,191	290,651
Intangible assets, net	2,322,723	2,134,700
Other long-term assets	1,324	1,165
Total Assets	2,948,791	2,641,967
Current liabilities
Accounts payable	38,296	46,115
Accrued interest payable	8,664	11,974
Other accrued liabilities	59,724	40,948
Total current liabilities	106,684	99,037
Long-term debt
Principal amount	1,652,500	1,593,600
Less unamortized debt costs	27,191	32,327
Long-term debt, net	1,625,309	1,561,273
Deferred income tax liabilities	469,622	351,569
Other long-term liabilities	2,840	2,464
Total Liabilities	$ 2,204,455	$ 2,014,343
Commitments and Contingencies
Stockholders’ Equity
Preferred stock – $0.01 par value; Authorized – 5,000 shares; Issued and outstanding – None	$ 0	$ 0
Common stock-$0.01 par value; Authorized – 250,000 shares; Issued – 53,066 shares and 52,562 shares at March 31, 2015 and 2014, respectively	530	525
Additional paid-in capital	445,182	426,584
Treasury stock, at cost – 306 shares at March 31, 2016 and 266 shares at March 31, 2015	(5,163)	(3,478)
Accumulated other comprehensive income (loss), net of tax	(23,525)	(23,412)
Retained earnings	327,312	227,405
Total Stockholders’ Equity	744,336	627,624
Total Liabilities and Stockholders’ Equity	$ 2,948,791	$ 2,641,967

Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2016	Mar. 31, 2015
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	53,066,000	52,562,000
Treasury stock, shares	306,000	266,000

Consolidated Statements of Changes in Stockholders' Equity and Comprehensive Income - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive (Loss) Income	Preferred Share Rights	Retained Earnings (Accumulated Deficit)
Balances at Mar. 31, 2013	$ 477,943	$ 513	$ 401,691	$ (687)	$ (104)	$ 283	$ 76,247
Common stock, shares at Mar. 31, 2013		51,311,000
Treasury stock, shares at Mar. 31, 2013				181,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	5,146		5,146
Exercise of stock options	$ 5,907	$ 6	5,901
Exercise of stock options, shares	605,000	605,000
Preferred share rights	$ 0					(283)	283
Issuance of shares related to restricted stock		$ 1	(1)
Issuance of shares related to restricted stock, shares		105,000
Treasury share repurchases	(744)			$ (744)
Treasury share repurchases, shares				25,000
Excess tax benefits from share-based awards	1,650		1,650
Components of comprehensive income:
Net income	72,615						72,615
Translation adjustments	843				843
Comprehensive income	73,458
Balances at Mar. 31, 2014	563,360	$ 520	414,387	$ (1,431)	739	0	149,145
Common stock, shares at Mar. 31, 2014		52,021,000
Treasury stock, shares at Mar. 31, 2014				206,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	6,918		6,918
Exercise of stock options	$ 3,954	$ 4	3,950
Exercise of stock options, shares	386,300	387,000
Issuance of shares related to restricted stock	$ 0	$ 1	(1)
Issuance of shares related to restricted stock, shares		154,000
Treasury share repurchases	(2,047)			$ (2,047)
Treasury share repurchases, shares				60,000
Excess tax benefits from share-based awards	1,330		1,330
Components of comprehensive income:
Net income	78,260						78,260
Translation adjustments	(24,151)				(24,151)
Comprehensive income	54,109
Balances at Mar. 31, 2015	$ 627,624	$ 525	426,584	$ (3,478)	(23,412)	0	227,405
Common stock, shares at Mar. 31, 2015		52,562,000
Treasury stock, shares at Mar. 31, 2015	266,000			266,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 9,954		9,954
Exercise of stock options	$ 6,688	$ 3	6,685
Exercise of stock options, shares	348,000	348,000
Issuance of shares related to restricted stock	$ 1	$ 2	(1)
Issuance of shares related to restricted stock, shares		156,000
Treasury share repurchases	(1,685)			$ (1,685)
Treasury share repurchases, shares				40,000
Excess tax benefits from share-based awards	1,960		1,960
Components of comprehensive income:
Net income	99,907						99,907
Translation adjustments	(113)				(113)
Comprehensive income	99,794
Balances at Mar. 31, 2016	$ 744,336	$ 530	$ 445,182	$ (5,163)	$ (23,525)	$ 0	$ 327,312
Common stock, shares at Mar. 31, 2016		53,066,000
Treasury stock, shares at Mar. 31, 2016	306,000			306,000

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Operating Activities
Net income	$ 99,907	$ 78,260	$ 72,615
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	23,676	17,740	13,486
Gain on sale of asset	0	(1,133)	0
Deferred income taxes	46,152	28,922	19,012
Long term income taxes payable	(332)	2,294	0
Amortization of debt origination costs	8,994	8,821	10,512
Stock-based compensation costs	9,954	6,918	5,146
Loss on extinguishment of debt	17,970	0	18,286
Premium payment on Senior Notes			(15,527)
Lease termination costs	0	785	0
(Gain) loss on sale or disposal of property and equipment	(35)	321	(3)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	1,824	1,608	9,735
Inventories	(3,005)	15,360	(2,850)
Prepaid expenses and other current assets	(7,921)	4,664	(2,130)
Accounts payable	(11,348)	(17,637)	(4,641)
Accrued liabilities	(1,328)	9,332	(12,059)
Net cash provided by operating activities	174,350	156,255	111,582
Investing Activities
Purchases of property and equipment	(3,568)	(6,101)	(2,764)
Proceeds from the sale of property and equipment	344	0	3
Proceeds from sale of business	0	18,500	0
Proceeds from sale of asset	0	10,000	0
Proceeds from Insight Pharmaceuticals working capital arbitration settlement	7,237	0	0
Net cash used in investing activities	(222,971)	(805,258)	(57,976)
Financing Activities
Borrowings under Bridge term loans	80,000	0	0
Repayments under Bridge term loans	(80,000)	0	0
Term loan borrowings	0	720,000	0
Term loan repayments	(60,000)	(130,000)	(157,500)
Borrowings under revolving credit agreement	115,000	124,600	50,000
Repayments under revolving credit agreement	(96,100)	(58,500)	(83,000)
Payments of debt origination costs	(11,828)	(16,072)	(7,466)
Proceeds from exercise of stock options	6,689	3,954	5,907
Proceeds from restricted stock exercises	544	57	0
Excess tax benefits from share-based awards	1,960	1,330	1,650
Fair value of shares surrendered as payment of tax withholding	(2,229)	(2,104)	(744)
Net cash (used in) provided by financing activities	54,036	643,265	(41,153)
Effects of exchange rate changes on cash and cash equivalents	497	(1,275)	208
Increase (decrease) in cash and cash equivalents	5,912	(7,013)	12,661
Cash and cash equivalents - beginning of year	21,318	28,331	15,670
Cash and cash equivalents - end of year	27,230	21,318	28,331
Interest paid	79,132	70,155	62,357
Income taxes paid	15,352	11,939	11,020
DenTek Oral Care, Inc.
Investing Activities
Acquisitions, less cash acquired	(226,984)	0	0
Insight Pharmaceuticals
Investing Activities
Proceeds from Insight Pharmaceuticals working capital arbitration settlement	7,237
Acquisitions, less cash acquired	0	(749,666)	0
Hydralyte
Investing Activities
Acquisitions, less cash acquired	0	(77,991)	0
Care Pharma
Investing Activities
Acquisitions, less cash acquired	0	0	(55,215)
2012 Senior Notes
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Premium payment on Senior Notes	(10,158)	0	0
Financing Activities
Repayment of Senior Notes	(250,000)	0	0
2010 Senior Notes
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Premium payment on Senior Notes	0	0	(15,527)
Financing Activities
Repayment of Senior Notes	0	0	(250,000)
2016 Senior Notes
Financing Activities
Proceeds from issuance of Senior Notes	350,000	0	0
2013 Senior Notes
Financing Activities
Proceeds from issuance of Senior Notes	$ 0	$ 0	$ 400,000

Business and Basis of Presentation

12 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business and Basis of Presentation

Nature of Business

Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, and club, convenience, and dollar stores in North America (the United States and Canada) and in Australia and certain other international markets. Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 9 to these Consolidated Financial Statements.

Basis of Presentation

Our Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). All significant intercompany transactions and balances have been eliminated in consolidation. Our fiscal year ends on March 31st of each year. References in these Consolidated Financial Statements or notes to a year (e.g., “2016”) mean our fiscal year ended on March 31st of that year.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances and inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.

Cash and Cash Equivalents

We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. Substantially all of our cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insure these balances, up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at March 31, 2016 are uninsured.

Accounts Receivable

We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers’ financial condition, (iii) monitor the payment history and aging of customers’ receivables, and (iv) monitor open orders against an individual customer’s outstanding receivable balance.

Inventories

Inventories are stated at the lower of cost or market value, where cost is determined by using the first-in, first-out method. We reduce inventories for the diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related asset.

Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income.

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Goodwill

The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in purchase business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Goodwill is tested for impairment at the product group level, which is one level below the operating segment level.

Intangible Assets

Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives, typically ranging from 10 to 30 years.

Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

Debt Origination Costs

We have incurred debt origination costs in connection with the issuance of long-term debt. Certain of these costs were recorded as deferred financing costs within long-term assets and others were recorded as a reduction to our long-term debt. These costs are amortized over the term of the related debt, using the effective interest method for our term loan facility and the straight-line method for our revolving credit facility. Effective April 1, 2015, in accordance with new accounting standards discussed below, we began reporting the costs related to our senior notes and the term loan facility as a reduction of debt. We continue to report the costs associated with our revolving credit facility as a long-term asset.

Revenue Recognition

We recognize revenue when the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) the selling price is fixed or determinable; (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of the risk of loss generally occurs when product is received by the customer and, accordingly, we recognize revenue at that time. Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.

As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of the promotional program, the estimated amounts are adjusted to actual results.

Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs. Warehousing, shipping and handling and storage costs were $39.2 million for 2016, $37.7 million for 2015 and $32.0 million for 2014.

Advertising and Promotion Costs

Advertising and promotion costs are expensed as incurred. Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales. Under these new distribution arrangements, the retailers allow our products to be placed on the stores’ shelves in exchange for such fees.

Stock-based Compensation

We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is to be recognized over the period an employee is required to provide service in exchange for the award, generally referred to as the requisite service period.

Income Taxes

Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied a more-likely-than-not recognition threshold for all tax uncertainties.

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period. Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period. Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options and unvested restricted stock units, are included in the earnings per share calculation to the extent that they are dilutive.

Recently Issued Accounting Standards

In April 2016, the FASB issued Accounting Standards Update ("ASU") 2016-10, Revenue from Contracts with Customers. The amendments in this update clarify the implementation guidance on identifying performance obligations and licensing in FASB ASC 606. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements of ASU 2014-09 described below. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. The amendments in this update involve several aspects of accounting for share-based payment transactions, including income tax consequences, classification of awards, and classification on the statement of cash flows. For public business entities, the amendments in this update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers. The amendments in this update clarify the implementation guidance on principals versus agent considerations in FASB ASC 606. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements of ASU 2014-09 described below. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

In February 2016, the FASB issued ASU 2016-02, Leases. The amendments in this update include a new FASB ASC Topic 842, which supersedes Topic 840. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all entities as of the beginning of interim or annual reporting periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. For public business entities, the amendments in this update include the elimination of the requirement to disclose the method(s) and significant assumptions used to estimate fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet, the requirement to use the exit price notion when measuring fair value of financial instruments for disclosure purposes, the requirement to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments, the requirement for separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or accompanying notes to the financial statements, and the amendments clarify that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity's other deferred tax assets. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption of the amendments in this update is not permitted, except that early application by public business entities to financial statements of fiscal years or interim periods that have not yet been issued or, by all other entities, that have not yet been made available for issuance are permitted as of the beginning of the fiscal year of adoption for the following amendment: An entity should present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk if the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. An entity should apply the amendments to this update by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The adoption of ASU 2016-01 is not expected to have a material impact on our Consolidated Financial Statements.

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes. The amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. For public business entities, the amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early application is permitted for all entities as of the beginning of interim or annual reporting periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

In September 2015, the FASB issued ASU 2015-16, Simplifying the Accounting for Measurement-Period Adjustments. The amendments in this update require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. To simplify the accounting for adjustments made to provisional amounts recognized in a business combination, the amendments in this update eliminate the requirement to retrospectively account for those adjustments. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The adoption of ASU 2015-16 is not expected to have a material impact on our Consolidated Financial Statements.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory. The amendments in this update more closely align the measurement of inventory in GAAP with the measurement of inventory in International Financial Reporting Standards, under which an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The adoption of ASU 2015-11 is not expected to have a material impact on our Consolidated Financial Statements.

In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs. The amendments in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The amendments in this update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. As permitted by the guidance, we have early adopted these provisions, as of the beginning of our first quarter of 2016. Given the absence of authoritative guidance within ASU 2015-03 for debt issuance costs related to line-of-credit arrangements, in August 2015, the FASB issued ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements, stating that the SEC staff would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. As a result, we reclassified $27.4 million of deferred financing costs as of March 31, 2015 from other long-term assets, and such costs are now presented as a direct deduction from the long-term debt liability.

In February 2015, the FASB issued ASU 2015-02, Amendments to the Consolidation Analysis. Update 2015-02 amended the process that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. The amendments in this update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. The adoption of ASU 2015-02 is not expected to have a material impact on our Consolidated Financial Statements.

In January 2015, the FASB issued ASU 2015-01, Income Statement - Extraordinary and Unusual Items. The amendments in this update eliminate the concept of extraordinary items in Subtopic 225-20, which required entities to consider whether an underlying event or transaction is extraordinary. However, the amendments retain the presentation and disclosure guidance for items that are unusual in nature or occur infrequently. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The adoption of ASU 2015-01 is not expected to have a material impact on our Consolidated Financial Statements.

In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This amendment states that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our Consolidated Financial Statements.

In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could Be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the new guidance does not allow for a performance target that affects vesting to be reflected in estimating the fair value of the award at the grant date. The amendments to this update are effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this update either prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We currently do not have any outstanding share-based payments with a performance target. The adoption of ASU 2014-12 is not expected to have a material impact on our Consolidated Financial Statements.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606, which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In August 2015, the FASB issued ASU 2015-14, which deferred the effective date of ASU 2014-09 from annual and interim periods beginning after December 15, 2016 to annual and interim periods beginning after December 15, 2017. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. The amendments in this update must be applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of ASU 2014-08 did not have a material impact on our Consolidated Financial Statements.

Acquisitions

12 Months Ended

Mar. 31, 2016

Business Combinations [Abstract]

Acquisitions

Acquisition of DenTek

On February 5, 2016, the Company completed the acquisition of DenTek Holdings, Inc. ("DenTek"), a privately-held marketer and distributor of specialty oral care products. The closing was finalized pursuant to the terms of the merger agreement, announced November 23, 2015, under which Prestige agreed to acquire DenTek from its stockholders, including TSG Consumer Partners, for a purchase price of $228.3 million. The acquisition expands Prestige's portfolio of brands, strengthens its existing oral care platform and increases its geographic reach in parts of Europe. The Company financed the transaction with a combination of available cash on hand, available cash from its Asset Based Loan ("ABL") revolver, and financing of an additional unsecured bridge loan. The DenTek brands are primarily included in the Company's North American and International OTC Healthcare segments.

The DenTek acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the February 5, 2016 acquisition date.



(In thousands)	February 5, 2016

Cash acquired	$	1,359
Accounts receivable	9,187
Inventories	14,304
Deferred income taxes	3,303
Prepaids and other current assets	6,728
Property, plant and equipment, net	3,555
Goodwill	76,529
Intangible assets, net	206,700
Total assets acquired	321,665

Accounts payable	3,261
Accrued expenses	16,488
Deferred income tax liabilities - long term	73,573
Total liabilities assumed	93,322
Total purchase price	$	228,343

Based on this preliminary analysis, we allocated $179.8 million to non-amortizable intangible assets and $26.9 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 18.5 years. The weighted average remaining life for amortizable intangible assets at March 31, 2016 was 18.4 years.

We also recorded goodwill of $76.5 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. Goodwill is not deductible for income tax purposes.

The pro forma effect of this acquisition on revenues and earnings was not material. However, revenues recorded during the period ended March 31, 2016 were $10.7 million since the date of the acquisition.

Acquisition of Insight Pharmaceuticals

On September 3, 2014, the Company completed the acquisition of Insight Pharmaceuticals Corporation ("Insight"), a marketer and distributor of feminine care and other OTC healthcare products, for $745.9 million in cash after receiving a return of approximately $7.2 million from escrow related to an arbitrator's ruling. The closing followed the Federal Trade Commission’s (“FTC”) approval of the acquisition and was finalized pursuant to the terms of the purchase agreement announced on April 25, 2014. Pursuant to the Insight purchase agreement, the Company acquired 27 OTC brands sold in North America (including related trademarks, contracts and inventory), which extended the Company's portfolio of OTC brands to include a leading feminine care platform in the United States and Canada anchored by Monistat, the leading North American brand in OTC yeast infection treatment. The acquisition also added brands to the Company's cough & cold, pain relief, ear care and dermatological platforms. In connection with the FTC's approval of the Insight acquisition, the Company sold one of the competing brands that it acquired from Insight on the same day as the Insight closing. Insight is primarily included in the Company's North American OTC Healthcare segment.

The Insight acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. During the quarter ended June 30, 2015, we adjusted the fair values of the assets acquired and liabilities assumed by increasing goodwill for certain immaterial items that came to our attention subsequent to the date of acquisition. Additionally, during the quarter ended December 31, 2015, we reduced goodwill, as we received $7.2 million as a result of a finalized arbitration ruling relating to the disputed working capital calculation, as determined under GAAP, as of the date of the Insight acquisition, which is clearly and directly related to the purchase price. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date, after giving effect of the adjustments noted above.



(In thousands)	September 3, 2014

Cash acquired	$	3,507
Accounts receivable	26,012
Inventories	23,456
Deferred income tax assets - current	1,032
Prepaids and other current assets	1,341
Property, plant and equipment	2,308
Goodwill	96,323
Intangible assets	724,374
Total assets acquired	878,353

Accounts payable	16,079
Accrued expenses	8,539
Deferred income tax liabilities - long term	107,799
Total liabilities assumed	132,417
Total purchase price	$	745,936

Based on this analysis, we allocated $599.6 million to indefinite-lived intangible assets and $124.8 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 16.2 years. The weighted average remaining life for amortizable intangible assets at March 31, 2016 was 14.6 years.

We also recorded goodwill of $96.3 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired after of the adjustments described above. Goodwill is not deductible for income tax purposes.

The operating results of Insight have been included in our Consolidated Financial Statements beginning September 3, 2014. On September 3, 2014, we sold one of the brands we acquired from the Insight acquisition for $18.5 million, for which we had allocated $17.7 million, $0.6 million and $0.2 million to intangible assets, inventory and property, plant and equipment, respectively.

The following table provides our unaudited pro forma revenues, net income and net income per basic and diluted common share had the results of Insight's operations been included in our operations commencing on April 1, 2013, based upon available information related to Insight's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Insight acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results.



	Year Ended March 31,
	2015		2014
(In thousands, except per share data)	(Unaudited)
Revenues	$	783,217	$	767,897
Net income	$	86,844	$	82,762

Earnings per share:
Basic	$	1.66	$	1.60

Diluted	$	1.65	$	1.58

Acquisition of the Hydralyte brand

On April 30, 2014, we completed the acquisition of the Hydralyte brand in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia, which was funded through a combination of cash on hand and our existing senior secured credit facility.

Hydralyte is the leading OTC brand in oral rehydration in Australia and is marketed and sold through our Care Pharmaceuticals Pty Ltd. subsidiary ("Care Pharma"). Hydralyte is available in pharmacies in multiple forms and is indicated for oral rehydration following diarrhea, vomiting, fever, heat and other ailments. Hydralyte is included in our International OTC Healthcare segment.

The Hydralyte acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.

We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date.



(In thousands)	April 30, 2014

Inventories	$	1,970
Property, plant and equipment, net	1,267
Goodwill	1,224
Intangible assets, net	73,580
Total assets acquired	78,041

Accrued expenses	38
Other long term liabilities	12
Total liabilities assumed	50
Net assets acquired	$	77,991

Based on this analysis, we allocated $73.6 million to non-amortizable intangible assets and no allocation was made to amortizable intangible assets.

We also recorded goodwill of $1.2 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. Goodwill is not deductible for income tax purposes.

The pro forma effect of this acquisition on revenues and earnings was not material.

Acquisition of Care Pharmaceuticals Pty Ltd.

On July 1, 2013, we completed the acquisition of Care Pharma, which was funded through a combination of our existing senior secured credit facility and cash on hand.

The Care Pharma brands include the Fess line of cold/allergy and saline nasal health products, which is the leading saline spray for both adults and children in Australia. Other key brands include Painstop analgesic, Rectogesic for rectal discomfort, and the Fab line of nutritional supplements. Care Pharma also carries a line of brands for children including Little Allergies, Little Eyes, and Little Coughs. The brands acquired are complementary to our OTC Healthcare portfolio.

This acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.



(In thousands)	July 1, 2013

Cash acquired	$	1,546
Accounts receivable	1,658
Inventories	2,465
Deferred income tax assets	283
Prepaids and other current assets	647
Property, plant and equipment	163
Goodwill	23,122
Intangible assets	31,502
Total assets acquired	61,386

Accounts payable	1,537
Accrued expenses	2,788
Other long term liabilities	300
Total liabilities assumed	4,625

Net assets acquired	$	56,761

Based on this analysis, we allocated $29.8 million to non-amortizable intangible assets and $1.7 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 15.1 years. The weighted average remaining life for amortizable intangible assets at March 31, 2016 was 12.5 years.

We also recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is deductible for income tax purposes.

The pro forma effect of this acquisition on revenues and earnings was not material.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Accounts Receivable

12 Months Ended

Mar. 31, 2016

Receivables [Abstract]

Accounts Receivable

Accounts receivable consist of the following:



	March 31,
(In thousands)	2016			2015
Components of Accounts Receivable
Trade accounts receivable	$	105,592		$	95,411
Other receivables	1,261			2,353
	106,853			97,764
Less allowances for discounts, returns and uncollectible accounts	(11,606		)	(9,906		)
Accounts receivable, net	$	95,247		$	87,858

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Inventories

12 Months Ended

Mar. 31, 2016

Inventory Disclosure [Abstract]

Inventories

Inventories consist of the following:



	March 31,
(In thousands)	2016		2015
Components of Inventories
Packaging and raw materials	$	7,563	$	7,588
Finished goods	83,700		66,412
Inventories	$	91,263	$	74,000

Inventories are carried and depicted above at the lower of cost or market, which includes a reduction in inventory values of $4.8 million and $4.1 million at March 31, 2016 and 2015, respectively, related to obsolete and slow-moving inventory.

Property and Equipment

12 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and equipment consist of the following:



	March 31,
(In thousands)	2016			2015
Components of Property and Equipment
Machinery	$	7,734		$	4,743
Computer equipment	12,793			11,339
Furniture and fixtures	2,445			2,484
Leasehold improvements	7,389			7,134
	30,361			25,700
Accumulated depreciation	(14,821		)	(11,956		)
Property and equipment, net	$	15,540		$	13,744

We recorded depreciation expense of $5.2 million, $3.8 million, and $3.2 million for 2016, 2015, and 2014, respectively.

Goodwill

12 Months Ended

Mar. 31, 2016

Goodwill [Abstract]

Goodwill

The following table summarizes the changes in the carrying value of goodwill by operating segment for each of 2014, 2015, and 2016:



(In thousands)	North American OTC Healthcare			International OTC Healthcare			Household Cleaning			Consolidated
Balance – March 31, 2013
Goodwill	$	290,327		$	—		$	72,549		$	362,876
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance – March 31, 2013	160,157			—			7,389			167,546

2014 additions	—			23,122			—			23,122
Effects of foreign currency exchange rates	—			243			—			243

Balance – March 31, 2014
Goodwill	290,327			23,365			72,549			386,241
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance – March 31, 2014	160,157			23,365			7,389			190,911

2015 additions	103,254			1,224			—			104,478
2015 reductions	—			—			(589		)	(589		)
Effects of foreign currency exchange rates	—			(4,149		)	—			(4,149		)

Balance – March 31, 2015
Goodwill	393,581			20,440			71,960			485,981
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance - March 31, 2015	263,411			20,440			6,800			290,651

2016 additions	74,441			2,393			—			76,834
2016 reductions	(7,237		)	—			—			(7,237		)
Effects of foreign currency exchange rates	—			(57		)	—			(57		)

Balance – March 31, 2016
Goodwill	460,785			22,776			71,960			555,521
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance - March 31, 2016	$	330,615		$	22,776		$	6,800		$	360,191

As discussed in Note 2, on July 1, 2013, we completed the acquisition of Care Pharma. In connection with this acquisition, we recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired.

As discussed in Note 2, we completed two acquisitions during the year ended March 31, 2015. On September 3, 2014, we completed the acquisition of Insight and recorded goodwill of $96.3 million, reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of net assets acquired, after giving affect to the following adjustments. During the quarter ended June 30, 2015, we increased goodwill by $0.3 million for certain immaterial items. During the quarter ending December 31, 2015, we decreased goodwill by $7.2 million, as we received that amount from escrow pursuant to an arbitrator's ruling in December 31, 2015 related to a disputed working capital calculation, as determined under GAAP, associated with the Insight acquisition, which is clearly and directly related to the purchase price. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and recorded goodwill of $1.2 million, reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of the net assets acquired.

As further discussed in Note 7, in December 2014, we completed a transaction to sell rights to use of the Comet brand in certain Eastern European countries to a third-party licensee. As a result, we recorded a gain on the sale of $1.3 million and reduced the carrying value of our intangible assets and goodwill.

As discussed in Note 2, on February 5, 2016, we completed the acquisition of DenTek. In connection with this acquisition, we recorded goodwill of $76.5 million based on the amount by which the purchase price exceeded the fair value of net assets acquired.

Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount. At February 29, 2016 and February 28, 2015, in conjunction with the annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in 2016 or 2015.

We identify our reporting units in accordance with the FASB ASC Subtopic 280. The carrying value and fair value for intangible assets and goodwill for a reporting unit are calculated based on key assumptions and valuation methodologies previously discussed. The discounted cash flow methodology is a widely-accepted valuation technique utilized by market participants in the transaction evaluation process and has been applied consistently. We also considered our market capitalization at February 29, 2016, February 28, 2015 and March 31, 2014, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future.

The aggregate fair value of our reporting units exceeded the carrying value by 76.4% with no reporting unit's fair value exceeding the carrying value by less than 10%.

Intangible Assets

12 Months Ended

Mar. 31, 2016

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Intangible Assets

A reconciliation of the activity affecting intangible assets for each of 2014, 2015, and 2016 is as follows:



	Year Ended March 31, 2014
(In thousands)	Indefinite Lived Trademarks		Finite Lived Trademarks and Customer Relationships		Non Compete Agreement			Totals
Gross Amount
Balance – March 31, 2013	$	1,243,718	$	203,066	$	158		$	1,446,942
Additions	29,845		1,657		—			31,502
Reductions	—		—		(158		)	(158		)
Effects of foreign currency exchange rates	315		17		—			332
Balance – March 31, 2014	$	1,273,878	$	204,740	$	—		$	1,478,618

Accumulated Amortization
Balance – March 31, 2013	$	—	$	73,544	$	158		$	73,702
Additions	—		10,256		—			10,256
Reductions	—		—		(158		)	(158		)
Effects of foreign currency exchange rates	—		1		—			1
Balance – March 31, 2014	—		83,801		—			83,801

Intangibles, net – March 31, 2014	$	1,273,878	$	120,939	$	—		$	1,394,817

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,123,897	$	93,242	$	—		$	1,217,139
International OTC Healthcare	30,161		1,530		—			31,691
Household Cleaning	119,820		26,167		—			145,987
Intangible assets, net – March 31, 2014	$	1,273,878	$	120,939	$	—		$	1,394,817



	Year Ended March 31, 2015
(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks and Customer Relationships			Non Compete Agreement		Totals
Gross Amount
Balance – March 31, 2014	$	1,273,878		$	204,740		$	—	$	1,478,618
Additions	673,180			124,774			—		797,954
Reclassifications	(46,506		)	46,506			—		—
Reductions	(9,548		)	(17,674		)	—		(27,222		)
Effects of foreign currency exchange rates	(17,600		)	(280		)	—		(17,880		)
Balance – March 31, 2015	$	1,873,404		$	358,066		$	—	$	2,231,470

Accumulated Amortization
Balance – March 31, 2014	$	—		$	83,801		$	—	$	83,801
Additions	—			12,995			—		12,995
Effects of foreign currency exchange rates	—			(26		)	—		(26		)
Balance – March 31, 2015	$	—		$	96,770		$	—	$	96,770

Intangibles, net – March 31, 2015	$	1,873,404		$	261,296		$	—	$	2,134,700

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,676,991		$	235,642		$	—	$	1,912,633
International OTC Healthcare	86,141			1,231			—		87,372
Household Cleaning	110,272			24,423			—		134,695
Intangible assets, net – March 31, 2015	$	1,873,404		$	261,296		$	—	$	2,134,700



	Year Ended March 31, 2016
(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks and Customer Relationships			Non Compete Agreement		Totals
Gross Amount
Balance – March 31, 2015	$	1,873,404		$	358,066		$	—	$	2,231,470
Additions	179,800			26,900			—		206,700
Reclassifications	(32,918		)	32,918			—		—
Reductions	—			—			—		—
Effects of foreign currency exchange rates	(240		)	(4		)	—		(244		)
Balance – March 31, 2016	$	2,020,046		$	417,880		$	—	$	2,437,926

Accumulated Amortization
Balance – March 31, 2015	$	—		$	96,770		$	—	$	96,770
Additions	—			18,430			—		18,430
Effects of foreign currency exchange rates	—			3			—		3
Balance – March 31, 2016	$	—		$	115,203		$	—	$	115,203

Intangibles, net – March 31, 2016	$	2,020,046		$	302,677		$	—	$	2,322,723

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,823,873		$	277,762		$	—	$	2,101,635
International OTC Healthcare	85,901			2,237			—		88,138
Household Cleaning	110,272			22,678			—		132,950
Intangible assets, net – March 31, 2016	$	2,020,046		$	302,677		$	—	$	2,322,723

As discussed in Note 2, on July 1, 2013, we completed the acquisition of Care Pharma. In connection with this acquisition, we allocated $31.5 million to intangible assets based on our analysis.

As discussed in Note 2, we completed two acquisitions during the year ended March 31, 2015. On September 3, 2014, we completed the acquisition of Insight and allocated $724.4 million to intangible assets based on our analysis. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and allocated $73.6 million to intangible assets based on our preliminary analysis. Furthermore, on September 3, 2014, we sold one of the brands that we acquired from Insight, for which we had allocated $17.7 million to intangible assets.

As discussed in Note 2, on February 5, 2016, we completed the acquisition of DenTek. In connection with this acquisition, we allocated $206.7 million to intangible assets based on our analysis.

Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.

We utilized the discounted cash flow method to estimate the fair value of our reporting units as part of the goodwill impairment test and the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. The discount rate utilized in the analyses, as well as future cash flows, may be influenced by such factors as changes in interest rates and rates of inflation. Additionally, should the related fair values of goodwill and intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer preferences, technological advances or reductions in advertising and promotional expenses, we may be required to record impairment charges in the future. In addition, we considered our market capitalization at February 29, 2016, which was the date of our annual review, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. As a result of our analysis, we determined that the fair values exceeded the carrying values and as such, no impairment charge was recorded in 2016.

Based on our analysis, the aggregate fair value of our reporting units exceeded the carrying value by 76.4%, with no reporting unit's fair value exceeding the carrying value by less than 10%. The aggregate fair value of the indefinite-lived intangible assets exceeded the carrying value by 55.8%. Three of the individual indefinite-lived trade names exceeded their carrying values by less than 10%. The fair value of Beano, New Skin and Debrox, exceed their carrying values of $78.4 million, $37.2 million and $76.3 million, by 9.0%, 8.2% and 5.1%, respectively.

Given the competitive landscape, including private label, Beano has experienced declines in revenues in recent periods. However, we continue to believe that the fair value exceeds the carrying value of Beano. The significant assumptions supporting the fair value of Beano include a discount rate of 9.5%, and returning to revenue growth, coupled with advertising and promotion investments that are in line with historical performance. A decrease in the annual cash flow of approximately 21.6% compared to the projected cash flow utilized in our analysis, or an increase in the discount rate of approximately 82 basis points could result in the carrying value of our trade name exceeding its fair value, which would result in an impairment charge.

The significant assumptions supporting the fair value of New Skin and Debrox include a discount rate of 9.5%, coupled with modest revenue growth, and advertising and promotion investments that are in line with historical performance. Revenue declines in each of the brands or changes in assumptions utilized in our quantitative indefinite lived asset impairment analysis may result in the fair value no longer exceeding their respective carrying values. For example, a decrease in the annual cash flow of approximately 19.6% and 12.6% for New Skin and Debrox, respectively, compared to the projected cash flow utilized in our analysis, or an increase in the discount rate of approximately 73 and 45 basis points, respectively, could result in the carrying value of our trade name exceeding its fair value, which would result in an impairment charge. We will continue to review our results against forecasts and assess our assumptions to ensure they continue to be appropriate.

Based on recent declines in the business and a strategic review of our brands during the fourth quarter ended March 31, 2016 and our annual impairment review, we have reassessed the useful life of the Ecotrin brand as of February 29, 2016 and determined it to be 20 years. As such, we have reclassified $32.9 million from an indefinite-lived to a finite lived intangible asset. At the time of this change in useful life, the fair value exceeded its carrying value.

Although we experienced revenue declines in Pediacare and in certain other brands in the past, we continue to believe that the fair value of our brands exceed their carrying values. However, sustained or significant future declines in revenue, profitability, lost distribution, other adverse changes in expected operating results, and / or unfavorable changes in economic factors used to estimate fair value of certain brands could indicate that the fair value no longer exceeds the carrying in which case a non-cash impairment charge may be recorded in future periods.

The weighted average remaining life for finite-lived intangible assets at March 31, 2016 was approximately 14.4 years, and the amortization expense for the year ended March 31, 2016 was $18.4 million. At March 31, 2016, finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 30 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):



Year Ending March 31,
2017	21,236
2018	21,072
2019	21,072
2020	21,072
2021	20,650
Thereafter	197,575
	$	302,677

Sale of asset

Historically, we received royalty income from the licensing of the name of certain of our brands in geographic areas or markets in which we do not directly compete. We have had a royalty agreement for our Comet brand for several years, which included an option on behalf of the licensee to purchase the rights in certain geographic areas and markets in perpetuity. In December 2014, we amended the agreement to allow the licensee to buy out a portion of the agreement early, but retaining the remaining stream of royalty payments. In December 2014, in connection with this amendment, we sold rights to use of the Comet brand in certain Eastern European countries to a third-party licensee and received $10.0 million as a partial early buyout. As a result, we recorded a gain on sale of $1.3 million, and reduced the carrying value of our intangible assets and goodwill. The licensee will continue to make quarterly payments at least through June 30, 2016 of approximately $1.0 million. The licensee has the option to purchase (which we expect the licensee will elect to exercise such option) the remaining territories and markets, as defined in the agreement, at any time after July 1, 2016.

Long-Term Debt

12 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Long-Term Debt

2012 Senior Notes:

On January 31, 2012, Prestige Brands, Inc. (the "Borrower") issued $250.0 million of senior unsecured notes at par value, with an interest rate of 8.125% and a maturity date of February 1, 2020 (the "2012 Senior Notes"). The Borrower could earlier redeem some or all of the 2012 Senior Notes at redemption prices set forth in the indenture governing the 2012 Senior Notes. The 2012 Senior Notes were guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees were joint and several. There were no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2012 Senior Notes offering, we incurred $12.6 million of costs, which were capitalized as deferred financing costs and were being amortized over the term of the 2012 Senior Notes. As of March 31, 2016, there were no outstanding balances as the Company used the net proceeds from the 2016 Senior Notes issuance (discussed below) to repay all of the balances associated with the 2012 Senior Notes.

2012 Term Loan and 2012 ABL Revolver:

On January 31, 2012, the Borrower also entered into a new senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a 7-year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a 5-year maturity. In subsequent years, we have utilized portions of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $85.0 million to $135.0 million and reduced our borrowing rate on the 2012 ABL Revolver by 0.25% (discussed below). The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Borrower of $650.1 million. In connection with these loan facilities, we incurred $20.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the terms of the facilities. The 2012 Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.

On February 21, 2013, we entered into Amendment No. 1 (the "Term Loan Amendment No. 1") to the 2012 Term Loan. Term Loan Amendment No. 1 provided for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans (the "Term B-1 Loans"). The interest rate on the Term B-1 Loans under the Term Loan Amendment No. 1 was based, at the Borrower's option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin. The new Term B-1 Loans would have matured on the same date as the Term B Loans' original maturity date. In addition, Term Loan Amendment No. 1 provided the Borrower with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver. In connection with Term Loan Amendment No. 1, during the fourth quarter ended March 31, 2013, we recognized a $1.4 million loss on the extinguishment of debt.

On September 3, 2014, we entered into Amendment No. 2 ("Term Loan Amendment No. 2") to the 2012 Term Loan. Term Loan Amendment No. 2 provides for (i) the creation of a new class of Term B-2 Loans under the 2012 Term Loan (the "Term B-2 Loans") in an aggregate principal amount of $720.0 million, (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility and financial maintenance covenant relief, and (iii) an interest rate on (x) the Term B-1 Loans that was based, at our option, on a LIBOR rate plus a margin of 3.125% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin, and (y) the Term B-2 Loans that was based, at our option, on a LIBOR rate plus a margin of 3.50% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin (with a margin step-down to 3.25% per annum, based upon achievement of a specified secured net leverage ratio).

Also, on September 3, 2014, the Borrower entered into ABL Amendment No. 3. ABL Amendment No. 3 provides for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility. Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin, plus, at the Borrower's option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., and (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The initial applicable margin for borrowings under the 2012 ABL Revolver is 1.75% with respect to LIBOR borrowings and 0.75% with respect to base-rate borrowings. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments by an amount set forth in the credit agreement covering the 2012 ABL Revolver. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty.

On May 8, 2015, we entered into Amendment No. 3 (the "Term Loan Amendment No. 3") to the 2012 Term Loan. Term Loan Amendment No. 3 provides for (i) the creation of a new class of Term B-3 Loans under the 2012 Term Loan (the "Term B-3 Loans") in an aggregate principal amount of $852.5 million, which combined the outstanding balances of the Term B-1 Loans of $207.5 million and the Term B-2 Loans of $645.0 million, (ii) increased flexibility under the credit agreement governing the 2012 Term Loan, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief, and (iii) an interest rate on the Term B-3 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 0.75%, or an alternate base rate, with a floor of 1.75%, plus a margin. The maturity date of the Term B-3 Loans remains the same as the Term B-2 Loans' original maturity date of September 3, 2021.

The 2012 Term Loan, as amended, bears interest at a rate per annum equal to an applicable margin plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% and (d) a floor of 1.75% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, with a floor of 0.75%. For the year ended March 31, 2016, the average interest rate on the 2012 Term Loan was 4.4%.

Under the 2012 Term Loan, the Borrower was originally required to make quarterly payments each equal to 0.25% of the original principal amount of the 2012 Term Loan, with the balance expected to be due on the seventh anniversary of the closing date. However, since the Borrower has previously made significant optional payments that exceeded all of our required quarterly payments, the Borrower will not be required to make another payment until the maturity date of March 31, 2019.

On June 9, 2015, we entered into Amendment No. 4 (“ABL Amendment No. 4”) to the 2012 ABL Revolver. ABL Amendment No. 4 provides for (i) a $35.0 million increase in the accordion feature under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief and (iii) extended the maturity date of the 2012 ABL Revolver to June 9, 2020, which is five years from the effective date. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. For the year ended March 31, 2016, the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 2.1%.

In connection with the Bridge Credit Agreement (discussed below) and DenTek acquisition on February 5, 2016, we entered into Amendment No. 5 (the “ABL Amendment No. 5”) to the 2012 ABL Revolver. ABL Amendment No. 5 temporarily suspends certain financial and related reporting covenants in the 2012 ABL Revolver until the earliest of (i) the date that is 60 calendar days following February 4, 2016, (ii) the date upon which certain of DenTek’s assets are included in the Company’s borrowing base under the 2012 ABL Revolver and (iii) the date upon which the Company receives net proceeds from an offering of debt securities.

2013 Senior Notes:

On December 17, 2013, the Borrower issued $400.0 million of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2013 Senior Notes offering, we incurred $7.2 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2013 Senior Notes.

2016 Bridge Term Loans:

On February 4, 2016, Prestige Brands Holdings, Inc. and the Borrower, entered into a bridge credit agreement. The Bridge Credit Agreement provides for term loans in an aggregate principal amount of $80.0 million (the “Bridge Term Loans”), at an applicable interest rate margin equal to (i) for the period beginning on the closing date and ending on the 179th day following the closing date, 4.75% for Eurocurrency rate loans and 3.75% for base rate loans, (ii) for the period from and including the 180th day following the closing date and ending on the 269th day following the closing date, 5.00% for Eurocurrency rate loans and 4.00% for base rate loans, and (iii) for the period from and after the 270th day following the closing date, 5.25% for Eurocurrency rate loans and 4.25% for base rate loans. The Bridge Term Loans would have matured on February 2, 2017. The proceeds were used to partially fund the acquisition of DenTek. However, as of March 31, 2016, there were no outstanding balances as the Company used the net proceeds from the 2016 Senior Notes issuance (discussed below) to repay all of these Bridge Term Loans on February 19, 2016. In connection with the repayment of the Bridge Loan on February 19, 2016, we expensed $1.9 million of unamortized debt issuance costs which were classified as interest expense.

2016 Senior Notes:

On February 19, 2016, the Borrower completed the sale of $350.0 million aggregate principal amount of 6.375% senior notes due 2024 (the “2016 Senior Notes”), pursuant to a purchase agreement, dated February 16, 2016, among the Borrower, the guarantors party thereto (the “Guarantors”) and the initial purchasers party thereto. The 2016 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the Guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2016 Senior Notes offering, we incurred $5.5 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2016 Senior Notes. The proceeds were used to redeem the 2012 Senior Notes and repay the Bridge Term Loans that were utilized to partially fund the acquisition of DenTek.

The 2016 Senior Notes were issued pursuant to an indenture, dated February 19, 2016 (the “Indenture”). The Indenture provides, among other things, that interest will be payable on the 2016 Senior Notes on March 1 and September 1 of each year, beginning on September 1, 2016, until their maturity date of March 1, 2024. The 2016 Senior Notes are senior unsecured obligations of the Borrower.

Redemptions and Restrictions:

On February 19, 2016, the Company used the net proceeds from the 2016 Senior Notes issuance to redeem all of the 2012 Senior Notes at a redemption price equal to 104.063%, plus accrued and unpaid interest, and repay all of the Bridge Term Loans.

At any time prior to December 15, 2016, have the option to redeem the 2013 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of notes redeemed, plus an applicable "make-whole premium" calculated as set forth in the indenture governing the 2013 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after December 15, 2016, we have have the option to redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. In addition, at any time prior to December 15, 2016, we have to the option to redeem up to 35% of the aggregate principal amount of the 2013 Senior Notes at a redemption price equal to 105.375% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2013 Senior Notes, the Borrower will be required to make an offer to purchase the 2013 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2013 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

The Borrower has the option to redeem all or a portion of the 2016 Senior Notes at any time on or after March 1, 2019 at the redemption prices set forth in the Indenture, plus accrued and unpaid interest, if any. The Borrower may also redeem all or any portion of the 2016 Senior Notes at any time prior to March 1, 2019, at a price equal to 100% of the aggregate principal amount thereof, plus a make-whole premium and accrued and unpaid interest, if any. In addition, before March 1, 2019, the Borrower may redeem up to 40% of the aggregate principal amount of the 2016 Senior Notes with the net proceeds of certain equity offerings at the redemption price set forth in the Indenture, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control (as defined in the Indenture), the Borrower will be required to make an offer to purchase the 2016 Senior Notes at a price equal to 101% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

The indentures governing the 2013 Senior Notes and the 2016 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement with respect to the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2016 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2016 Senior Notes. At March 31, 2016, we were in compliance with the covenants under our long-term indebtedness.

Effective April 1, 2015, the Company elected to change its method of presentation relating to debt issuance costs in accordance with ASU 2015-03. Prior to 2016, the Company's policy was to present these costs in other-long term assets on the balance sheet, net of accumulated amortization. Beginning in 2016, the Company has presented these fees as a direct deduction to the related long-term debt. As a result, we reclassified $27.4 million of deferred financing costs as of March 31, 2015 from other long-term assets, and such costs are now presented as a direct deduction from the long-term debt liability.

At March 31, 2016, we had an aggregate of $1.3 million of unamortized debt costs related to the 2012 ABL Revolver, and $27.2 million of unamortized debt costs, the total of which is comprised of $5.4 million related to the 2013 Senior Notes, $5.4 million related to the 2016 Senior Notes, and $16.4 million related to the 2012 Term Loan.

At March 31, 2015 we had an aggregate of $1.2 million of unamortized debt costs related to the 2012 ABL Revolver, and $32.3 million of unamortized debts costs, the total of which is comprised of $8.7 million related to the 2012 Senior Notes, $6.2 million related to the 2013 Senior Notes, and $17.4 million related to the 2012 Term Loan.

At March 31, 2016, we had $85.0 million outstanding on the 2012 ABL Revolver and a borrowing capacity of $37.9 million.

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	March 31, 2016			March 31, 2015
2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024.	350,000			—
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	400,000			400,000
2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	—			250,000
2012 Term B-3 Loans bearing interest at the Borrower's option at either a base rate with a floor of 1.75% plus applicable margin or LIBOR with a floor of 0.75% plus applicable margin, due on September 3, 2021.	817,500			877,500
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on June 9, 2020.	85,000			66,100
Total long-term debt (including current portion)	1,652,500			1,593,600
Current portion of long-term debt	—			—
Long-term debt	1,652,500			1,593,600
Less: unamortized debt costs	(27,191		)	(32,327		)
Long-term debt, net	$	1,625,309		$	1,561,273

As of March 31, 2016, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2016 Senior Notes and the 2013 Senior Notes are as follows:



(In thousands)
Year Ending March 31,	Amount
2017	$	—
2018	—
2019	—
2020	5,494
2021	93,525
Thereafter	1,553,481
	$	1,652,500

Fair Value Measurements

12 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts.

The Fair Value Measurements and Disclosures topic of the FASB ASC 820 requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created:

Level 1 - Quoted market prices for identical instruments in active markets;

Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and

Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant.

The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2016 Senior Notes, the 2013 Senior Notes, the 2012 Senior Notes, the Term B-3 loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy (see summary below detailing the carrying amounts and estimated fair values of these borrowings at March 31, 2016 and 2015).



	March 31, 2016				March 31, 2015
(In thousands)	Carrying Value		Fair Value		Carrying Value		Fair Value
2016 Senior Notes	$	350,000	$	363,125	$	—	$	—
2013 Senior Notes	400,000		408,000		400,000		405,000
2012 Senior Notes	—		—		250,000		268,100
Term B-3 Loans	817,500		818,522		877,500		880,500
2012 ABL Revolver	85,000		85,000		66,100		65,700

At March 31, 2016 and 2015, we did not have any assets or liabilities measured in Level 1 or 3. During 2016, 2015 and 2014, there were no transfers of assets or liabilities between Levels 1, 2 and 3.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid on the Company's common stock through March 31, 2016. Pursuant to the provisions of various employee restricted stock awards, we repurchased 40,316 shares and 59,933 shares of restricted common stock from our employees during the years ended March 31, 2016 and 2015, respectively. The repurchases during the years ended March 31, 2016 and 2015 were at an average price of $41.80 and $34.16, respectively. All of the repurchased shares have been recorded as treasury stock.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Earnings Per Share

12 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Earnings Per Share

Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options, and restricted stock units. The following table sets forth the computation of basic and diluted earnings per share:



	Year Ended March 31,
(In thousands, except per share data)	2016		2015		2014
Numerator
Net income	$	99,907	$	78,260	$	72,615

Denominator
Denominator for basic earnings per share- weighted average shares outstanding	52,754		52,170		51,641
Dilutive effect of unvested restricted stock units and options issued to employees and directors	389		500		708
Denominator for diluted earnings per share	53,143		52,670		52,349

Earnings per Common Share:
Basic net earnings per share	$	1.89	$	1.50	$	1.41

Diluted net earnings per share	$	1.88	$	1.49	$	1.39

For 2016, 2015, and 2014 there were less than 0.1 million, 0.3 million, and 0.2 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

Share-Based Compensation

12 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-based Compensation

Share-Based Compensation

In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, the stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the Plan, increased the maximum number of shares subject to stock options that may be awarded to any one participant under the Plan during any 12-month period from 1.0 million to 2.5 million shares and extended the term of the Plan by ten years, to February 2025. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.

During 2016, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $10.0 million and $3.5 million, respectively.

During 2015, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $6.9 million and $1.9 million, respectively.

During 2014, pre-tax share-based compensation costs charged against income and the related income tax benefit recognized were $5.1 million and $1.5 million, respectively.

On April 22, 2015, we announced that Matthew M. Mannelly, our President and Chief Executive Officer and member of the Board of Directors, would retire effective June 1, 2015. In conjunction with his retirement, the Board of Directors accelerated the vesting of his previously unvested restricted stock units and stock options, and we recorded additional compensation expense of approximately $0.8 million associated with this acceleration. Effective June 1, 2015, the Board of Directors appointed Ron M. Lombardi, our then current Chief Financial Officer, to succeed Mr. Mannelly as President and Chief Executive Officer and as a member of the Board of Directors. In connection with his appointment, Mr. Lombardi was granted 57,924 restricted stock units on April 22, 2015.

On October 28, 2015, we announced that David S. Marberger has been appointed as Chief Financial Officer of the Company, effective November 10, 2015. In connection with Mr. Marberger’s appointment as Chief Financial Officer, on October 28, 2015, the Company entered into an employment agreement with Mr. Marberger, which sets forth the terms of his compensation as approved by the Compensation Committee of the Board of Directors. In accordance with the terms of his employment agreement, on October 28, 2015, the Company granted to Mr. Marberger 6,612 shares of restricted stock units and stock options to acquire 8,079 shares of our common stock under the Plan. The restricted stock units vest in their entirety on the three-year anniversary of the date of grant. Upon vesting, the units will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $50.42 per share, which is equal to the closing price of our common stock on the date of grant.

On May 11, 2015, the Compensation Committee of our Board of Directors (the "Compensation Committee") granted 185,904 restricted stock units and stock options to acquire 186,302 shares of our common stock to certain executive officers and employees under the Plan. Of those grants, 163,404 restricted stock units vest in their entirety on the three-year anniversary of the date of grant and 22,500 restricted stock units vest 33.3% per year over three years. Upon vesting, the units will be settled in shares of our common stock. The stock options vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $41.44 per share, which is equal to the closing price of our common stock on the date of grant. On July 1, 2015, the Compensation Committee granted 2,841 restricted stock units, which vest on the three-year anniversary of the date of grant, and stock options to acquire 13,861 shares of our common stock to certain employees under the Plan. The stock options vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $46.58 per share, which is equal to the closing price of our common stock on the date of grant.

Restricted Shares

Restricted shares granted to employees under the Plan generally vest in three to five years, primarily upon the attainment of certain time vesting thresholds, and may also be contingent on the attainment of certain performance goals of the Company, including revenue and earnings before income taxes, depreciation and amortization targets. The restricted share awards provide for accelerated vesting if there is a change of control, as defined in the Plan. The restricted stock units granted to employees generally vest in their entirety on the three-year anniversary of the date of the grant. Termination of employment prior to vesting will result in forfeiture of the restricted stock units. The restricted stock units granted to directors will vest in their entirety one year after the date of grant so long as the membership on the Board of Directors continues through the vesting date, with the settlement in common stock to occur on the earliest of the director's death, disability or six-month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. Upon vesting, the units will be settled in shares of our common stock.

Each of our six independent members of the Board of Directors received a grant of 2,075 restricted stock units on August 4, 2015 under the Plan. Additionally, on May 11, 2015, the Compensation Committee granted 362 restricted stock units to a newly appointed Board member. The restricted stock units vest on the one year anniversary of the date of grant and will be settled by delivery to the director of one share of common stock of the Company for each vested restricted stock unit promptly following the earliest of the director's (i) death, (ii) disability or (iii) the six-month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability.

The fair value of the restricted stock units is determined using the closing price of our common stock on the day of the grant. The weighted-average grant-date fair value during 2016, 2015, and 2014 was $42.41, $33.33 and $30.19, respectively.

A summary of the Company’s restricted shares granted under the Plan is presented below:



Restricted Shares	Shares (in thousands)		Weighted-Average Grant-Date Fair Value
Vested and Nonvested at March 31, 2013	421.3		$	11.01

Granted	126.6		30.19
Vested and issued	(104.8	)	9.98
Forfeited	(5.6	)	15.11
Vested and nonvested at March 31, 2014	437.5		16.76
Vested at March 31, 2014	69.6		9.34

Granted	106.9		33.33
Vested and issued	(154.4	)	13.37
Forfeited	(27.7	)	21.45
Vested and nonvested at March 31, 2015	362.3		22.74
Vested at March 31, 2015	76.6		11.62

Granted	266.1		42.41
Vested and issued	(155.6	)	18.31
Forfeited	(5.0	)	39.61
Vested and nonvested at March 31, 2016	467.8		35.22
Vested at March 31, 2016	69.8		14.76

Options

The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide for accelerated vesting in the event of a change in control, as defined in the Plan. Termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination of employment, subject to the terms of the Plan.

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from our historical experience, management’s estimates, and consideration of information derived from the public filings of companies similar to us, and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted options.

The weighted-average grant-date fair values of the options granted during 2016, 2015, and 2014 were $17.24, $15.95, and $13.94, respectively.



	Year Ended March 31,
	2016		2015		2014
Expected volatility	40.2	%	47.3	%	48.0	%
Expected dividends	—		—		—
Expected term in years	6.0		6.0		6.0
Risk-free rate	1.7	%	2.2	%	1.3	%

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted-Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)

Outstanding at March 31, 2013	1,386.4		$	10.43

Granted	227.7		29.94
Exercised	(605.0	)	9.76
Forfeited or expired	(14.2	)	14.56
Outstanding at March 31, 2014	994.9		15.24

Granted	317.9		33.54
Exercised	(386.3	)	10.24
Forfeited or expired	(55.3	)	26.77
Outstanding at March 31, 2015	871.2		23.40

Granted	208.2		42.13
Exercised	(348.0	)	19.22
Forfeited or expired	(3.7	)	35.72
Outstanding at March 31, 2016	727.7		30.70		7.6	$	16,512
Exercisable at March 31, 2016	308.4		21.75		6.5	9,756

The aggregate intrinsic value of options exercised during 2016, 2015 and 2014 was $8.6 million, $9.3 million and $14.0 million, respectively.

At March 31, 2016, there were $10.1 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management’s estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted-average period of 1.0 years. The total fair value of options and restricted shares vested during 2016, 2015, and 2014 was $7.0 million, $4.7 million and $3.4 million, respectively. Cash received from the exercise of stock options was $6.7 million during 2016, and we realized $2.1 million in tax benefits for the tax deductions resulting from option exercises in 2016. Cash received from the exercise of stock options was $4.0 million during 2015, and we realized $2.2 million in tax benefits for the tax deductions resulting from option exercises in 2015. Cash received from the exercise of stock options was $5.9 million during 2014, and we realized $1.7 million in tax benefits for the tax deductions from option exercises in 2014. At March 31, 2016, there were 2.6 million shares available for issuance under the Plan.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Income Taxes

12 Months Ended

Mar. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

Income before income taxes consists of the following:



	Year Ended March 31,
	2016		2015		2014
(In thousands)
United States	$	142,253	$	122,588	$	98,786
Foreign	14,932		4,870		2,962
	$	157,185	$	127,458	$	101,748

The provision for income taxes consists of the following:



	Year Ended March 31,
(In thousands)	2016			2015			2014
Current
Federal	$	6,080		$	13,066		$	7,801
State	1,171			760			625
Foreign	3,905			3,228			1,675
Deferred
Federal	44,787			31,012			27,045
State	1,678			1,162			(7,879		)
Foreign	(343		)	(30		)	(134		)
Total provision for income taxes	$	57,278		$	49,198		$	29,133

The principal components of our deferred tax balances are as follows:



	March 31,
(In thousands)	2016			2015
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$	5,083		$	4,106
Inventory capitalization	1,838			1,550
Inventory reserves	1,367			1,495
Net operating loss carryforwards	12,350			23,800
State income taxes	10,293			7,557
Accrued liabilities	2,162			619
Stock compensation	4,411			3,517
Other	300			834
Total deferred tax assets	37,804			43,478

Deferred Tax Liabilities
Property and equipment	(833		)	(1,143		)
Intangible assets	(496,485		)	(385,807		)
Total deferred tax liabilities	(497,318		)	(386,950		)

Net deferred tax liability	$	(459,514	)	$	(343,472	)

At March 31, 2016, a 100% owned subsidiary of the Company had a net operating loss carryforward of approximately $32.0 million ($11.2 million, tax effected), which may be used to offset future taxable income of the consolidated group and begins to expire in 2025. The Company expects to fully utilize the loss carryover before it expires. The net operating loss carryforward is subject to an annual limitation as to usage under Internal Revenue Code Section 382 of approximately $33.0 million.

A reconciliation of the effective tax rate compared to the statutory U.S. Federal tax rate is as follows:



	Year Ended March 31,
	2016					2015					2014
(In thousands)				%					%					%
Income tax provision at statutory rate	$	55,015		35.0		$	44,610		35.0		$	35,612		35.0
Foreign tax benefit	(2,894		)	(1.8	)	(2,019		)	(1.6	)	(918		)	(0.9	)
State income taxes, net of federal income tax benefit	3,284			2.0		2,865			2.3		2,004			2.0
Decrease in net deferred tax liability resulting from a change in the effective state tax rate	—			—		—			—		(8,892		)	(8.7	)
Goodwill adjustment for sale of asset	—			—		206			0.2		—			—
Nondeductible transaction costs	1,071			0.7		2,936			2.3		—			—
Nondeductible compensation	758			0.5		566			0.4		1,011			1.0
Other	44			—		34			—		316			0.3
Total provision for income taxes	$	57,278		36.4		$	49,198		38.6		$	29,133		28.7

Uncertain tax liability activity is as follows:



	2016		2015			2014
(In thousands)
Balance – beginning of year	$	3,420	$	1,236		$	1,016
Additions based on tax positions related to the current year	664		2,229			360
Reductions based on lapse of statute of limitations	—		(45		)	(140		)
Balance – end of year	$	4,084	$	3,420		$	1,236

We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. We did not incur any material interest or penalties related to income taxes in 2014, 2015 or 2016. The amount of unrecognized tax benefits at March 31, 2016, 2015, and 2014 was $4.1 million, $3.4 million, and $1.2 million, respectively, which would reduce the effective tax rate by 2.6%, 2.7%, and 1.2%, respectively, if recognized. We do not anticipate any events or circumstances that would cause a significant change to these uncertainties during 2017. We are subject to taxation in the United States and various state and foreign jurisdictions, and we are generally open to examination from the year ended March 31, 2013 forward.

The Company does not provide for United States income taxes on the undistributed earnings of foreign subsidiaries, which are intended to be indefinitely reinvested in operations outside of the United States. As of March 31, 2016, the cumulative amount of earnings upon which United States income taxes have not been provided is approximately $27.8 million. As of March 31, 2016, the amount of unrecognized deferred tax liability related to these earnings is estimated to be $2.2 million.

Commitments and Contingencies

12 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

We are involved from time to time in routine legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess probability and amount of potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition, or results from operations.

Lease Commitments

We have operating leases for office facilities and equipment, including New York, Wyoming, and other locations, which expire at various dates through fiscal 2021. These amounts have been included in the table below.

The following summarizes future minimum lease payments for our operating leases ^(a):



(In thousands)	Facilities		Equipment		Total
Year Ending March 31,
2017	$	1,923	$	77	$	2,000
2018	1,934		—		1,934
2019	1,926		—		1,926
2020	1,757		—		1,757
2021	817		—		817
	$	8,357	$	77	$	8,434

(a) Minimum lease payments have not been reduced by minimum sublease rentals of $1.2 million due in the future under noncancelable subleases.

The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals:



	Year ending March 31,
(In thousands)	2016			2015
Minimum lease payments	$	8,434		$	9,957
Less: Sublease rentals	(1,165		)	(1,401		)
	$	7,269		$	8,556

Rent expense was $1.8 million, $1.6 million, and $1.5 million for 2016, 2015, and 2014, respectively.

Purchase Commitments

Effective November 1, 2009, we entered into a ten year supply agreement for the exclusive manufacture of a portion of one of our Household Cleaning products. Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.



(In thousands)
Year Ending March 31,
2017	1,044
2018	1,013
2019	982
2020	560
2021	—
Thereafter	—
	$	3,599

Concentrations of Risk	12 Months Ended
Concentrations of Risk	Mar. 31, 2016
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products. We sell our products to mass merchandisers, food and drug stores, and dollar and club stores. During 2016, 2015, and 2014, approximately 41.9%, 38.2%, and 38.3%, respectively, of our gross revenues were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for each of the periods presented. During 2016, 2015, and 2014, Walmart accounted for approximately 20.2%, 18.1%, and 19.5%, respectively, of our gross revenues. Our next largest customer accounted for approximately 9.6% of our gross revenues during 2016. At March 31, 2016, approximately 24.7% and 10.4% of accounts receivable were owed by Walmart and Walgreens, respectively. We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri. A serious disruption, such as a flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center. As a result, any such disruption could have a material adverse effect on our business, sales and profitability. At March 31, 2016, we had relationships with 119 third-party manufacturers. Of those, we had long-term contracts with 55 manufacturers that produced items that accounted for approximately 79.9% of our gross sales for 2016, compared to 44 manufacturers with long-term contracts that accounted for approximately 82.9% of gross sales in 2015. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results from operations. Although we are in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach agreement which could have a material adverse effect on our business.

Business Segments

12 Months Ended

Mar. 31, 2016

Segment Reporting [Abstract]

Business Segments

Segment information has been prepared in accordance with the Segment Reporting topic of FASB ASC 280. Our current reportable segments consist of (i) North American OTC Healthcare, (ii) International OTC Healthcare and (iii) Household Cleaning. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses.

The tables below summarize information about our operating and reportable segments.



	Year Ended March 31, 2016
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues*	$	660,518		$	57,670	$	87,561	$	805,749
Elimination of intersegment revenues	(2,661		)	—		—		(2,661		)
Third-party segment revenues	657,857			57,670		87,561		803,088
Other revenues*	14			43		3,102		3,159
Total segment revenues	657,871			57,713		90,663		806,247
Cost of sales	250,018			21,676		67,342		339,036
Gross profit	407,853			36,037		23,321		467,211
Advertising and promotion	97,393			11,114		2,295		110,802
Contribution margin	$	310,460		$	24,923	$	21,026	356,409
Other operating expenses								96,094
Operating income								260,315
Other expense								103,130
Income before income taxes								157,185
Provision for income taxes								57,278
Net income								$	99,907



	Year Ended March 31, 2015
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues*	$	569,643		$	57,729	$	86,085	$	713,457
Elimination of intersegment revenues	(3,387		)	—		—		(3,387		)
Third-party segment revenues	566,256			57,729		86,085		710,070
Other revenues	637			64		3,852		4,553
Total segment revenues	566,893			57,793		89,937		714,623
Cost of sales	216,781			22,820		68,799		308,400
Gross profit	350,112			34,973		21,138		406,223
Advertising and promotion	86,897			10,922		1,832		99,651
Contribution margin	$	263,215		$	24,051	$	19,306	306,572
Other operating expenses								99,013
Operating income								207,559
Other expense								80,101
Income before income taxes								127,458
Provision for income taxes								49,198
Net income								$	78,260



	Year Ended March 31, 2014
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues*	$	485,323		$	26,687	$	83,629	$	595,639
Elimination of intersegment revenues	(3,185		)	—		—		(3,185		)
Third-party segment revenues	482,138			26,687		83,629		592,454
Other revenues	749			42		4,136		4,927
Total segment revenues	482,887			26,729		87,765		597,381
Cost of sales	184,796			12,646		64,388		261,830
Gross profit	298,091			14,083		23,377		335,551
Advertising and promotion	77,083			5,264		2,621		84,968
Contribution margin	$	221,008		$	8,819	$	20,756	250,583
Other operating expenses								61,967
Operating income								188,616
Other expense								86,868
Income before income taxes								101,748
Provision for income taxes								29,133
Net income								$	72,615

*Certain immaterial amounts relating to intersegment revenues and other revenues were reclassified between the International OTC Healthcare segment and the North American OTC Healthcare segment. There were no changes to the consolidated financial statements for any periods presented.

The tables below summarize information about our segment revenues from similar product groups.



	Year Ended March 31, 2016
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	117,337	$	2,128	$	—	$	119,465
Cough & Cold	100,148		16,422		—		116,570
Women's Health	132,184		2,982		—		135,166
Gastrointestinal	74,568		20,019		—		94,587
Eye & Ear Care	95,515		11,983		—		107,498
Dermatologicals	82,941		2,133		—		85,074
Oral Care	49,099		2,026		—		51,125
Other OTC	6,079		20		—		6,099
Household Cleaning	—		—		90,663		90,663
Total segment revenues	$	657,871	$	57,713	$	90,663	$	806,247



	Year Ended March 31, 2015
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	111,954	$	2,597	$	—	$	114,551
Cough & Cold	103,686		18,080		—		121,766
Women's Health	71,506		2,261		—		73,767
Gastrointestinal	77,596		19,372		—		96,968
Eye & Ear Care	85,236		12,689		—		97,925
Dermatologicals	64,806		2,289		—		67,095
Oral Care	45,916		483		—		46,399
Other OTC	6,193		22		—		6,215
Household Cleaning	—		—		89,937		89,937
Total segment revenues	$	566,893	$	57,793	$	89,937	$	714,623



	Year Ended March 31, 2014
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	108,101	$	1,883	$	—	$	109,984
Cough & Cold	100,060		13,365		—		113,425
Women's Health	1,960		1,835		—		3,795
Gastrointestinal	81,469		838		—		82,307
Eye & Ear Care	78,753		6,738		—		85,491
Dermatologicals	56,436		1,655		—		58,091
Oral Care	47,900		413		—		48,313
Other OTC	8,208		2		—		8,210
Household Cleaning	—		—		87,765		87,765
Total segment revenues	$	482,887	$	26,729	$	87,765	$	597,381

During fiscal 2016, 2015, and 2014, approximately 87.4%, 85.2%, and 86.9%, respectively, of our total segment revenues were from customers in the United States. Other than the United States, no individual geographical area accounted for more than 10% of total segment revenues in any of the periods presented. During fiscal 2016, 2015, and 2014, our Canada sales accounted for approximately 5.2%, 5.9%, and 7.7%, respectively, of our total segment revenues. During fiscal 2016, 2015 and 2014, our Australia sales accounted for approximately 5.6%, 6.9% and 3.0%, respectively, of our total segment revenues.

At March 31, 2016 and 2015, approximately 95.9% and 95.6%, respectively, of our consolidated goodwill and intangible assets were located in the United States and approximately 4.1% and 4.4%, respectively,were located in Australia. These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:



March 31, 2016 (In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	330,615	$	22,776	$	6,800	$	360,191

Intangible assets
Indefinite-lived	1,823,873		85,901		110,272		2,020,046
Finite-lived	277,762		2,237		22,678		302,677
Intangible assets, net	2,101,635		88,138		132,950		2,322,723
Total	$	2,432,250	$	110,914	$	139,750	$	2,682,914



March 31, 2015 (In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	263,411	$	20,440	$	6,800	$	290,651

Intangible assets
Indefinite-lived	1,676,991		86,141		110,272		1,873,404
Finite-lived	235,642		1,231		24,423		261,296
Intangible assets, net	1,912,633		87,372		134,695		2,134,700
Total	$	2,176,044	$	107,812	$	141,495	$	2,425,351

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Unaudited Quarterly Financial Information

12 Months Ended

Mar. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

Unaudited Quarterly Financial Information

Unaudited quarterly financial information for 2016 and 2015 is as follows:

Year Ended March 31, 2016



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2015			September 30, 2015			December 31, 2015		March 31, 2016
Total revenues	$	192,132		$	206,065		$	200,195	$	207,855
Cost of sales (exclusive of depreciation shown below)	79,896			86,125			83,411		89,604
Gross profit	112,236			119,940			116,784		118,251

Operating expenses
Advertising and promotion	26,422			27,893			29,935		26,552
General and administrative	17,589			16,462			18,135		20,232
Depreciation and amortization	5,720			5,687			6,071		6,198
	49,731			50,042			54,141		52,982
Operating income	62,505			69,898			62,643		65,269
Net interest expense	21,884			20,667			19,462		23,147
Loss on extinguishment of debt	451			—			—		17,519
Income before income taxes	40,170			49,231			43,181		24,603
Provision for income taxes	13,997			17,428			15,186		10,667
Net income	$	26,173		$	31,803		$	27,995	$	13,936


Earnings per share:
Basic	$	0.50		$	0.60		$	0.53	$	0.26
Diluted	$	0.49		$	0.60		$	0.53	$	0.26

Weighted average shares outstanding:
Basic	52,548			52,803			52,824		52,833
Diluted	52,958			53,151			53,203		53,252

Comprehensive income, net of tax:
Currency translation adjustments	(405		)	(11,079		)	4,922		6,449
Total other comprehensive income (loss)	(405		)	(11,079		)	4,922		6,449
Comprehensive income	$	25,768		$	20,724		$	32,917	$	20,385

Year Ended March 31, 2015



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2014		September 30, 2014			December 31, 2014			March 31, 2015
Total revenues	$	145,702	$	181,269		$	197,606		$	190,046
Cost of sales (exclusive of depreciation shown below)	63,836		78,727			85,861			79,976
Gross profit	81,866		102,542			111,745			110,070

Operating expenses
Advertising and promotion	19,096		25,044			30,144			25,367
General and administrative	17,006		27,128			19,454			17,685
Depreciation and amortization	2,961		3,852			5,154			5,773
	39,063		56,024			54,752			48,825
Operating income	42,803		46,518			56,993			61,245
Net interest expense	14,653		18,193			24,592			23,796
Gain on settlement	—		—			(1,133		)	—
Income before income taxes	28,150		28,325			33,534			37,449
Provision for income taxes	11,418		11,862			12,241			13,677
Net income	$	16,732	$	16,463		$	21,293		$	23,772

Earnings per share:
Basic	$	0.32	$	0.32		$	0.41		$	0.45
Diluted	$	0.32	$	0.31		$	0.40		$	0.45

Weighted average shares outstanding:
Basic	51,956		52,088			52,278			52,356
Diluted	52,533		52,594			52,730			52,821

Comprehensive income, net of tax:
Currency translation adjustments	2,726		(10,830		)	(8,779		)	(7,268		)
Total other comprehensive income (loss)	2,726		(10,830		)	(8,779		)	(7,268		)
Comprehensive income	$	19,458	$	5,633		$	12,514		$	16,504

Condensed Consolidating Financial Statements

12 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Condensed Consolidating Financial Statements

As described in Note 9, Prestige Brands Holdings, Inc., together with certain of our 100% owned subsidiaries, has fully and unconditionally guaranteed, on a joint and several basis, the obligations of Prestige Brands, Inc. (a 100% owned subsidiary of the Company) set forth in the indentures governing the 2016 Senior Notes and the 2013 Senior Notes, including the obligation to pay principal and interest with respect to the 2016 Senior Notes and the 2013 Senior Notes. The 100% owned subsidiaries of the Company that have guaranteed the 2016 Senior Notes and the 2013 Senior Notes are as follows: Prestige Services Corp., Prestige Brands Holdings, Inc. (a Virginia corporation), Prestige Brands International, Inc., Medtech Holdings, Inc., Medtech Products Inc., The Cutex Company, The Spic and Span Company, Blacksmith Brands, Inc., Insight Pharmaceuticals Corporation, Insight Pharmaceuticals, LLC, Practical Health Products, Inc., and DenTek Holdings, Inc. (collectively, the "Subsidiary Guarantors"). A significant portion of our operating income and cash flow is generated by our subsidiaries. As a result, funds necessary to meet Prestige Brands, Inc.'s debt service obligations are provided in part by distributions or advances from our subsidiaries. Under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2016 Senior Notes and the 2013 Senior Notes. Although holders of the 2016 Senior Notes and the 2013 Senior Notes will be direct creditors of the guarantors of the 2016 Senior Notes and the 2013 Senior Notes by virtue of the guarantees, we have indirect subsidiaries located primarily in the United Kingdom, the Netherlands and Australia (collectively, the "Non-Guarantor Subsidiaries") that have not guaranteed the 2016 Senior Notes or the 2013 Senior Notes, and such subsidiaries will not be obligated with respect to the 2016 Senior Notes or the 2013 Senior Notes. As a result, the claims of creditors of the Non-Guarantor Subsidiaries will effectively have priority with respect to the assets and earnings of such companies over the claims of the holders of the 2016 Senior Notes and the 2013 Senior Notes.

Presented below are supplemental Condensed Consolidating Balance Sheets as of March 31, 2016 and 2015 and Condensed Consolidating Income and Comprehensive Income Statements and Condensed Consolidating Statements of Cash Flows for each year in the three year period ended March 31, 2016. Such consolidating information includes separate columns for:

a) Prestige Brands Holdings, Inc., the parent,

b) Prestige Brands, Inc., the Issuer or the Borrower,

c) Combined Subsidiary Guarantors,

d) Combined Non-Guarantor Subsidiaries, and

e) Elimination entries necessary to consolidate the Company and all of its subsidiaries.

The Condensed Consolidating Financial Statements are presented using the equity method of accounting for investments in our 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries' cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this footnote should be read in conjunction with the Consolidated Financial Statements presented and other notes related thereto contained in this Annual Report on Form 10-K for the fiscal year ended March 31, 2016.

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2016



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	111,747		$	643,330		$	50,672		$	(2,661	)	$	803,088
Other revenues	—			347			3,116			1,776			(2,080		)	3,159
Total revenues	—			112,094			646,446			52,448			(4,741		)	806,247

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			45,763			280,169			18,459			(5,355		)	339,036
Gross profit	—			66,331			366,277			33,989			614			467,211

Operating Expenses
Advertising and promotion	—			9,465			90,353			10,984			—			110,802
General and administrative	5,737			9,098			51,198			6,385			—			72,418
Depreciation and amortization	4,050			594			18,617			415			—			23,676
Total operating expenses	9,787			19,157			160,168			17,784			—			206,896
Operating income (loss)	(9,787		)	47,174			206,109			16,205			614			260,315

Other (income) expense
Interest income	(48,342		)	(85,882		)	(5,087		)	(531		)	139,680			(162		)
Interest expense	34,553			84,822			100,540			5,087			(139,680		)	85,322
Loss on extinguishment of debt	—			17,970			—			—			—			17,970
Equity in (income) loss of subsidiaries	(98,803		)	(70,953		)	(8,564		)	—			178,320			—
Total other (income) expense	(112,592		)	(54,043		)	86,889			4,556			178,320			103,130
Income (loss) before income taxes	102,805			101,217			119,220			11,649			(177,706		)	157,185
Provision for income taxes	2,898			11,016			40,279			3,085			—			57,278
Net income (loss)	$	99,907		$	90,201		$	78,941		$	8,564		$	(177,706	)	$	99,907

Comprehensive income, net of tax:
Currency translation adjustments	(113		)	(113		)	(113		)	(113		)	339			(113		)
Total other comprehensive income (loss)	(113		)	(113		)	(113		)	(113		)	339			(113		)
Comprehensive income (loss)	$	99,794		$	90,088		$	78,828		$	8,451		$	(177,367	)	$	99,794

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	106,439		$	555,388		$	51,630		$	(3,387	)	$	710,070
Other revenues	—			385			4,452			1,497			(1,781		)	4,553
Total revenues	—			106,824			559,840			53,127			(5,168		)	714,623

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			39,637			254,670			19,127			(5,034		)	308,400
Gross profit	—			67,187			305,170			34,000			(134		)	406,223

Operating Expenses
Advertising and promotion	—			8,828			79,944			10,879			—			99,651
General and administrative	4,571			9,090			55,209			12,403			—			81,273
Depreciation and amortization	3,381			592			12,752			1,015			—			17,740
Total operating expenses	7,952			18,510			147,905			24,297			—			198,664
Operating income (loss)	(7,952		)	48,677			157,265			9,703			(134		)	207,559

Other (income) expense
Interest income	(48,543		)	(73,755		)	(5,373		)	(456		)	128,035			(92		)
Interest expense	34,198			81,326			88,464			5,373			(128,035		)	81,326
Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
Equity in (income) loss of subsidiaries	(76,383		)	(51,573		)	(2,013		)	—			129,969			—
Total other expense (income)	(90,728		)	(44,002		)	79,945			4,917			129,969			80,101
Income (loss) before income taxes	82,776			92,679			77,320			4,786			(130,103		)	127,458
Provision for income taxes	4,516			14,798			27,111			2,773			—			49,198
Net income (loss)	$	78,260		$	77,881		$	50,209		$	2,013		$	(130,103	)	$	78,260

Comprehensive income, net of tax:
Currency translation adjustments	(24,151		)	(24,151		)	(24,151		)	(24,151		)	72,453			(24,151		)
Total other comprehensive income (loss)	(24,151		)	(24,151		)	(24,151		)	(24,151		)	72,453			(24,151		)
Comprehensive income (loss)	$	54,109		$	53,730		$	26,058		$	(22,138	)	$	(57,650	)	$	54,109

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	97,509		$	474,338		$	23,286		$	(2,679	)	$	592,454
Other revenues	—			295			4,886			1,639			(1,893		)	4,927
Total revenues	—			97,804			479,224			24,925			(4,572		)	597,381

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			37,272			218,692			9,428			(3,562		)	261,830
Gross profit	—			60,532			260,532			15,497			(1,010		)	335,551

Operating Expenses
Advertising and promotion	—			10,223			69,583			5,162			—			84,968
General and administrative	3,140			8,026			34,469			2,846			—			48,481
Depreciation and amortization	2,994			577			9,715			200			—			13,486
Total operating expenses	6,134			18,826			113,767			8,208			—			146,935
Operating Income (loss)	(6,134		)	41,706			146,765			7,289			(1,010		)	188,616

Other (income) expense
Interest income	(48,730		)	(57,446		)	(2,327		)	(382		)	108,825			(60		)
Interest expense	34,436			68,642			72,064			2,325			(108,825		)	68,642
Loss on extinguishment of debt	—			18,286			—			—			—			18,286
Equity in (income) loss of subsidiaries	(66,739		)	(53,836		)	(4,052		)	—			124,627			—
Total other expense (income)	(81,033		)	(24,354		)	65,685			1,943			124,627			86,868
Income (loss) before income taxes	74,899			66,060			81,080			5,346			(125,637		)	101,748
Provision for income taxes	2,284			3,500			22,055			1,294			—			29,133
Net income (loss)	$	72,615		$	62,560		$	59,025		$	4,052		$	(125,637	)	$	72,615

Comprehensive income, net of tax:
Currency translation adjustments	843			843			843			843			(2,529		)	843
Total other comprehensive income (loss)	843			843			843			843			(2,529		)	843
Comprehensive income (loss)	$	73,458		$	63,403		$	59,868		$	4,895		$	(128,166	)	$	73,458

Condensed Consolidating Balance Sheet

March 31, 2016



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	4,440		$	—		$	2,899		$	19,891		$	—		$	27,230
Accounts receivable, net	—			12,025			74,446			8,776			—			95,247
Inventories	—			9,411			72,296			10,088			(532		)	91,263
Deferred income tax assets	316			681			8,293			818			—			10,108
Prepaid expenses and other current assets	15,311			257			8,379			1,218			—			25,165
Total current assets	20,067			22,374			166,313			40,791			(532		)	249,013

Property and equipment, net	9,166			210			5,528			636			—			15,540
Goodwill	—			66,007			271,409			22,775			—			360,191
Intangible assets, net	—			191,789			2,042,640			88,294			—			2,322,723
Other long-term assets	—			1,324			—			—			—			1,324
Intercompany receivables	1,457,011			2,703,192			1,083,488			10,738			(5,254,429		)	—
Investment in subsidiary	1,641,477			1,527,718			81,545						(3,250,740		)	—
Total Assets	$	3,127,721		$	4,512,614		$	3,650,923		$	163,234		$	(8,505,701	)	$	2,948,791

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	2,914		$	7,643		$	24,437		$	3,302		$	—		$	38,296
Accrued interest payable	—			8,664			—			—			—			8,664
Other accrued liabilities	12,285			1,714			38,734			6,991			—			59,724
Total current liabilities	15,199			18,021			63,171			10,293			—			106,684

Long-term debt
Principal amount	—			1,652,500			—			—			—			1,652,500
Less unamortized debt costs	—			(27,191		)	—			—			—			(27,191		)
Long-term debt, net	—			1,625,309			—			—			—			1,625,309

Deferred income tax liabilities	—			60,317			408,893			412			—			469,622
Other long-term liabilities	—			—			2,682			158			—			2,840
Intercompany payables	2,368,186			1,241,084			1,570,265			74,894			(5,254,429		)	—
Total Liabilities	2,383,385			2,944,731			2,045,011			85,757			(5,254,429		)	2,204,455

Stockholders' Equity
Common stock	530			—			—			—			—			530
Additional paid-in capital	445,182			1,280,947			1,359,921			78,774			(2,719,642		)	445,182
Treasury stock, at cost	(5,163		)	—			—			—			—			(5,163		)
Accumulated other comprehensive income (loss), net of tax	(23,525		)	(23,525		)	(23,525		)	(23,525		)	70,575			(23,525		)
Retained earnings (accumulated deficit)	327,312			310,461			269,516			22,228			(602,205		)	327,312
Total Stockholders' Equity	744,336			1,567,883			1,605,912			77,477			(3,251,272		)	744,336
Total Liabilities and Stockholders' Equity	$	3,127,721		$	4,512,614		$	3,650,923		$	163,234		$	(8,505,701	)	$	2,948,791

Condensed Consolidating Balance Sheet

March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	11,387		$	—		$	—		$	9,931		$	—		$	21,318
Accounts receivable, net	—			14,539			66,523			6,796			—			87,858
Inventories	—			8,667			60,297			6,182			(1,146		)	74,000
Deferred income tax assets	452			674			6,497			474			—			8,097
Prepaid expenses and other current assets	5,731			141			3,804			758			—			10,434
Total current assets	17,570			24,021			137,121			24,141			(1,146		)	201,707

Property and equipment, net	10,726			175			2,207			636			—			13,744
Goodwill	—			66,007			204,205			20,439			—			290,651
Intangible assets, net	—			192,325			1,854,798			87,577			—			2,134,700
Other long-term assets	—			1,165			—			—			—			1,165
Intercompany receivables	1,210,017			2,607,054			668,169			8,764			(4,494,004		)	—
Investment in subsidiary	1,545,575			1,228,535			65,564			—			(2,839,674		)	—
Total Assets	$	2,783,888		$	4,119,282		$	2,932,064		$	141,557		$	(7,334,824	)	$	2,641,967

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	1,959		$	6,829		$	32,898		$	4,429		$	—		$	46,115
Accrued interest payable	—			11,974			—			—			—			11,974
Other accrued liabilities	10,378			1,153			25,795			3,622			—			40,948
Total current liabilities	12,337			19,956			58,693			8,051			—			99,037

Long-term debt
Principal amount	—			1,593,600			—			—			—			1,593,600
Less unamortized debt costs	—			(32,327		)	—			—			—			(32,327		)
Long-term debt, net	—			1,561,273			—			—			—			1,561,273

Deferred income tax liabilities	—			59,038			292,504			27			—			351,569
Other long-term liabilities	—			—			2,293			171			—			2,464
Intercompany payables	2,143,927			1,001,219			1,279,833			69,025			(4,494,004		)	—
Total Liabilities	2,156,264			2,641,486			1,633,323			77,274			(4,494,004		)	2,014,343

Stockholders' Equity
Common Stock	525			—			—			—			—			525
Additional paid-in capital	426,584			1,280,948			1,131,578			74,031			(2,486,557		)	426,584
Treasury stock, at cost	(3,478		)	—			—			—			—			(3,478		)
Accumulated other comprehensive income (loss), net of tax	(23,412		)	(23,412		)	(23,412		)	(23,412		)	70,236			(23,412		)
Retained earnings (accumulated deficit)	227,405			220,260			190,575			13,664			(424,499		)	227,405
Total Stockholders' Equity	627,624			1,477,796			1,298,741			64,283			(2,840,820		)	627,624
Total Liabilities and Stockholders’ Equity	$	2,783,888		$	4,119,282		$	2,932,064		$	141,557		$	(7,334,824	)	$	2,641,967

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2016



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	99,907		$	90,201		$	78,941		$	8,564		$	(177,706	)	$	99,907
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	4,050			594			18,617			415			—			23,676
Deferred income taxes	136			1,272			45,070			(326		)	—			46,152
Long term income taxes payable	—			—			(332		)	—			—			(332		)
Amortization of debt origination costs	—			8,994			—			—			—			8,994
Stock-based compensation costs	9,794			—			—			160			—			9,954
Loss on extinguishment of debt	—			17,970			—			—			—			17,970
Premium payment on 2012 Senior Notes	—			(10,158		)	—			—			—			(10,158		)
(Gain) loss on sale or disposal of property and equipment	—			—			1			(36		)	—			(35		)
Equity in income of subsidiaries	(98,803		)	(70,953		)	(8,564		)	—			178,320			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	—			2,514			(388		)	(302		)	—			1,824
Inventories	—			(744		)	213			(1,860		)	(614		)	(3,005		)
Prepaid expenses and other current assets	(9,580		)	(116		)	1,977			(202		)	—			(7,921		)
Accounts payable	929			814			(11,284		)	(1,807		)	—			(11,348		)
Accrued liabilities	1,907			(2,749		)	(1,943		)	1,457			—			(1,328		)
Net cash provided by operating activities	8,340			37,639			122,308			6,063			—			174,350

Investing Activities
Purchases of property and equipment	(2,460		)	(93		)	(521		)	(494		)	—			(3,568		)
Proceeds from the sale of property and equipment	—			—			—			344			—			344
Proceeds from Insight Pharmaceuticals working capital arbitration settlement	—			—			7,237			—			—			7,237
Acquisition of DenTek, less cash acquired	—			—			(226,984		)	—			—			(226,984		)
Intercompany activity, net	—			(228,343		)	228,343			—			—			—
Net cash (used in) provided by investing activities	(2,460		)	(228,436		)	8,075			(150		)	—			(222,971		)

Financing Activities
Proceeds from issuance of 2016 Senior Notes	—			350,000			—			—			—			350,000
Repayment of 2012 Senior Notes	—			(250,000		)	—			—			—			(250,000		)
Borrowings under Bridge term loans	—			80,000			—			—			—			80,000
Repayments under Bridge term loans	—			(80,000		)	—			—			—			(80,000		)
Term loan repayments	—			(60,000		)	—			—			—			(60,000		)
Borrowings under revolving credit agreement	—			115,000			—			—			—			115,000
Repayments under revolving credit agreement	—			(96,100		)	—			—			—			(96,100		)
Payments of debt origination costs	—			(11,828		)	—			—			—			(11,828		)
Proceeds from exercise of stock options	6,689			—			—			—			—			6,689
Proceeds from restricted stock exercises	544			—			—			—			—			544
Excess tax benefits from share-based awards	1,960			—			—			—			—			1,960
Fair value of shares surrendered as payment of tax withholding	(2,229		)	—			—			—			—			(2,229		)
Intercompany activity, net	(19,791		)	143,725			(127,484		)	3,550			—			—
Net cash provided by (used in) financing activities	(12,827		)	190,797			(127,484		)	3,550			—			54,036

Effects of exchange rate changes on cash and cash equivalents	—			—			—			497			—			497
Increase (decrease) in cash and cash equivalents	(6,947		)	—			2,899			9,960			—			5,912
Cash and cash equivalents - beginning of year	11,387			—			—			9,931			—			21,318
Cash and cash equivalents - end of year	$	4,440		$	—		$	2,899		$	19,891		$	—		$	27,230

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	78,260		$	77,881		$	50,209		$	2,013		$	(130,103	)	$	78,260
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	3,381			592			12,752			1,015			—			17,740
Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
Deferred income taxes	(192		)	2,462			26,795			(143		)	—			28,922
Long-term income taxes payable	—			—			2,294			—			—			2,294
Amortization of debt origination costs	—			8,821			—			—			—			8,821
Stock-based compensation costs	6,918			—			—			—			—			6,918
Lease termination costs	—			—			785			—			—			785
Loss on sale or disposal of equipment	—			—			—			321			—			321
Equity in income of subsidiaries	(76,383		)	(51,573		)	(2,013		)	—			129,969			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	473			(294		)	5,146			(3,717		)	—			1,608
Inventories	—			5,690			8,981			555			134			15,360
Prepaid expenses and other current assets	2,273			(28		)	2,631			(212		)	—			4,664
Accounts payable	(2,457		)	(829		)	(16,734		)	2,383			—			(17,637		)
Accrued liabilities	2,650			1,384			3,560			1,738			—			9,332
Net cash provided by operating activities	14,923			44,106			93,273			3,953			—			156,255

Investing Activities
Purchases of property and equipment	(5,029		)	(119		)	(739		)	(214		)	—			(6,101		)
Proceeds from sale of business	—			—			18,500			—			—			18,500
Proceeds from sale of asset	—			—			10,000			—			—			10,000
Acquisition of Insight Pharmaceuticals, less cash acquired	—			—			(749,666		)	—			—			(749,666		)
Acquisition of the Hydralyte brand	—			—			—			(77,991		)	—			(77,991		)
Intercompany activity, net	—			(809,157		)	731,166			77,991			—			—
Net cash (used in) provided by investing activities	(5,029		)	(809,276		)	9,261			(214		)	—			(805,258		)

Financing Activities
Term loan borrowings	—			720,000			—			—			—			720,000
Term loan repayments	—			(130,000		)	—			—			—			(130,000		)
Borrowings under revolving credit agreement	—			124,600			—			—			—			124,600
Repayments under revolving credit agreement	—			(58,500		)	—			—			—			(58,500		)
Payments of debt origination costs	—			(16,072		)	—			—			—			(16,072		)
Proceeds from exercise of stock options	3,954			—			—			—			—			3,954
Proceeds from restricted stock exercises	57			—			—			—			—			57
Excess tax benefits from share-based awards	1,330			—			—			—			—			1,330
Fair value of shares surrendered as payment of tax withholding	(2,104		)	—			—			—			—			(2,104		)
Intercompany activity, net	(26,388		)	125,142			(102,534		)	3,780			—			—
Net cash provided by (used in) financing activities	(23,151		)	765,170			(102,534		)	3,780			—			643,265

Effect of exchange rate changes on cash and cash equivalents	—			—			—			(1,275		)	—			(1,275		)
(Decrease) Increase in cash and cash equivalents	(13,257		)	—			—			6,244			—			(7,013		)
Cash and cash equivalents - beginning of year	24,644			—			—			3,687			—			28,331
Cash and cash equivalents - end of year	$	11,387		$	—		$	—		$	9,931		$	—		$	21,318

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	72,615		$	62,560		$	59,025		$	4,052		$	(125,637	)	$	72,615
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	2,994			577			9,715			200			—			13,486
Deferred income taxes	(42		)	1,466			17,765			(177		)	—			19,012
Amortization of debt origination costs	—			10,512			—			—			—			10,512
Stock-based compensation costs	5,146			—			—			—			—			5,146
Loss on extinguishment of debt	—			18,286			—			—			—			18,286
Premium payment on 2010 Senior Notes	—			(15,527		)	—			—			—			(15,527		)
Gain on disposal of equipment	—			—			(3		)	—			—			(3		)
Equity in income of subsidiaries	(66,739		)	(53,836		)	(4,052		)	—			124,627			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(452		)	(370		)	12,460			(1,903		)	—			9,735
Inventories	—			(3,193		)	2,165			(2,832		)	1,010			(2,850		)
Prepaid expenses and other current assets	(3,062		)	(20		)	711			241			—			(2,130		)
Accounts payable	1,815			(2,942		)	(4,142		)	628			—			(4,641		)
Accrued liabilities	(4,966		)	(3,835		)	(2,664		)	(594		)	—			(12,059		)
Net cash provided by (used in) operating activities	7,309			13,678			90,980			(385		)	—			111,582

Investing Activities
Purchases of property and equipment	(2,351		)	(119		)	(108		)	(186		)	—			(2,764		)
Proceeds from sale of property and equipment	—			—			3			—			—			3
Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
Intercompany activity, net	—			(55,215		)	—			55,215			—			—
Net cash used in investing activities	(2,351		)	(55,334		)	(105		)	(186		)	—			(57,976		)

Financing Activities
Proceeds from issuance of 2013 Senior Notes	—			400,000			—			—			—			400,000
Repayment of 2010 Senior Notes	—			(250,000		)	—			—			—			(250,000		)
Term loan repayments	—			(157,500		)	—			—			—			(157,500		)
Borrowings under revolving credit agreement	—			50,000			—			—			—			50,000
Repayment under revolving credit agreement	—			(83,000		)	—			—			—			(83,000		)
Payments of debt origination costs	—			(7,466		)	—			—			—			(7,466		)
Proceeds from exercise of stock options	5,907			—			—			—			—			5,907
Excess tax benefits from share-based awards	1,650			—			—			—			—			1,650
Fair value of shares surrendered as payment of tax withholding	(744		)	—			—			—			—			(744		)
Intercompany activity, net	(1,847		)	89,622			(90,875		)	3,100			—			—
Net cash (used in) provided by financing activities	4,966			41,656			(90,875		)	3,100			—			(41,153		)

Effect of exchange rate changes on cash and cash equivalents	—			—			—			208			—			208
Increase in cash and cash equivalents	9,924			—			—			2,737			—			12,661
Cash and cash equivalents - beginning of year	14,720			—			—			950			—			15,670
Cash and cash equivalents - end of year	$	24,644		$	—		$	—		$	3,687		$	—		$	28,331

Subsequent Events	12 Months Ended
Subsequent Events	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Share based compensation: On May 9, 2016, the Compensation Committee of our Board of Directors granted 51,266 shares of restricted common stock units and stock options to acquire 236,116 shares of our common stock to certain executive officers and employees under the Plan. All of the shares of restricted common stock units vest in their entirety on the three-year anniversary of the date of grant. Upon vesting, the units will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $57.18 per share, which is equal to the closing price for our common stock on the day of the grant. Termination of employment prior to vesting will result in forfeiture of the unvested restricted common stock units and the unvested stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan.

Schedule II Valuation and Qualifying Accounts

12 Months Ended

Mar. 31, 2016

Valuation and Qualifying Accounts [Abstract]

Schedule II Valuation and Qualifying Accounts

VALUATION AND QUALIFYING ACCOUNTS



(In thousands)	Balance at Beginning of Year		Amounts Charged to Expense			Deductions			Other			Balance at End of Year
Year Ended March 31, 2016
Reserves for sales returns and allowance	$	6,716	$	41,217		$	(40,085	)	$	975	^(a)	$	8,823
Reserves for trade promotions	9,932		62,331			(62,409		)	2,787		^(a)	12,641
Reserves for consumer coupon redemptions	1,672		6,235			(5,637		)	2,053		^(a)	4,323
Allowance for doubtful accounts	1,277		(276		)	(186		)	—			815

Year Ended March 31, 2015
Reserves for sales returns and allowance	7,395		34,598			(35,277		)	—			6,716
Reserves for trade promotions	6,101		60,499			(56,668		)	—			9,932
Reserves for consumer coupon redemptions	1,742		5,089			(5,159		)	—			1,672
Allowance for doubtful accounts	1,035		340			(98		)	—			1,277

Year Ended March 31, 2014
Reserves for sales returns and allowance	6,446		38,314			(37,365		)	—			7,395
Reserves for trade promotions	8,523		39,967			(42,389		)	—			6,101
Reserves for consumer coupon redemptions	4,249		2,755			(5,262		)	—			1,742
Allowance for doubtful accounts	863		134			(6		)	44			1,035

(a) Reflects the applicable amounts acquired from the purchase of DenTek on February 5, 2016.

Business and Basis of Presentation (Policies)

12 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Use of Estimates

Cash and Cash Equivalents

Accounts Receivable

Inventories

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related asset.

Goodwill

Intangible Assets

Deferred Financing Costs

Debt Origination Costs

Revenue Recognition

Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.

Advertising and Promotion Costs

Stock-based Compensation

Income Taxes

We are subject to taxation in the United States and various state and foreign jurisdictions.

We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.

Earnings Per Share

Recently Issued Accounting Standards

Business and Basis of Presentation (Tables)

12 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related asset.

Property and equipment consist of the following:



	March 31,
(In thousands)	2016			2015
Components of Property and Equipment
Machinery	$	7,734		$	4,743
Computer equipment	12,793			11,339
Furniture and fixtures	2,445			2,484
Leasehold improvements	7,389			7,134
	30,361			25,700
Accumulated depreciation	(14,821		)	(11,956		)
Property and equipment, net	$	15,540		$	13,744

Acquisitions (Tables)

12 Months Ended

Mar. 31, 2016

DenTek Oral Care, Inc.

Business Acquisition [Line Items]

Purchase Price Allocation

The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the February 5, 2016 acquisition date.



(In thousands)	February 5, 2016

Cash acquired	$	1,359
Accounts receivable	9,187
Inventories	14,304
Deferred income taxes	3,303
Prepaids and other current assets	6,728
Property, plant and equipment, net	3,555
Goodwill	76,529
Intangible assets, net	206,700
Total assets acquired	321,665

Accounts payable	3,261
Accrued expenses	16,488
Deferred income tax liabilities - long term	73,573
Total liabilities assumed	93,322
Total purchase price	$	228,343

Insight Pharmaceuticals Corporation

Business Acquisition [Line Items]

Purchase Price Allocation

The following table summarizes our allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date, after giving effect of the adjustments noted above.



(In thousands)	September 3, 2014

Cash acquired	$	3,507
Accounts receivable	26,012
Inventories	23,456
Deferred income tax assets - current	1,032
Prepaids and other current assets	1,341
Property, plant and equipment	2,308
Goodwill	96,323
Intangible assets	724,374
Total assets acquired	878,353

Accounts payable	16,079
Accrued expenses	8,539
Deferred income tax liabilities - long term	107,799
Total liabilities assumed	132,417
Total purchase price	$	745,936

Pro Forma Information



	Year Ended March 31,
	2015		2014
(In thousands, except per share data)	(Unaudited)
Revenues	$	783,217	$	767,897
Net income	$	86,844	$	82,762

Earnings per share:
Basic	$	1.66	$	1.60

Diluted	$	1.65	$	1.58

Hydralyte

Business Acquisition [Line Items]

Purchase Price Allocation

The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date.



(In thousands)	April 30, 2014

Inventories	$	1,970
Property, plant and equipment, net	1,267
Goodwill	1,224
Intangible assets, net	73,580
Total assets acquired	78,041

Accrued expenses	38
Other long term liabilities	12
Total liabilities assumed	50
Net assets acquired	$	77,991

Care Pharma

Business Acquisition [Line Items]

Purchase Price Allocation

The following table summarizes our allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.



(In thousands)	July 1, 2013

Cash acquired	$	1,546
Accounts receivable	1,658
Inventories	2,465
Deferred income tax assets	283
Prepaids and other current assets	647
Property, plant and equipment	163
Goodwill	23,122
Intangible assets	31,502
Total assets acquired	61,386

Accounts payable	1,537
Accrued expenses	2,788
Other long term liabilities	300
Total liabilities assumed	4,625

Net assets acquired	$	56,761

Inventories (Tables)

12 Months Ended

Mar. 31, 2016

Inventory Disclosure [Abstract]

Inventories

Inventories consist of the following:



	March 31,
(In thousands)	2016		2015
Components of Inventories
Packaging and raw materials	$	7,563	$	7,588
Finished goods	83,700		66,412
Inventories	$	91,263	$	74,000

Property and Equipment (Tables)

12 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:



	Years
Machinery	5
Computer equipment and software	3
Furniture and fixtures	7
Leasehold improvements	*

*Leasehold improvements are amortized over the lesser of the lease term or the estimated useful life of the related asset.

Property and equipment consist of the following:



	March 31,
(In thousands)	2016			2015
Components of Property and Equipment
Machinery	$	7,734		$	4,743
Computer equipment	12,793			11,339
Furniture and fixtures	2,445			2,484
Leasehold improvements	7,389			7,134
	30,361			25,700
Accumulated depreciation	(14,821		)	(11,956		)
Property and equipment, net	$	15,540		$	13,744

Goodwill (Tables)

12 Months Ended

Mar. 31, 2016

Goodwill [Abstract]

Summary of Changes in Goodwill

The following table summarizes the changes in the carrying value of goodwill by operating segment for each of 2014, 2015, and 2016:



(In thousands)	North American OTC Healthcare			International OTC Healthcare			Household Cleaning			Consolidated
Balance – March 31, 2013
Goodwill	$	290,327		$	—		$	72,549		$	362,876
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance – March 31, 2013	160,157			—			7,389			167,546

2014 additions	—			23,122			—			23,122
Effects of foreign currency exchange rates	—			243			—			243

Balance – March 31, 2014
Goodwill	290,327			23,365			72,549			386,241
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance – March 31, 2014	160,157			23,365			7,389			190,911

2015 additions	103,254			1,224			—			104,478
2015 reductions	—			—			(589		)	(589		)
Effects of foreign currency exchange rates	—			(4,149		)	—			(4,149		)

Balance – March 31, 2015
Goodwill	393,581			20,440			71,960			485,981
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance - March 31, 2015	263,411			20,440			6,800			290,651

2016 additions	74,441			2,393			—			76,834
2016 reductions	(7,237		)	—			—			(7,237		)
Effects of foreign currency exchange rates	—			(57		)	—			(57		)

Balance – March 31, 2016
Goodwill	460,785			22,776			71,960			555,521
Accumulated impairment losses	(130,170		)	—			(65,160		)	(195,330		)
Balance - March 31, 2016	$	330,615		$	22,776		$	6,800		$	360,191

Intangible Assets (Tables)

12 Months Ended

Mar. 31, 2016

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Reconciliation of the Activity Affecting Intangible Assets

A reconciliation of the activity affecting intangible assets for each of 2014, 2015, and 2016 is as follows:



	Year Ended March 31, 2014
(In thousands)	Indefinite Lived Trademarks		Finite Lived Trademarks and Customer Relationships		Non Compete Agreement			Totals
Gross Amount
Balance – March 31, 2013	$	1,243,718	$	203,066	$	158		$	1,446,942
Additions	29,845		1,657		—			31,502
Reductions	—		—		(158		)	(158		)
Effects of foreign currency exchange rates	315		17		—			332
Balance – March 31, 2014	$	1,273,878	$	204,740	$	—		$	1,478,618

Accumulated Amortization
Balance – March 31, 2013	$	—	$	73,544	$	158		$	73,702
Additions	—		10,256		—			10,256
Reductions	—		—		(158		)	(158		)
Effects of foreign currency exchange rates	—		1		—			1
Balance – March 31, 2014	—		83,801		—			83,801

Intangibles, net – March 31, 2014	$	1,273,878	$	120,939	$	—		$	1,394,817

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,123,897	$	93,242	$	—		$	1,217,139
International OTC Healthcare	30,161		1,530		—			31,691
Household Cleaning	119,820		26,167		—			145,987
Intangible assets, net – March 31, 2014	$	1,273,878	$	120,939	$	—		$	1,394,817



	Year Ended March 31, 2015
(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks and Customer Relationships			Non Compete Agreement		Totals
Gross Amount
Balance – March 31, 2014	$	1,273,878		$	204,740		$	—	$	1,478,618
Additions	673,180			124,774			—		797,954
Reclassifications	(46,506		)	46,506			—		—
Reductions	(9,548		)	(17,674		)	—		(27,222		)
Effects of foreign currency exchange rates	(17,600		)	(280		)	—		(17,880		)
Balance – March 31, 2015	$	1,873,404		$	358,066		$	—	$	2,231,470

Accumulated Amortization
Balance – March 31, 2014	$	—		$	83,801		$	—	$	83,801
Additions	—			12,995			—		12,995
Effects of foreign currency exchange rates	—			(26		)	—		(26		)
Balance – March 31, 2015	$	—		$	96,770		$	—	$	96,770

Intangibles, net – March 31, 2015	$	1,873,404		$	261,296		$	—	$	2,134,700

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,676,991		$	235,642		$	—	$	1,912,633
International OTC Healthcare	86,141			1,231			—		87,372
Household Cleaning	110,272			24,423			—		134,695
Intangible assets, net – March 31, 2015	$	1,873,404		$	261,296		$	—	$	2,134,700



	Year Ended March 31, 2016
(In thousands)	Indefinite Lived Trademarks			Finite Lived Trademarks and Customer Relationships			Non Compete Agreement		Totals
Gross Amount
Balance – March 31, 2015	$	1,873,404		$	358,066		$	—	$	2,231,470
Additions	179,800			26,900			—		206,700
Reclassifications	(32,918		)	32,918			—		—
Reductions	—			—			—		—
Effects of foreign currency exchange rates	(240		)	(4		)	—		(244		)
Balance – March 31, 2016	$	2,020,046		$	417,880		$	—	$	2,437,926

Accumulated Amortization
Balance – March 31, 2015	$	—		$	96,770		$	—	$	96,770
Additions	—			18,430			—		18,430
Effects of foreign currency exchange rates	—			3			—		3
Balance – March 31, 2016	$	—		$	115,203		$	—	$	115,203

Intangibles, net – March 31, 2016	$	2,020,046		$	302,677		$	—	$	2,322,723

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	1,823,873		$	277,762		$	—	$	2,101,635
International OTC Healthcare	85,901			2,237			—		88,138
Household Cleaning	110,272			22,678			—		132,950
Intangible assets, net – March 31, 2016	$	2,020,046		$	302,677		$	—	$	2,322,723

Schedule of Expected Amortization Expense

At March 31, 2016, finite-lived intangible assets are expected to be amortized over their estimated useful life, which ranges from a period of 10 to 30 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):



Year Ending March 31,
2017	21,236
2018	21,072
2019	21,072
2020	21,072
2021	20,650
Thereafter	197,575
	$	302,677

Long-Term Debt Long-Term Debt (Tables)

12 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Schedule of Long-term Debt

Long-term debt consists of the following, as of the dates indicated:



(In thousands, except percentages)	March 31, 2016			March 31, 2015
2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024.	350,000			—
2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	400,000			400,000
2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	—			250,000
2012 Term B-3 Loans bearing interest at the Borrower's option at either a base rate with a floor of 1.75% plus applicable margin or LIBOR with a floor of 0.75% plus applicable margin, due on September 3, 2021.	817,500			877,500
2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on June 9, 2020.	85,000			66,100
Total long-term debt (including current portion)	1,652,500			1,593,600
Current portion of long-term debt	—			—
Long-term debt	1,652,500			1,593,600
Less: unamortized debt costs	(27,191		)	(32,327		)
Long-term debt, net	$	1,625,309		$	1,561,273

Schedule of Future Principal Payments



(In thousands)
Year Ending March 31,	Amount
2017	$	—
2018	—
2019	—
2020	5,494
2021	93,525
Thereafter	1,553,481
	$	1,652,500

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Fair Value Measurements (Tables)

12 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Schedule of Carrying Values and Estimated Fair Values of Debt Instruments



	March 31, 2016				March 31, 2015
(In thousands)	Carrying Value		Fair Value		Carrying Value		Fair Value
2016 Senior Notes	$	350,000	$	363,125	$	—	$	—
2013 Senior Notes	400,000		408,000		400,000		405,000
2012 Senior Notes	—		—		250,000		268,100
Term B-3 Loans	817,500		818,522		877,500		880,500
2012 ABL Revolver	85,000		85,000		66,100		65,700

Earnings Per Share (Tables)

12 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share:



	Year Ended March 31,
(In thousands, except per share data)	2016		2015		2014
Numerator
Net income	$	99,907	$	78,260	$	72,615

Denominator
Denominator for basic earnings per share- weighted average shares outstanding	52,754		52,170		51,641
Dilutive effect of unvested restricted stock units and options issued to employees and directors	389		500		708
Denominator for diluted earnings per share	53,143		52,670		52,349

Earnings per Common Share:
Basic net earnings per share	$	1.89	$	1.50	$	1.41

Diluted net earnings per share	$	1.88	$	1.49	$	1.39

Share-Based Compensation (Tables)

12 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Restricted Shares

A summary of the Company’s restricted shares granted under the Plan is presented below:



Restricted Shares	Shares (in thousands)		Weighted-Average Grant-Date Fair Value
Vested and Nonvested at March 31, 2013	421.3		$	11.01

Granted	126.6		30.19
Vested and issued	(104.8	)	9.98
Forfeited	(5.6	)	15.11
Vested and nonvested at March 31, 2014	437.5		16.76
Vested at March 31, 2014	69.6		9.34

Granted	106.9		33.33
Vested and issued	(154.4	)	13.37
Forfeited	(27.7	)	21.45
Vested and nonvested at March 31, 2015	362.3		22.74
Vested at March 31, 2015	76.6		11.62

Granted	266.1		42.41
Vested and issued	(155.6	)	18.31
Forfeited	(5.0	)	39.61
Vested and nonvested at March 31, 2016	467.8		35.22
Vested at March 31, 2016	69.8		14.76

Stock Options, Valuation Assumptions

The weighted-average grant-date fair values of the options granted during 2016, 2015, and 2014 were $17.24, $15.95, and $13.94, respectively.



	Year Ended March 31,
	2016		2015		2014
Expected volatility	40.2	%	47.3	%	48.0	%
Expected dividends	—		—		—
Expected term in years	6.0		6.0		6.0
Risk-free rate	1.7	%	2.2	%	1.3	%

Stock Option Activity

A summary of option activity under the Plan is as follows:



Options	Shares (in thousands)		Weighted-Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)

Outstanding at March 31, 2013	1,386.4		$	10.43

Granted	227.7		29.94
Exercised	(605.0	)	9.76
Forfeited or expired	(14.2	)	14.56
Outstanding at March 31, 2014	994.9		15.24

Granted	317.9		33.54
Exercised	(386.3	)	10.24
Forfeited or expired	(55.3	)	26.77
Outstanding at March 31, 2015	871.2		23.40

Granted	208.2		42.13
Exercised	(348.0	)	19.22
Forfeited or expired	(3.7	)	35.72
Outstanding at March 31, 2016	727.7		30.70		7.6	$	16,512
Exercisable at March 31, 2016	308.4		21.75		6.5	9,756

Income Taxes (Tables)

12 Months Ended

Mar. 31, 2016

Income Tax Disclosure [Abstract]

Income from Continuing Operations Before Income Taxes, Domestic and Foreign

Income before income taxes consists of the following:



	Year Ended March 31,
	2016		2015		2014
(In thousands)
United States	$	142,253	$	122,588	$	98,786
Foreign	14,932		4,870		2,962
	$	157,185	$	127,458	$	101,748

Components of Provision for Income Taxes

The provision for income taxes consists of the following:



	Year Ended March 31,
(In thousands)	2016			2015			2014
Current
Federal	$	6,080		$	13,066		$	7,801
State	1,171			760			625
Foreign	3,905			3,228			1,675
Deferred
Federal	44,787			31,012			27,045
State	1,678			1,162			(7,879		)
Foreign	(343		)	(30		)	(134		)
Total provision for income taxes	$	57,278		$	49,198		$	29,133

Components of Deferred Tax Balances

The principal components of our deferred tax balances are as follows:



	March 31,
(In thousands)	2016			2015
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$	5,083		$	4,106
Inventory capitalization	1,838			1,550
Inventory reserves	1,367			1,495
Net operating loss carryforwards	12,350			23,800
State income taxes	10,293			7,557
Accrued liabilities	2,162			619
Stock compensation	4,411			3,517
Other	300			834
Total deferred tax assets	37,804			43,478

Deferred Tax Liabilities
Property and equipment	(833		)	(1,143		)
Intangible assets	(496,485		)	(385,807		)
Total deferred tax liabilities	(497,318		)	(386,950		)

Net deferred tax liability	$	(459,514	)	$	(343,472	)

Reconciliation of Effective Tax Rate

A reconciliation of the effective tax rate compared to the statutory U.S. Federal tax rate is as follows:



	Year Ended March 31,
	2016					2015					2014
(In thousands)				%					%					%
Income tax provision at statutory rate	$	55,015		35.0		$	44,610		35.0		$	35,612		35.0
Foreign tax benefit	(2,894		)	(1.8	)	(2,019		)	(1.6	)	(918		)	(0.9	)
State income taxes, net of federal income tax benefit	3,284			2.0		2,865			2.3		2,004			2.0
Decrease in net deferred tax liability resulting from a change in the effective state tax rate	—			—		—			—		(8,892		)	(8.7	)
Goodwill adjustment for sale of asset	—			—		206			0.2		—			—
Nondeductible transaction costs	1,071			0.7		2,936			2.3		—			—
Nondeductible compensation	758			0.5		566			0.4		1,011			1.0
Other	44			—		34			—		316			0.3
Total provision for income taxes	$	57,278		36.4		$	49,198		38.6		$	29,133		28.7

Uncertain Tax Liability Activity

Uncertain tax liability activity is as follows:



	2016		2015			2014
(In thousands)
Balance – beginning of year	$	3,420	$	1,236		$	1,016
Additions based on tax positions related to the current year	664		2,229			360
Reductions based on lapse of statute of limitations	—		(45		)	(140		)
Balance – end of year	$	4,084	$	3,420		$	1,236

Commitments and Contingencies (Tables)

12 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

The following summarizes future minimum lease payments for our operating leases ^(a):



(In thousands)	Facilities		Equipment		Total
Year Ending March 31,
2017	$	1,923	$	77	$	2,000
2018	1,934		—		1,934
2019	1,926		—		1,926
2020	1,757		—		1,757
2021	817		—		817
	$	8,357	$	77	$	8,434

(a) Minimum lease payments have not been reduced by minimum sublease rentals of $1.2 million due in the future under noncancelable subleases.

The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals:



	Year ending March 31,
(In thousands)	2016			2015
Minimum lease payments	$	8,434		$	9,957
Less: Sublease rentals	(1,165		)	(1,401		)
	$	7,269		$	8,556

Unrecorded Unconditional Purchase Obligations



(In thousands)
Year Ending March 31,
2017	1,044
2018	1,013
2019	982
2020	560
2021	—
Thereafter	—
	$	3,599

Business Segments (Tables)

12 Months Ended

Mar. 31, 2016

Segment Reporting [Abstract]

Information about our Operating and Reportable Segments

The tables below summarize information about our operating and reportable segments.



	Year Ended March 31, 2016
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues*	$	660,518		$	57,670	$	87,561	$	805,749
Elimination of intersegment revenues	(2,661		)	—		—		(2,661		)
Third-party segment revenues	657,857			57,670		87,561		803,088
Other revenues*	14			43		3,102		3,159
Total segment revenues	657,871			57,713		90,663		806,247
Cost of sales	250,018			21,676		67,342		339,036
Gross profit	407,853			36,037		23,321		467,211
Advertising and promotion	97,393			11,114		2,295		110,802
Contribution margin	$	310,460		$	24,923	$	21,026	356,409
Other operating expenses								96,094
Operating income								260,315
Other expense								103,130
Income before income taxes								157,185
Provision for income taxes								57,278
Net income								$	99,907



	Year Ended March 31, 2015
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues*	$	569,643		$	57,729	$	86,085	$	713,457
Elimination of intersegment revenues	(3,387		)	—		—		(3,387		)
Third-party segment revenues	566,256			57,729		86,085		710,070
Other revenues	637			64		3,852		4,553
Total segment revenues	566,893			57,793		89,937		714,623
Cost of sales	216,781			22,820		68,799		308,400
Gross profit	350,112			34,973		21,138		406,223
Advertising and promotion	86,897			10,922		1,832		99,651
Contribution margin	$	263,215		$	24,051	$	19,306	306,572
Other operating expenses								99,013
Operating income								207,559
Other expense								80,101
Income before income taxes								127,458
Provision for income taxes								49,198
Net income								$	78,260



	Year Ended March 31, 2014
(In thousands)	North American OTC Healthcare			International OTC Healthcare		Household Cleaning		Consolidated
Gross segment revenues*	$	485,323		$	26,687	$	83,629	$	595,639
Elimination of intersegment revenues	(3,185		)	—		—		(3,185		)
Third-party segment revenues	482,138			26,687		83,629		592,454
Other revenues	749			42		4,136		4,927
Total segment revenues	482,887			26,729		87,765		597,381
Cost of sales	184,796			12,646		64,388		261,830
Gross profit	298,091			14,083		23,377		335,551
Advertising and promotion	77,083			5,264		2,621		84,968
Contribution margin	$	221,008		$	8,819	$	20,756	250,583
Other operating expenses								61,967
Operating income								188,616
Other expense								86,868
Income before income taxes								101,748
Provision for income taxes								29,133
Net income								$	72,615

Information about our Revenues from Similar Product Groups

The tables below summarize information about our segment revenues from similar product groups.



	Year Ended March 31, 2016
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	117,337	$	2,128	$	—	$	119,465
Cough & Cold	100,148		16,422		—		116,570
Women's Health	132,184		2,982		—		135,166
Gastrointestinal	74,568		20,019		—		94,587
Eye & Ear Care	95,515		11,983		—		107,498
Dermatologicals	82,941		2,133		—		85,074
Oral Care	49,099		2,026		—		51,125
Other OTC	6,079		20		—		6,099
Household Cleaning	—		—		90,663		90,663
Total segment revenues	$	657,871	$	57,713	$	90,663	$	806,247



	Year Ended March 31, 2015
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	111,954	$	2,597	$	—	$	114,551
Cough & Cold	103,686		18,080		—		121,766
Women's Health	71,506		2,261		—		73,767
Gastrointestinal	77,596		19,372		—		96,968
Eye & Ear Care	85,236		12,689		—		97,925
Dermatologicals	64,806		2,289		—		67,095
Oral Care	45,916		483		—		46,399
Other OTC	6,193		22		—		6,215
Household Cleaning	—		—		89,937		89,937
Total segment revenues	$	566,893	$	57,793	$	89,937	$	714,623



	Year Ended March 31, 2014
(In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Analgesics	$	108,101	$	1,883	$	—	$	109,984
Cough & Cold	100,060		13,365		—		113,425
Women's Health	1,960		1,835		—		3,795
Gastrointestinal	81,469		838		—		82,307
Eye & Ear Care	78,753		6,738		—		85,491
Dermatologicals	56,436		1,655		—		58,091
Oral Care	47,900		413		—		48,313
Other OTC	8,208		2		—		8,210
Household Cleaning	—		—		87,765		87,765
Total segment revenues	$	482,887	$	26,729	$	87,765	$	597,381

Allocation of Long-Term Assets to Segments

These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:



March 31, 2016 (In thousands)	North American OTC Healthcare		International OTC Healthcare		Household Cleaning		Consolidated
Goodwill	$	330,615	$	22,776	$	6,800	$	360,191

Intangible assets
Indefinite-lived	1,823,873		85,901		110,272		2,020,046
Finite-lived	277,762		2,237		22,678		302,677
Intangible assets, net	2,101,635		88,138		132,950		2,322,723
Total	$	2,432,250	$	110,914	$	139,750	$	2,682,914

Unaudited Quarterly Financial Information (Tables)

12 Months Ended

Mar. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information

Unaudited quarterly financial information for 2016 and 2015 is as follows:

Year Ended March 31, 2016



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2015			September 30, 2015			December 31, 2015		March 31, 2016
Total revenues	$	192,132		$	206,065		$	200,195	$	207,855
Cost of sales (exclusive of depreciation shown below)	79,896			86,125			83,411		89,604
Gross profit	112,236			119,940			116,784		118,251

Operating expenses
Advertising and promotion	26,422			27,893			29,935		26,552
General and administrative	17,589			16,462			18,135		20,232
Depreciation and amortization	5,720			5,687			6,071		6,198
	49,731			50,042			54,141		52,982
Operating income	62,505			69,898			62,643		65,269
Net interest expense	21,884			20,667			19,462		23,147
Loss on extinguishment of debt	451			—			—		17,519
Income before income taxes	40,170			49,231			43,181		24,603
Provision for income taxes	13,997			17,428			15,186		10,667
Net income	$	26,173		$	31,803		$	27,995	$	13,936


Earnings per share:
Basic	$	0.50		$	0.60		$	0.53	$	0.26
Diluted	$	0.49		$	0.60		$	0.53	$	0.26

Weighted average shares outstanding:
Basic	52,548			52,803			52,824		52,833
Diluted	52,958			53,151			53,203		53,252

Comprehensive income, net of tax:
Currency translation adjustments	(405		)	(11,079		)	4,922		6,449
Total other comprehensive income (loss)	(405		)	(11,079		)	4,922		6,449
Comprehensive income	$	25,768		$	20,724		$	32,917	$	20,385

Year Ended March 31, 2015



	Quarterly Period Ended
(In thousands, except for per share data)	June 30, 2014		September 30, 2014			December 31, 2014			March 31, 2015
Total revenues	$	145,702	$	181,269		$	197,606		$	190,046
Cost of sales (exclusive of depreciation shown below)	63,836		78,727			85,861			79,976
Gross profit	81,866		102,542			111,745			110,070

Operating expenses
Advertising and promotion	19,096		25,044			30,144			25,367
General and administrative	17,006		27,128			19,454			17,685
Depreciation and amortization	2,961		3,852			5,154			5,773
	39,063		56,024			54,752			48,825
Operating income	42,803		46,518			56,993			61,245
Net interest expense	14,653		18,193			24,592			23,796
Gain on settlement	—		—			(1,133		)	—
Income before income taxes	28,150		28,325			33,534			37,449
Provision for income taxes	11,418		11,862			12,241			13,677
Net income	$	16,732	$	16,463		$	21,293		$	23,772

Earnings per share:
Basic	$	0.32	$	0.32		$	0.41		$	0.45
Diluted	$	0.32	$	0.31		$	0.40		$	0.45

Weighted average shares outstanding:
Basic	51,956		52,088			52,278			52,356
Diluted	52,533		52,594			52,730			52,821

Comprehensive income, net of tax:
Currency translation adjustments	2,726		(10,830		)	(8,779		)	(7,268		)
Total other comprehensive income (loss)	2,726		(10,830		)	(8,779		)	(7,268		)
Comprehensive income	$	19,458	$	5,633		$	12,514		$	16,504

Condensed Consolidating Financial Statements (Tables)

12 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Condensed Consolidating Statements of Income and Comprehensive Income

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2016



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	111,747		$	643,330		$	50,672		$	(2,661	)	$	803,088
Other revenues	—			347			3,116			1,776			(2,080		)	3,159
Total revenues	—			112,094			646,446			52,448			(4,741		)	806,247

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			45,763			280,169			18,459			(5,355		)	339,036
Gross profit	—			66,331			366,277			33,989			614			467,211

Operating Expenses
Advertising and promotion	—			9,465			90,353			10,984			—			110,802
General and administrative	5,737			9,098			51,198			6,385			—			72,418
Depreciation and amortization	4,050			594			18,617			415			—			23,676
Total operating expenses	9,787			19,157			160,168			17,784			—			206,896
Operating income (loss)	(9,787		)	47,174			206,109			16,205			614			260,315

Other (income) expense
Interest income	(48,342		)	(85,882		)	(5,087		)	(531		)	139,680			(162		)
Interest expense	34,553			84,822			100,540			5,087			(139,680		)	85,322
Loss on extinguishment of debt	—			17,970			—			—			—			17,970
Equity in (income) loss of subsidiaries	(98,803		)	(70,953		)	(8,564		)	—			178,320			—
Total other (income) expense	(112,592		)	(54,043		)	86,889			4,556			178,320			103,130
Income (loss) before income taxes	102,805			101,217			119,220			11,649			(177,706		)	157,185
Provision for income taxes	2,898			11,016			40,279			3,085			—			57,278
Net income (loss)	$	99,907		$	90,201		$	78,941		$	8,564		$	(177,706	)	$	99,907

Comprehensive income, net of tax:
Currency translation adjustments	(113		)	(113		)	(113		)	(113		)	339			(113		)
Total other comprehensive income (loss)	(113		)	(113		)	(113		)	(113		)	339			(113		)
Comprehensive income (loss)	$	99,794		$	90,088		$	78,828		$	8,451		$	(177,367	)	$	99,794

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	106,439		$	555,388		$	51,630		$	(3,387	)	$	710,070
Other revenues	—			385			4,452			1,497			(1,781		)	4,553
Total revenues	—			106,824			559,840			53,127			(5,168		)	714,623

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			39,637			254,670			19,127			(5,034		)	308,400
Gross profit	—			67,187			305,170			34,000			(134		)	406,223

Operating Expenses
Advertising and promotion	—			8,828			79,944			10,879			—			99,651
General and administrative	4,571			9,090			55,209			12,403			—			81,273
Depreciation and amortization	3,381			592			12,752			1,015			—			17,740
Total operating expenses	7,952			18,510			147,905			24,297			—			198,664
Operating income (loss)	(7,952		)	48,677			157,265			9,703			(134		)	207,559

Other (income) expense
Interest income	(48,543		)	(73,755		)	(5,373		)	(456		)	128,035			(92		)
Interest expense	34,198			81,326			88,464			5,373			(128,035		)	81,326
Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
Equity in (income) loss of subsidiaries	(76,383		)	(51,573		)	(2,013		)	—			129,969			—
Total other expense (income)	(90,728		)	(44,002		)	79,945			4,917			129,969			80,101
Income (loss) before income taxes	82,776			92,679			77,320			4,786			(130,103		)	127,458
Provision for income taxes	4,516			14,798			27,111			2,773			—			49,198
Net income (loss)	$	78,260		$	77,881		$	50,209		$	2,013		$	(130,103	)	$	78,260

Comprehensive income, net of tax:
Currency translation adjustments	(24,151		)	(24,151		)	(24,151		)	(24,151		)	72,453			(24,151		)
Total other comprehensive income (loss)	(24,151		)	(24,151		)	(24,151		)	(24,151		)	72,453			(24,151		)
Comprehensive income (loss)	$	54,109		$	53,730		$	26,058		$	(22,138	)	$	(57,650	)	$	54,109

Condensed Consolidating Statement of Income and Comprehensive Income

Year Ended March 31, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Revenues
Net sales	$	—		$	97,509		$	474,338		$	23,286		$	(2,679	)	$	592,454
Other revenues	—			295			4,886			1,639			(1,893		)	4,927
Total revenues	—			97,804			479,224			24,925			(4,572		)	597,381

Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			37,272			218,692			9,428			(3,562		)	261,830
Gross profit	—			60,532			260,532			15,497			(1,010		)	335,551

Operating Expenses
Advertising and promotion	—			10,223			69,583			5,162			—			84,968
General and administrative	3,140			8,026			34,469			2,846			—			48,481
Depreciation and amortization	2,994			577			9,715			200			—			13,486
Total operating expenses	6,134			18,826			113,767			8,208			—			146,935
Operating Income (loss)	(6,134		)	41,706			146,765			7,289			(1,010		)	188,616

Other (income) expense
Interest income	(48,730		)	(57,446		)	(2,327		)	(382		)	108,825			(60		)
Interest expense	34,436			68,642			72,064			2,325			(108,825		)	68,642
Loss on extinguishment of debt	—			18,286			—			—			—			18,286
Equity in (income) loss of subsidiaries	(66,739		)	(53,836		)	(4,052		)	—			124,627			—
Total other expense (income)	(81,033		)	(24,354		)	65,685			1,943			124,627			86,868
Income (loss) before income taxes	74,899			66,060			81,080			5,346			(125,637		)	101,748
Provision for income taxes	2,284			3,500			22,055			1,294			—			29,133
Net income (loss)	$	72,615		$	62,560		$	59,025		$	4,052		$	(125,637	)	$	72,615

Comprehensive income, net of tax:
Currency translation adjustments	843			843			843			843			(2,529		)	843
Total other comprehensive income (loss)	843			843			843			843			(2,529		)	843
Comprehensive income (loss)	$	73,458		$	63,403		$	59,868		$	4,895		$	(128,166	)	$	73,458

Condensed Consolidating Balance Sheet

March 31, 2016



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	4,440		$	—		$	2,899		$	19,891		$	—		$	27,230
Accounts receivable, net	—			12,025			74,446			8,776			—			95,247
Inventories	—			9,411			72,296			10,088			(532		)	91,263
Deferred income tax assets	316			681			8,293			818			—			10,108
Prepaid expenses and other current assets	15,311			257			8,379			1,218			—			25,165
Total current assets	20,067			22,374			166,313			40,791			(532		)	249,013

Property and equipment, net	9,166			210			5,528			636			—			15,540
Goodwill	—			66,007			271,409			22,775			—			360,191
Intangible assets, net	—			191,789			2,042,640			88,294			—			2,322,723
Other long-term assets	—			1,324			—			—			—			1,324
Intercompany receivables	1,457,011			2,703,192			1,083,488			10,738			(5,254,429		)	—
Investment in subsidiary	1,641,477			1,527,718			81,545						(3,250,740		)	—
Total Assets	$	3,127,721		$	4,512,614		$	3,650,923		$	163,234		$	(8,505,701	)	$	2,948,791

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	2,914		$	7,643		$	24,437		$	3,302		$	—		$	38,296
Accrued interest payable	—			8,664			—			—			—			8,664
Other accrued liabilities	12,285			1,714			38,734			6,991			—			59,724
Total current liabilities	15,199			18,021			63,171			10,293			—			106,684

Long-term debt
Principal amount	—			1,652,500			—			—			—			1,652,500
Less unamortized debt costs	—			(27,191		)	—			—			—			(27,191		)
Long-term debt, net	—			1,625,309			—			—			—			1,625,309

Deferred income tax liabilities	—			60,317			408,893			412			—			469,622
Other long-term liabilities	—			—			2,682			158			—			2,840
Intercompany payables	2,368,186			1,241,084			1,570,265			74,894			(5,254,429		)	—
Total Liabilities	2,383,385			2,944,731			2,045,011			85,757			(5,254,429		)	2,204,455

Stockholders' Equity
Common stock	530			—			—			—			—			530
Additional paid-in capital	445,182			1,280,947			1,359,921			78,774			(2,719,642		)	445,182
Treasury stock, at cost	(5,163		)	—			—			—			—			(5,163		)
Accumulated other comprehensive income (loss), net of tax	(23,525		)	(23,525		)	(23,525		)	(23,525		)	70,575			(23,525		)
Retained earnings (accumulated deficit)	327,312			310,461			269,516			22,228			(602,205		)	327,312
Total Stockholders' Equity	744,336			1,567,883			1,605,912			77,477			(3,251,272		)	744,336
Total Liabilities and Stockholders' Equity	$	3,127,721		$	4,512,614		$	3,650,923		$	163,234		$	(8,505,701	)	$	2,948,791

Condensed Consolidating Balance Sheet

March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Assets
Current assets
Cash and cash equivalents	$	11,387		$	—		$	—		$	9,931		$	—		$	21,318
Accounts receivable, net	—			14,539			66,523			6,796			—			87,858
Inventories	—			8,667			60,297			6,182			(1,146		)	74,000
Deferred income tax assets	452			674			6,497			474			—			8,097
Prepaid expenses and other current assets	5,731			141			3,804			758			—			10,434
Total current assets	17,570			24,021			137,121			24,141			(1,146		)	201,707

Property and equipment, net	10,726			175			2,207			636			—			13,744
Goodwill	—			66,007			204,205			20,439			—			290,651
Intangible assets, net	—			192,325			1,854,798			87,577			—			2,134,700
Other long-term assets	—			1,165			—			—			—			1,165
Intercompany receivables	1,210,017			2,607,054			668,169			8,764			(4,494,004		)	—
Investment in subsidiary	1,545,575			1,228,535			65,564			—			(2,839,674		)	—
Total Assets	$	2,783,888		$	4,119,282		$	2,932,064		$	141,557		$	(7,334,824	)	$	2,641,967

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	1,959		$	6,829		$	32,898		$	4,429		$	—		$	46,115
Accrued interest payable	—			11,974			—			—			—			11,974
Other accrued liabilities	10,378			1,153			25,795			3,622			—			40,948
Total current liabilities	12,337			19,956			58,693			8,051			—			99,037

Long-term debt
Principal amount	—			1,593,600			—			—			—			1,593,600
Less unamortized debt costs	—			(32,327		)	—			—			—			(32,327		)
Long-term debt, net	—			1,561,273			—			—			—			1,561,273

Deferred income tax liabilities	—			59,038			292,504			27			—			351,569
Other long-term liabilities	—			—			2,293			171			—			2,464
Intercompany payables	2,143,927			1,001,219			1,279,833			69,025			(4,494,004		)	—
Total Liabilities	2,156,264			2,641,486			1,633,323			77,274			(4,494,004		)	2,014,343

Stockholders' Equity
Common Stock	525			—			—			—			—			525
Additional paid-in capital	426,584			1,280,948			1,131,578			74,031			(2,486,557		)	426,584
Treasury stock, at cost	(3,478		)	—			—			—			—			(3,478		)
Accumulated other comprehensive income (loss), net of tax	(23,412		)	(23,412		)	(23,412		)	(23,412		)	70,236			(23,412		)
Retained earnings (accumulated deficit)	227,405			220,260			190,575			13,664			(424,499		)	227,405
Total Stockholders' Equity	627,624			1,477,796			1,298,741			64,283			(2,840,820		)	627,624
Total Liabilities and Stockholders’ Equity	$	2,783,888		$	4,119,282		$	2,932,064		$	141,557		$	(7,334,824	)	$	2,641,967

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2016



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	99,907		$	90,201		$	78,941		$	8,564		$	(177,706	)	$	99,907
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	4,050			594			18,617			415			—			23,676
Deferred income taxes	136			1,272			45,070			(326		)	—			46,152
Long term income taxes payable	—			—			(332		)	—			—			(332		)
Amortization of debt origination costs	—			8,994			—			—			—			8,994
Stock-based compensation costs	9,794			—			—			160			—			9,954
Loss on extinguishment of debt	—			17,970			—			—			—			17,970
Premium payment on 2012 Senior Notes	—			(10,158		)	—			—			—			(10,158		)
(Gain) loss on sale or disposal of property and equipment	—			—			1			(36		)	—			(35		)
Equity in income of subsidiaries	(98,803		)	(70,953		)	(8,564		)	—			178,320			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	—			2,514			(388		)	(302		)	—			1,824
Inventories	—			(744		)	213			(1,860		)	(614		)	(3,005		)
Prepaid expenses and other current assets	(9,580		)	(116		)	1,977			(202		)	—			(7,921		)
Accounts payable	929			814			(11,284		)	(1,807		)	—			(11,348		)
Accrued liabilities	1,907			(2,749		)	(1,943		)	1,457			—			(1,328		)
Net cash provided by operating activities	8,340			37,639			122,308			6,063			—			174,350

Investing Activities
Purchases of property and equipment	(2,460		)	(93		)	(521		)	(494		)	—			(3,568		)
Proceeds from the sale of property and equipment	—			—			—			344			—			344
Proceeds from Insight Pharmaceuticals working capital arbitration settlement	—			—			7,237			—			—			7,237
Acquisition of DenTek, less cash acquired	—			—			(226,984		)	—			—			(226,984		)
Intercompany activity, net	—			(228,343		)	228,343			—			—			—
Net cash (used in) provided by investing activities	(2,460		)	(228,436		)	8,075			(150		)	—			(222,971		)

Financing Activities
Proceeds from issuance of 2016 Senior Notes	—			350,000			—			—			—			350,000
Repayment of 2012 Senior Notes	—			(250,000		)	—			—			—			(250,000		)
Borrowings under Bridge term loans	—			80,000			—			—			—			80,000
Repayments under Bridge term loans	—			(80,000		)	—			—			—			(80,000		)
Term loan repayments	—			(60,000		)	—			—			—			(60,000		)
Borrowings under revolving credit agreement	—			115,000			—			—			—			115,000
Repayments under revolving credit agreement	—			(96,100		)	—			—			—			(96,100		)
Payments of debt origination costs	—			(11,828		)	—			—			—			(11,828		)
Proceeds from exercise of stock options	6,689			—			—			—			—			6,689
Proceeds from restricted stock exercises	544			—			—			—			—			544
Excess tax benefits from share-based awards	1,960			—			—			—			—			1,960
Fair value of shares surrendered as payment of tax withholding	(2,229		)	—			—			—			—			(2,229		)
Intercompany activity, net	(19,791		)	143,725			(127,484		)	3,550			—			—
Net cash provided by (used in) financing activities	(12,827		)	190,797			(127,484		)	3,550			—			54,036

Effects of exchange rate changes on cash and cash equivalents	—			—			—			497			—			497
Increase (decrease) in cash and cash equivalents	(6,947		)	—			2,899			9,960			—			5,912
Cash and cash equivalents - beginning of year	11,387			—			—			9,931			—			21,318
Cash and cash equivalents - end of year	$	4,440		$	—		$	2,899		$	19,891		$	—		$	27,230

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2015



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	78,260		$	77,881		$	50,209		$	2,013		$	(130,103	)	$	78,260
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	3,381			592			12,752			1,015			—			17,740
Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
Deferred income taxes	(192		)	2,462			26,795			(143		)	—			28,922
Long-term income taxes payable	—			—			2,294			—			—			2,294
Amortization of debt origination costs	—			8,821			—			—			—			8,821
Stock-based compensation costs	6,918			—			—			—			—			6,918
Lease termination costs	—			—			785			—			—			785
Loss on sale or disposal of equipment	—			—			—			321			—			321
Equity in income of subsidiaries	(76,383		)	(51,573		)	(2,013		)	—			129,969			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	473			(294		)	5,146			(3,717		)	—			1,608
Inventories	—			5,690			8,981			555			134			15,360
Prepaid expenses and other current assets	2,273			(28		)	2,631			(212		)	—			4,664
Accounts payable	(2,457		)	(829		)	(16,734		)	2,383			—			(17,637		)
Accrued liabilities	2,650			1,384			3,560			1,738			—			9,332
Net cash provided by operating activities	14,923			44,106			93,273			3,953			—			156,255

Investing Activities
Purchases of property and equipment	(5,029		)	(119		)	(739		)	(214		)	—			(6,101		)
Proceeds from sale of business	—			—			18,500			—			—			18,500
Proceeds from sale of asset	—			—			10,000			—			—			10,000
Acquisition of Insight Pharmaceuticals, less cash acquired	—			—			(749,666		)	—			—			(749,666		)
Acquisition of the Hydralyte brand	—			—			—			(77,991		)	—			(77,991		)
Intercompany activity, net	—			(809,157		)	731,166			77,991			—			—
Net cash (used in) provided by investing activities	(5,029		)	(809,276		)	9,261			(214		)	—			(805,258		)

Financing Activities
Term loan borrowings	—			720,000			—			—			—			720,000
Term loan repayments	—			(130,000		)	—			—			—			(130,000		)
Borrowings under revolving credit agreement	—			124,600			—			—			—			124,600
Repayments under revolving credit agreement	—			(58,500		)	—			—			—			(58,500		)
Payments of debt origination costs	—			(16,072		)	—			—			—			(16,072		)
Proceeds from exercise of stock options	3,954			—			—			—			—			3,954
Proceeds from restricted stock exercises	57			—			—			—			—			57
Excess tax benefits from share-based awards	1,330			—			—			—			—			1,330
Fair value of shares surrendered as payment of tax withholding	(2,104		)	—			—			—			—			(2,104		)
Intercompany activity, net	(26,388		)	125,142			(102,534		)	3,780			—			—
Net cash provided by (used in) financing activities	(23,151		)	765,170			(102,534		)	3,780			—			643,265

Effect of exchange rate changes on cash and cash equivalents	—			—			—			(1,275		)	—			(1,275		)
(Decrease) Increase in cash and cash equivalents	(13,257		)	—			—			6,244			—			(7,013		)
Cash and cash equivalents - beginning of year	24,644			—			—			3,687			—			28,331
Cash and cash equivalents - end of year	$	11,387		$	—		$	—		$	9,931		$	—		$	21,318

Condensed Consolidating Statement of Cash Flows

Year Ended March 31, 2014



(In thousands)	Prestige Brands Holdings, Inc.			Prestige Brands, Inc., the issuer			Combined Subsidiary Guarantors			Combined Non- Guarantor Subsidiaries			Eliminations			Consolidated
Operating Activities
Net income (loss)	$	72,615		$	62,560		$	59,025		$	4,052		$	(125,637	)	$	72,615
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	2,994			577			9,715			200			—			13,486
Deferred income taxes	(42		)	1,466			17,765			(177		)	—			19,012
Amortization of debt origination costs	—			10,512			—			—			—			10,512
Stock-based compensation costs	5,146			—			—			—			—			5,146
Loss on extinguishment of debt	—			18,286			—			—			—			18,286
Premium payment on 2010 Senior Notes	—			(15,527		)	—			—			—			(15,527		)
Gain on disposal of equipment	—			—			(3		)	—			—			(3		)
Equity in income of subsidiaries	(66,739		)	(53,836		)	(4,052		)	—			124,627			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(452		)	(370		)	12,460			(1,903		)	—			9,735
Inventories	—			(3,193		)	2,165			(2,832		)	1,010			(2,850		)
Prepaid expenses and other current assets	(3,062		)	(20		)	711			241			—			(2,130		)
Accounts payable	1,815			(2,942		)	(4,142		)	628			—			(4,641		)
Accrued liabilities	(4,966		)	(3,835		)	(2,664		)	(594		)	—			(12,059		)
Net cash provided by (used in) operating activities	7,309			13,678			90,980			(385		)	—			111,582

Investing Activities
Purchases of property and equipment	(2,351		)	(119		)	(108		)	(186		)	—			(2,764		)
Proceeds from sale of property and equipment	—			—			3			—			—			3
Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
Intercompany activity, net	—			(55,215		)	—			55,215			—			—
Net cash used in investing activities	(2,351		)	(55,334		)	(105		)	(186		)	—			(57,976		)

Financing Activities
Proceeds from issuance of 2013 Senior Notes	—			400,000			—			—			—			400,000
Repayment of 2010 Senior Notes	—			(250,000		)	—			—			—			(250,000		)
Term loan repayments	—			(157,500		)	—			—			—			(157,500		)
Borrowings under revolving credit agreement	—			50,000			—			—			—			50,000
Repayment under revolving credit agreement	—			(83,000		)	—			—			—			(83,000		)
Payments of debt origination costs	—			(7,466		)	—			—			—			(7,466		)
Proceeds from exercise of stock options	5,907			—			—			—			—			5,907
Excess tax benefits from share-based awards	1,650			—			—			—			—			1,650
Fair value of shares surrendered as payment of tax withholding	(744		)	—			—			—			—			(744		)
Intercompany activity, net	(1,847		)	89,622			(90,875		)	3,100			—			—
Net cash (used in) provided by financing activities	4,966			41,656			(90,875		)	3,100			—			(41,153		)

Effect of exchange rate changes on cash and cash equivalents	—			—			—			208			—			208
Increase in cash and cash equivalents	9,924			—			—			2,737			—			12,661
Cash and cash equivalents - beginning of year	14,720			—			—			950			—			15,670
Cash and cash equivalents - end of year	$	24,644		$	—		$	—		$	3,687		$	—		$	28,331

Business and Basis of Presentation (Property and Equipment) (Details)	12 Months Ended
	Mar. 31, 2016
Machinery
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	5 years
Computer Equipment and Software
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	3 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	7 years

Business and Basis of Presentation (Cost of Sales) (Details) - USD ($) $ in Millions	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Warehousing, shipping and handling, and storage costs	$ 39.2	$ 37.7	$ 32.0

Business and Basis of Presentation (Recently Issued Accounting Standards) (Details) - New Accounting Pronouncement, Early Adoption, Effect $ in Millions	Mar. 31, 2015 USD ($)
Other Long-term Assets
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred finance costs, net	$ (27.4)
Long-term Debt
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred finance costs, net	$ 27.4

Acquisitions (Narrative) (Details) $ in Thousands				2 Months Ended	3 Months Ended	12 Months Ended
Acquisitions (Narrative) (Details) $ in Thousands	Feb. 05, 2016 USD ($)	Sep. 03, 2014 USD ($) brand	Jul. 01, 2013 USD ($)	Mar. 31, 2016 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	Mar. 31, 2014 USD ($)	Apr. 30, 2014 USD ($)	Mar. 31, 2013 USD ($)
Business Acquisition [Line Items]
Finite-lived intangible assets, weighted average remaining period						14 years 4 months 24 days
Additions to goodwill						$ 76,834	$ 104,478	$ 23,122
Goodwill				$ 360,191		$ 360,191	$ 290,651	$ 190,911		$ 167,546
DenTek Oral Care, Inc.
Business Acquisition [Line Items]
Purchase price	$ 228,300
Indefinite-lived intangible assets	179,800
Finite-lived intangible assets	$ 26,900
Purchased amortizable intangible assets, weighted average useful life	18 years 6 months 12 days
Finite-lived intangible assets, weighted average remaining period	18 years 5 months 12 days
Additions to goodwill	$ 76,500
Pro forma, revenue since acquisition date, actual				$ 10,700
Goodwill	76,529
Intangible assets, net	$ 206,700
Insight Pharmaceuticals Corporation
Business Acquisition [Line Items]
Indefinite-lived intangible assets		$ 599,600
Finite-lived intangible assets		$ 124,800
Purchased amortizable intangible assets, weighted average useful life		16 years 2 months 12 days
Finite-lived intangible assets, weighted average remaining period						14 years 7 months
Purchase price, gross		$ 745,900
Goodwill, post-closing inventory and apportionment adjustment		$ 7,200			$ (300)
Number of brands acquired \| brand		27
Number of brands sold \| brand		1
Goodwill		$ 96,323
Assets sold on acquisition date, not included in consideration transferred		18,500
Intangible assets, net		724,374
Insight Pharmaceuticals Corporation \| Intangible assets
Business Acquisition [Line Items]
Assets sold on acquisition date, not included in consideration transferred		17,700
Insight Pharmaceuticals Corporation \| Inventory
Business Acquisition [Line Items]
Assets sold on acquisition date, not included in consideration transferred		600
Insight Pharmaceuticals Corporation \| Property, plant and equipment
Business Acquisition [Line Items]
Assets sold on acquisition date, not included in consideration transferred		$ 200
Hydralyte
Business Acquisition [Line Items]
Goodwill									$ 1,224
Intangible assets, net									$ 73,580
Care Pharma
Business Acquisition [Line Items]
Indefinite-lived intangible assets			$ 29,800
Finite-lived intangible assets			$ 1,700
Purchased amortizable intangible assets, weighted average useful life			15 years 1 month 6 days
Finite-lived intangible assets, weighted average remaining period						12 years 5 months 18 days
Goodwill			$ 23,122
Intangible assets, net			$ 31,502

Acquisitions (Allocations) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Feb. 05, 2016	Mar. 31, 2015	Sep. 03, 2014	Apr. 30, 2014	Mar. 31, 2014	Jul. 01, 2013	Mar. 31, 2013
Purchase Price
Goodwill	$ 360,191		$ 290,651			$ 190,911		$ 167,546
DenTek Oral Care, Inc.
Purchase Price
Cash acquired		$ 1,359
Accounts receivable		9,187
Inventories		14,304
Deferred income tax assets		3,303
Prepaids and other current assets		6,728
Property, plant and equipment		3,555
Goodwill		76,529
Intangible assets		206,700
Total assets acquired		321,665
Accounts payable		3,261
Accrued expenses		16,488
Deferred income tax liabilities - long term		73,573
Total liabilities assumed		93,322
Net assets acquired		$ 228,343
Insight Pharmaceuticals Corporation
Purchase Price
Cash acquired				$ 3,507
Accounts receivable				26,012
Inventories				23,456
Deferred income tax assets				1,032
Prepaids and other current assets				1,341
Property, plant and equipment				2,308
Goodwill				96,323
Intangible assets				724,374
Total assets acquired				878,353
Accounts payable				16,079
Accrued expenses				8,539
Deferred income tax liabilities - long term				107,799
Total liabilities assumed				132,417
Net assets acquired				$ 745,936
Hydralyte
Purchase Price
Inventories					$ 1,970
Property, plant and equipment					1,267
Goodwill					1,224
Intangible assets					73,580
Total assets acquired					78,041
Accrued expenses					38
Other long term liabilities					12
Total liabilities assumed					50
Net assets acquired					$ 77,991
Care Pharma
Purchase Price
Cash acquired							$ 1,546
Accounts receivable							1,658
Inventories							2,465
Deferred income tax assets							283
Prepaids and other current assets							647
Property, plant and equipment							163
Goodwill							23,122
Intangible assets							31,502
Total assets acquired							61,386
Accounts payable							1,537
Accrued expenses							2,788
Other long term liabilities							300
Total liabilities assumed							4,625
Net assets acquired							$ 56,761

Acquisitions (Pro Forma) (Details) - Insight Pharmaceuticals Corporation - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Pro Forma Information
Revenues	$ 783,217	$ 767,897
Net income	$ 86,844	$ 82,762
Earnings per share:
Basic (USD per share)	$ 1.66	$ 1.60
Diluted (USD per share)	$ 1.65	$ 1.58

Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 106,853	$ 97,764
Less allowances for discounts, returns and uncollectible accounts	(11,606)	(9,906)
Accounts receivable, net	95,247	87,858
Trade accounts receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	105,592	95,411
Other receivables
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 1,261	$ 2,353

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 7,563	$ 7,588
Finished goods	83,700	66,412
Inventories	91,263	74,000
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 4,800	$ 4,100

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Components of Property and Equipment
Property and equipment, gross	$ 30,361	$ 25,700
Accumulated depreciation	(14,821)	(11,956)
Property and equipment, net	15,540	13,744
Depreciation expense	5,200	3,800	$ 3,200
Machinery
Components of Property and Equipment
Property and equipment, gross	7,734	4,743
Computer equipment
Components of Property and Equipment
Property and equipment, gross	12,793	11,339
Furniture and fixtures
Components of Property and Equipment
Property and equipment, gross	2,445	2,484
Leasehold improvements
Components of Property and Equipment
Property and equipment, gross	$ 7,389	$ 7,134

Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
Goodwill (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Goodwill [Roll Forward]
Goodwill, gross, beginning	$ 485,981	$ 386,241	$ 362,876
Accumulated impairment losses	(195,330)	(195,330)	(195,330)	$ (195,330)
Goodwill, net, beginning	290,651	190,911	167,546
Additions	76,834	104,478	23,122
Reductions	(7,237)	(589)
Effects of foreign currency exchange rates	(57)	(4,149)	(243)
Goodwill, gross, ending	555,521	485,981	386,241
Goodwill, net, ending	360,191	290,651	190,911
North American OTC Healthcare
Goodwill [Roll Forward]
Goodwill, gross, beginning	393,581	290,327	290,327
Accumulated impairment losses	(130,170)	(130,170)	(130,170)	(130,170)
Goodwill, net, beginning	263,411	160,157	160,157
Additions	74,441	103,254	0
Reductions	(7,237)	0
Effects of foreign currency exchange rates	0	0	0
Goodwill, gross, ending	460,785	393,581	290,327
Goodwill, net, ending	330,615	263,411	160,157
International OTC Healthcare
Goodwill [Roll Forward]
Goodwill, gross, beginning	20,440	23,365	0
Accumulated impairment losses	0	0	0	0
Goodwill, net, beginning	20,440	23,365	0
Additions	2,393	1,224	23,122
Reductions	0	0
Effects of foreign currency exchange rates	(57)	(4,149)	(243)
Goodwill, gross, ending	22,776	20,440	23,365
Goodwill, net, ending	22,776	20,440	23,365
Household Cleaning
Goodwill [Roll Forward]
Goodwill, gross, beginning	71,960	72,549	72,549
Accumulated impairment losses	(65,160)	(65,160)	(65,160)	$ (65,160)
Goodwill, net, beginning	6,800	7,389	7,389
Additions	0	0	0
Reductions	0	(589)
Effects of foreign currency exchange rates	0	0	0
Goodwill, gross, ending	71,960	71,960	72,549
Goodwill, net, ending	$ 6,800	$ 6,800	$ 7,389

Goodwill (Narrative) (Details)		1 Months Ended	3 Months Ended					12 Months Ended
Goodwill (Narrative) (Details)	Sep. 03, 2014 USD ($)	Dec. 31, 2014 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2016 USD ($) acquisition unit	Mar. 31, 2015 USD ($) acquisition	Mar. 31, 2014 USD ($)	Feb. 05, 2016 USD ($)	Apr. 30, 2014 USD ($)	Jul. 01, 2013 USD ($)	Mar. 31, 2013 USD ($)
Goodwill [Line Items]
Goodwill				$ 290,651,000				$ 360,191,000	$ 290,651,000	$ 190,911,000				$ 167,546,000
Number of business acquisitions \| acquisition								2	2
Gain on sale of asset				$ 0	$ 1,133,000	$ 0	$ 0	$ 0	$ 1,133,000	$ 0
Goodwill impairment charge								$ 0	$ 0
Reporting unit, fair value in excess of carrying amount (percent)								76.40%
Number of reporting units with fair value exceeding carrying value by less than 10% \| unit								0
Comet Brand
Goodwill [Line Items]
Gain on sale of asset		$ 1,300,000
Care Pharma
Goodwill [Line Items]
Goodwill													$ 23,122,000
Insight Pharmaceuticals Corporation
Goodwill [Line Items]
Goodwill	$ 96,323,000
Goodwill, post-closing inventory and apportionment adjustment	$ (7,200,000)		$ 300,000
Hydralyte
Goodwill [Line Items]
Goodwill												$ 1,224,000
DenTek Oral Care, Inc.
Goodwill [Line Items]
Goodwill											$ 76,529,000

Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning	$ 1,873,404
Indefinite-lived intangibles, ending	2,020,046	$ 1,873,404
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite-lived intangibles, accumulated amortization, beginning	96,770	83,801	$ 73,702
Finite-lived intangibles, accumulated amortization, additions	18,430	12,995	10,256
Finite-lived intangibles, accumulated amortization, reductions			(158)
Finite-lived intangibles, accumulated amortization, effects of foreign currency exchange rates	3	(26)	1
Finite-lived intangibles, accumulated amortization, ending	115,203	96,770	83,801
Intangible Assets, Gross [Abstract]
Intangible assets, gross, beginning	2,231,470	1,478,618	1,446,942
Intangible assets, additions	206,700	797,954	31,502
Intangible assets, reclassifications	0	0
Intangible assets, reductions	0	(27,222)	(158)
Intangible assets, effects of foreign currency exchange rates	(244)	(17,880)	332
Intangible assets, gross, ending	2,437,926	2,231,470	1,478,618
Finite-lived intangible assets	302,677	261,296
Intangible assets, net	2,322,723	2,134,700	1,394,817
North American OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning	1,676,991
Indefinite-lived intangibles, ending	1,823,873	1,676,991
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	277,762	235,642
Intangible assets, net	2,101,635	1,912,633	1,217,139
International OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning	86,141
Indefinite-lived intangibles, ending	85,901	86,141
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	2,237	1,231
Intangible assets, net	88,138	87,372	31,691
Household Cleaning
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning	110,272
Indefinite-lived intangibles, ending	110,272	110,272
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	22,678	24,423
Intangible assets, net	132,950	134,695	145,987
Finite Lived Trademarks and Customer Relationships
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived intangibles, gross, beginning	358,066	204,740	203,066
Finite-lived intangibles, additions	26,900	124,774	1,657
Finite-lived intangibles, reclassifications	32,918	46,506
Finite-lived intangibles, reductions, gross	0	(17,674)	0
Finite-lived intangibles, effects of foreign currency exchange rates	(4)	(280)	17
Finite-lived intangibles, gross, ending	417,880	358,066	204,740
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite-lived intangibles, accumulated amortization, beginning	96,770	83,801	73,544
Finite-lived intangibles, accumulated amortization, additions	18,430	12,995	10,256
Finite-lived intangibles, accumulated amortization, reductions			0
Finite-lived intangibles, accumulated amortization, effects of foreign currency exchange rates	3	(26)	1
Finite-lived intangibles, accumulated amortization, ending	115,203	96,770	83,801
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	302,677	261,296	120,939
Finite Lived Trademarks and Customer Relationships \| North American OTC Healthcare
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	277,762	235,642	93,242
Finite Lived Trademarks and Customer Relationships \| International OTC Healthcare
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	2,237	1,231	1,530
Finite Lived Trademarks and Customer Relationships \| Household Cleaning
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	22,678	24,423	26,167
Noncompete Agreements
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived intangibles, gross, beginning	0	0	158
Finite-lived intangibles, additions	0	0	0
Finite-lived intangibles, reclassifications	0	0
Finite-lived intangibles, reductions, gross	0	0	(158)
Finite-lived intangibles, effects of foreign currency exchange rates	0	0	0
Finite-lived intangibles, gross, ending	0	0	0
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite-lived intangibles, accumulated amortization, beginning	0	0	158
Finite-lived intangibles, accumulated amortization, additions	0	0	0
Finite-lived intangibles, accumulated amortization, reductions			(158)
Finite-lived intangibles, accumulated amortization, effects of foreign currency exchange rates	0	0	0
Finite-lived intangibles, accumulated amortization, ending	0	0	0
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	0	0	0
Noncompete Agreements \| North American OTC Healthcare
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	0		0
Noncompete Agreements \| International OTC Healthcare
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	0		0
Noncompete Agreements \| Household Cleaning
Intangible Assets, Gross [Abstract]
Finite-lived intangible assets	0		0
Indefinite Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning	1,873,404	1,273,878	1,243,718
Indefinite-lived intangibles, additions	179,800	673,180	29,845
Indefinite-lived intangibles, reclassifications	(32,918)	(46,506)
Indefinite-lived intangibles, reductions	0	(9,548)	0
Indefinite-lived intangibles, effects of foreign currency exchange rates	(240)	(17,600)	315
Indefinite-lived intangibles, ending	2,020,046	1,873,404	1,273,878
Indefinite Lived Trademarks \| North American OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning	1,676,991	1,123,897
Indefinite-lived intangibles, ending	1,823,873	1,676,991	1,123,897
Indefinite Lived Trademarks \| International OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning	86,141	30,161
Indefinite-lived intangibles, ending	85,901	86,141	30,161
Indefinite Lived Trademarks \| Household Cleaning
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived intangibles, beginning	110,272	119,820
Indefinite-lived intangibles, ending	$ 110,272	$ 110,272	$ 119,820

Intangible Assets (Narrative) (Details)						1 Months Ended	3 Months Ended							12 Months Ended
Intangible Assets (Narrative) (Details)	Jun. 30, 2016 USD ($)	Feb. 29, 2016 USD ($)	Feb. 05, 2016 USD ($)	Sep. 03, 2014 USD ($) brand	Jul. 01, 2013 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2016 USD ($) acquisition unit brand	Mar. 31, 2015 USD ($) acquisition	Mar. 31, 2014 USD ($)	Apr. 30, 2014 USD ($)
Schedule of Intangible Assets [Line Items]
Intangible assets acquired during period														$ 206,700,000	$ 797,954,000	$ 31,502,000
Number of business acquisitions \| acquisition														2	2
Impairment of intangible assets														$ 0
Reporting unit, fair value in excess of carrying amount (percent)														76.40%
Number of reporting units with fair value exceeding carrying value by less than 10% \| unit														0
Number of indefinite-lived trade names exceeding carrying value by less than 10% \| brand														3
Finite-lived intangible assets, weighted average remaining period														14 years 4 months 24 days
Amortization of intangible assets														$ 18,430,000	$ 12,995,000	10,256,000
Proceeds from sale of asset															10,000,000
Gain on sale of asset										$ 0	$ 1,133,000	$ 0	$ 0	$ 0	1,133,000	$ 0
Minimum
Schedule of Intangible Assets [Line Items]
Intangible assets, useful lives														10 years
Maximum
Schedule of Intangible Assets [Line Items]
Intangible assets, useful lives														30 years
Ecotrin brand
Schedule of Intangible Assets [Line Items]
Intangible assets, useful lives		20 years
Indefinite-lived intangibles, reclassifications		$ 32,900,000
Comet Brand
Schedule of Intangible Assets [Line Items]
Proceeds from sale of asset						$ 10,000,000	$ 1,000,000	$ 1,000,000	$ 1,000,000	$ 1,000,000
Gain on sale of asset						$ 1,300,000
Care Pharma
Schedule of Intangible Assets [Line Items]
Intangible assets acquired during period					$ 31,500,000
Intangible assets acquired					$ 31,502,000
Finite-lived intangible assets, weighted average remaining period														12 years 5 months 18 days
Insight Pharmaceuticals Corporation
Schedule of Intangible Assets [Line Items]
Intangible assets acquired				$ 724,374,000
Number of brands sold \| brand				1
Finite-lived intangible assets, weighted average remaining period														14 years 7 months
Insight Pharmaceuticals Corporation \| One Brand Acquired from Insight Subsequently Sold
Schedule of Intangible Assets [Line Items]
Intangible assets acquired				$ 17,700,000
Hydralyte
Schedule of Intangible Assets [Line Items]
Intangible assets acquired																	$ 73,580,000
DenTek Oral Care, Inc.
Schedule of Intangible Assets [Line Items]
Intangible assets acquired			$ 206,700,000
Finite-lived intangible assets, weighted average remaining period			18 years 5 months 12 days
Indefinite Lived Trademarks
Schedule of Intangible Assets [Line Items]
Reporting unit, fair value in excess of carrying amount (percent)														55.80%
Indefinite-lived intangibles, reclassifications														$ 32,918,000	$ 46,506,000
Beano Brand
Schedule of Intangible Assets [Line Items]
Reporting unit, fair value in excess of carrying amount (percent)														9.00%
Indefinite-lived intangible assets														$ 78,400,000
Fair value input, discount rate														9.50%
Decrease in annual cash flows, percent														(21.60%)
Increase in discount rate														82.00%
New Skin and Debrox Brands
Schedule of Intangible Assets [Line Items]
Fair value input, discount rate														9.50%
New Skin
Schedule of Intangible Assets [Line Items]
Reporting unit, fair value in excess of carrying amount (percent)														8.20%
Indefinite-lived intangible assets														$ 37,200,000
Decrease in annual cash flows, percent														19.60%
Increase in discount rate														73.00%
Debrox
Schedule of Intangible Assets [Line Items]
Reporting unit, fair value in excess of carrying amount (percent)														5.10%
Indefinite-lived intangible assets														$ 76,300,000
Decrease in annual cash flows, percent														12.60%
Increase in discount rate														45.00%
Scenario, Forecast \| Comet Brand
Schedule of Intangible Assets [Line Items]
Proceeds from sale of asset	$ 1,000,000

Intangible Assets (Expected Amortization Expense) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
Intangible Assets, Net (Excluding Goodwill) [Abstract]
2017	$ 21,236
2018	21,072
2019	21,072
2020	21,072
2021	20,650
Thereafter	197,575
Intangible assets, net	$ 302,677	$ 261,296

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
Payables and Accruals [Abstract]
Accrued marketing costs	$ 26,373	$ 16,903
Accrued compensation costs	9,574	8,840
Accrued broker commissions	1,497	1,134
Income taxes payable	3,675	2,642
Accrued professional fees	1,787	2,769
Deferred rent	836	1,021
Accrued production costs	3,324	5,610
Accrued lease termination costs	448	669
Business Combination, Separately Recognized Transactions, Liabilities Recognized	6,354	0
Other accrued liabilities	5,856	1,360
Total other accrued liabilities	$ 59,724	$ 40,948

Long-Term Debt (Narrative 2012 Senior Notes) (Details) - 2012 Senior Notes - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Jan. 31, 2013	Jan. 31, 2012
Debt Instrument [Line Items]
Debt issuance costs capitalized				$ 12,600,000
Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount				$ 250,000,000.0
Debt instrument, stated interest rate		8.125%	8.125%
Long-term debt	$ 0

Long-Term Debt (Narrative 2012 Term Loan and 2012 ABL Revolver) (Details) - USD ($)						3 Months Ended					12 Months Ended			38 Months Ended
	Jun. 09, 2015	May. 08, 2015	Sep. 03, 2014	Feb. 21, 2013	Jan. 31, 2012	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2013	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015
Debt Instrument [Line Items]
Loss on extinguishment of debt						$ 17,519,000	$ 0	$ 0	$ 451,000		$ 17,970,000	$ 0	$ 18,286,000
2012 Term Loan and ABL Revolver
Debt Instrument [Line Items]
Debt issuance costs capitalized					$ 20,600,000
Term Loans \| 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount					$ 660,000,000.0
Debt instrument, term					7 years
Debt instrument, discount, percentage					1.50%
Proceeds from issuance of long-term debt					$ 650,100,000
Term Loans \| 2012 Term Loan, Amendment No. 1
Debt Instrument [Line Items]
Loss on extinguishment of debt										$ 1,400,000
Term Loans \| 2012 Term Loan, Amendment No. 2
Debt Instrument [Line Items]
Debt instrument, reference rate floor			1.00%
Term Loans \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, average interest rate											4.40%
Quarterly payment, percent of original principal amount			0.25%
2012 Term B-1 Loan \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, face amount		$ 207,500,000.0
2012 Term B-2 Loan \| 2012 Term Loan, Amendment No. 2
Debt Instrument [Line Items]
Debt instrument, face amount			$ 720,000,000.0
2012 Term B-2 Loan \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, face amount		645,000,000.0
2012 Term B-3 Loan \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, face amount		$ 852,500,000.0
Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, term					5 years
Line of credit facility, maximum borrowing capacity					$ 50,000,000	135,000,000					$ 135,000,000
Revolving credit facility, increase in borrowing capacity						$ 85,000,000					$ 85,000,000
Debt instrument, interest rate, decrease														0.25%
Line of credit facility, commitment fee percentage					0.50%
Line of credit facility, conditional commitment fee percentage											0.375%
Revolver increase in accordion feature	$ 35,000,000.0
Weighted average interest rate						2.10%					2.10%
Revolving Credit Facility \| 2012 ABL Revolver, Amendment No. 3
Debt Instrument [Line Items]
Revolving credit facility, increase in borrowing capacity			$ 40.0
LIBOR \| Term Loans \| 2012 Term Loan, Amendment No. 1
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)				2.75%
Debt instrument, reference rate floor				1.00%
LIBOR \| Term Loans \| 2012 Term Loan, Amendment No. 2
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)			3.125%
LIBOR \| Term Loans \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component			1.00%
LIBOR \| 2012 Term B-2 Loan \| 2012 Term Loan, Amendment No. 2
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)			3.50%
Debt instrument, reference rate floor			1.00%
LIBOR \| 2012 Term B-3 Loan \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)		2.75%
LIBOR \| Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component			1.00%
Debt instrument, variable rate			1.75%
LIBOR \| Minimum \| Term Loans \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)			0.75%								0.75%	0.75%
LIBOR \| Minimum \| 2012 Term B-3 Loan \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, stated interest rate		0.75%
LIBOR \| Minimum \| Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, conditional variable rate			2.00%
LIBOR \| Maximum \| Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, conditional variable rate			2.25%
Base Rate \| Term Loans \| 2012 Term Loan, Amendment No. 1
Debt Instrument [Line Items]
Debt instrument, reference rate floor				2.00%
Base Rate \| Term Loans \| 2012 Term Loan, Amendment No. 2
Debt Instrument [Line Items]
Debt instrument, reference rate floor			2.00%
Base Rate \| Term Loans \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component			1.75%			1.75%					1.75%	1.75%		1.75%
Base Rate \| 2012 Term B-2 Loan \| 2012 Term Loan, Amendment No. 2
Debt Instrument [Line Items]
Debt instrument, reference rate floor			2.00%
Interest rate, contingent margin step-down per annum (percent)			3.25%
Base Rate \| Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, variable rate			0.75%
Base Rate \| Minimum \| 2012 Term B-3 Loan \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, stated interest rate		1.75%
Base Rate \| Minimum \| Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, conditional variable rate			1.00%
Base Rate \| Maximum \| Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, conditional variable rate			1.25%
Federal Funds Rate \| Term Loans \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component			0.50%
Federal Funds Rate \| Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component			0.50%

Long-Term Debt (Narrative 2013 Senior Notes) (Details) - Senior Notes - 2013 Senior Notes - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Dec. 17, 2013
Debt Instrument [Line Items]
Debt instrument, face amount			$ 400,000,000.0
Debt instrument, stated interest rate	5.375%	5.375%	5.375%
Debt issuance costs capitalized			$ 7,200,000

Long-Term Debt (Narrative 2016 Bridge Term Loans) (Details) - 2016 Bridge Term Loan - USD ($) $ in Millions	Feb. 19, 2016	Feb. 02, 2017	Aug. 05, 2016	Mar. 31, 2016	Feb. 04, 2016
Eurodollar
Short-term Debt [Line Items]
Debt instrument, variable rate					4.75%
Eurodollar \| Scenario, Forecast
Short-term Debt [Line Items]
Debt instrument, variable rate		5.25%	5.00%
Bridge Loan
Short-term Debt [Line Items]
Debt instrument, face amount					$ 80.0
Bridge credit agreement				$ 0.0
Debt issuance costs expensed	$ 1.9
Minimum \| Base Rate
Short-term Debt [Line Items]
Debt instrument, stated interest rate					3.75%
Minimum \| Base Rate \| Scenario, Forecast
Short-term Debt [Line Items]
Debt instrument, stated interest rate		4.25%	4.00%

Long-Term Debt (Narrative 2016 Senior Notes) (Details) - Senior Notes - 2016 Senior Notes - USD ($) $ in Millions	Mar. 31, 2016	Feb. 19, 2016
Debt Instrument [Line Items]
Debt instrument, face amount		$ 350.0
Debt instrument, stated interest rate	6.375%	6.375%
Debt issuance costs capitalized		$ 5.5

Long-Term Debt (Narrative Redemptions and Restrictions) (Details) - USD ($) $ in Thousands		12 Months Ended
	Feb. 19, 2016	Mar. 31, 2016	Mar. 31, 2015
Debt Instrument [Line Items]
Less unamortized debt costs		$ 27,191	$ 32,327
Senior Notes \| 2016 Senior Notes
Debt Instrument [Line Items]
Less unamortized debt costs		$ 5,400
Senior Notes \| 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount		101.00%
Less unamortized debt costs		$ 5,400	6,200
Senior Notes \| 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount	104.063%
Less unamortized debt costs			8,700
Term Loans \| 2012 Term Loan
Debt Instrument [Line Items]
Less unamortized debt costs		16,400	17,400
Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Less unamortized debt costs		1,300	1,200
Repayments of long-term debt		85,000
Revolving credit facility, remaining borrowing capacity		$ 37,900
Long-term Debt \| New Accounting Pronouncement, Early Adoption, Effect
Debt Instrument [Line Items]
Deferred finance costs, net			27,400
Other Long-term Assets \| New Accounting Pronouncement, Early Adoption, Effect
Debt Instrument [Line Items]
Deferred finance costs, net			$ (27,400)
Prior to December 15, 2016 \| Senior Notes \| 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount		100.00%
Debt instrument, redemption price, percentage of principal amount, using proceeds of equity offerings		105.375%
Debt Instrument, Redemption, Period Two \| Senior Notes \| 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount	100.00%
Maximum \| Prior to December 15, 2016 \| Senior Notes \| 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, percentage of principal amount which can be redeemed		35.00%
Maximum \| Debt Instrument, Redemption, Period Two \| Senior Notes \| 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, percentage of principal amount which can be redeemed	40.00%
Indirect Guarantee of Indebtedness [Member] \| Senior Notes \| 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount	101.00%

Long-Term Debt (Schedule of Long-term Debt) (Details) - USD ($) $ in Thousands		12 Months Ended
	Sep. 03, 2014	Mar. 31, 2016	Mar. 31, 2015	Feb. 19, 2016	Dec. 17, 2013	Jan. 31, 2013
Debt Instrument [Line Items]
Long-term debt, gross		$ 1,652,500	$ 1,593,600
Current portion of long-term debt		0	0
Long-term debt, gross, excluding current maturities		1,652,500	1,593,600
Less: unamortized debt costs		(27,191)	(32,327)
Long-term debt, net		$ 1,625,309	1,561,273
Senior Notes \| 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate		6.375%		6.375%
Long-term debt, gross		$ 350,000	$ 0
Less: unamortized debt costs		$ (5,400)
Senior Notes \| 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate		5.375%	5.375%		5.375%
Long-term debt, gross		$ 400,000	$ 400,000
Less: unamortized debt costs		(5,400)	$ (6,200)
Senior Notes \| 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate			8.125%			8.125%
Long-term debt, gross		0	$ 250,000
Less: unamortized debt costs			(8,700)
Term Loans \| 2012 Term B-1 Loan
Debt Instrument [Line Items]
Long-term debt, gross		817,500	877,500
Revolving Credit Facility \| 2012 ABL Revolver
Debt Instrument [Line Items]
Long-term debt, gross		$ 85,000	$ 66,100
Base Rate \| Term Loans \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component	1.75%	1.75%	1.75%
LIBOR \| Term Loans \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component	1.00%
Minimum \| LIBOR \| Term Loans \| 2012 Term Loan, Amendment No. 3
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)	0.75%	0.75%	0.75%

Long-Term Debt (Maturities of Long-term Debt) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
Debt Disclosure [Abstract]
2017	$ 0
2018	0
2019	0
2020	5,494
2021	93,525
Thereafter	1,553,481
Aggregate future principal payments	$ 1,652,500	$ 1,593,600

Fair Value Measurements (Details) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Senior Notes \| 2016 Senior Notes \| Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	$ 350,000,000	$ 0
Senior Notes \| 2016 Senior Notes \| Fair value \| Fair Value, Measurements, Nonrecurring \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	363,125,000	0
Senior Notes \| 2013 Senior Notes \| Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	400,000,000	400,000,000
Senior Notes \| 2013 Senior Notes \| Fair value \| Fair Value, Measurements, Nonrecurring \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	408,000,000	405,000,000
Senior Notes \| 2012 Senior Notes \| Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	0	250,000,000
Senior Notes \| 2012 Senior Notes \| Fair value \| Fair Value, Measurements, Nonrecurring \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	0	268,100,000
Term Loans \| 2012 Term Loan \| Carrying value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	817,500,000	877,500,000
Term Loans \| 2012 Term Loan \| Fair value \| Fair Value, Measurements, Nonrecurring \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	818,522,000	880,500,000
Revolving Credit Facility \| 2012 ABL Revolver
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Line of credit, fair value disclosure	85,000,000	66,100,000
Revolving Credit Facility \| 2012 ABL Revolver \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Line of credit, fair value disclosure	$ 85,000,000	$ 65,700,000

Stockholders' Equity (Details)	12 Months Ended
Stockholders' Equity (Details)	Mar. 31, 2016 USD ($) vote / shares $ / shares shares	Mar. 31, 2015 $ / shares shares
Class of Stock [Line Items]
Common stock, shares authorized \| shares	250,000,000	250,000,000
Common stock, par value (in USD per share) \| $ / shares	$ 0.01	$ 0.01
Preferred stock, shares authorized \| shares	5,000,000	5,000,000
Preferred stock, par value (in USD per share) \| $ / shares	$ 0.01	$ 0.01
Voting rights, number of votes per common share owned \| vote / shares	1
Dividends declared on common stock \| $	$ 0
Dividends paid on common stock \| $	$ 0
Restricted Shares
Class of Stock [Line Items]
Restricted stock repurchased during period, shares \| shares	40,316	59,933
Restricted stock acquired, average cost per share \| $ / shares	$ 41.80	$ 34.16

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Numerator
Net income	$ 13,936	$ 27,995	$ 31,803	$ 26,173	$ 23,772	$ 21,293	$ 16,463	$ 16,732	$ 99,907	$ 78,260	$ 72,615
Denominator
Denominator for basic earnings per share- weighted average shares (in shares)	52,833	52,824	52,803	52,548	52,356	52,278	52,088	51,956	52,754	52,170	51,641
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors (in shares)									389	500	708
Denominator for diluted earnings per share (in shares)	53,252	53,203	53,151	52,958	52,821	52,730	52,594	52,533	53,143	52,670	52,349
Earnings per Common Share:
Basic net earnings per share (in USD per share)	$ 0.26	$ 0.53	$ 0.60	$ 0.50	$ 0.45	$ 0.41	$ 0.32	$ 0.32	$ 1.89	$ 1.50	$ 1.41
Diluted net earnings per share (in USD per share)	$ 0.26	$ 0.53	$ 0.60	$ 0.49	$ 0.45	$ 0.40	$ 0.31	$ 0.32	$ 1.88	$ 1.49	$ 1.39

Earnings Per Share (Antidilutive Securities) (Details) - shares	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	100,000.0	300,000.0	200,000.0

Share-Based Compensation (Narrative) (Details) $ / shares in Units, $ in Thousands								1 Months Ended	12 Months Ended
	Oct. 28, 2015 $ / shares shares	Aug. 04, 2015 shares	Jul. 01, 2015 $ / shares shares	Jun. 01, 2015 USD ($)	May. 11, 2015 $ / shares shares	Apr. 22, 2015 shares	May. 31, 2014 shares	Jun. 30, 2014 shares	Mar. 31, 2016 USD ($) $ / shares shares	Mar. 31, 2015 USD ($) $ / shares shares	Mar. 31, 2014 USD ($) $ / shares shares	Aug. 04, 2014 director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation costs charged against income \| $									$ 9,954	$ 6,918	$ 5,146
Tax benefit recognized from share-based compensation expense \| $									$ 3,500	$ 1,900	$ 1,500
Restricted Shares
Options granted, shares									208,200	317,900	227,700
Options granted, weighted-average exercise price (in USD per share) \| $ / shares									$ 42.13	$ 33.54	$ 29.94
Number of directors, board of directors \| director												6
Options
Options exercised, intrinsic value \| $									$ 8,600	$ 9,300	$ 14,000
Share-based compensation expense, not yet recognized \| $									$ 10,100
Share-based compensation expense, not yet recognized, period for recognition									12 months 12 days
Fair value of awards vested during period \| $									$ 7,000	4,700	3,400
Proceeds from exercise of stock awards \| $									6,689	3,954	5,907
Income tax benefit realized from exercise of stock awards \| $									$ 2,100	$ 2,200	$ 1,700
President and Chief Executive Officer
Restricted Shares
Accelerated stock-based compensation cost \| $				$ 800
Restricted common stock units granted in period, shares						57,924
Restricted Stock Units (RSUs)
Restricted Shares
Restricted common stock units granted in period, shares		2,075	2,841		185,904
Award vesting period		1 year	3 years
Period following director's term In which stock awards may be settled		6 months
Granted, weighted-average grant-date fair value (in USD per share) \| $ / shares									$ 42.41	$ 33.33	$ 30.19
Restricted Stock Units (RSUs) \| Tranche 1
Restricted Shares
Restricted common stock units granted in period, shares					163,404
Award vesting period					3 years
Restricted Stock Units (RSUs) \| Tranche 2
Restricted Shares
Restricted common stock units granted in period, shares					22,500
Award vesting period					3 years
Award vesting rights, percentage					33.30%
Restricted Stock Units (RSUs) \| Chief Financial Officer
Restricted Shares
Restricted common stock units granted in period, shares	6,612
Award vesting period	3 years
Restricted Stock Units (RSUs) \| Employee
Restricted Shares
Award vesting period									3 years
Restricted Stock Units (RSUs) \| Director
Restricted Shares
Restricted common stock units granted in period, shares					362
Award vesting period									1 year
Award settlement period									6 months
Restricted stock units, number of securities into which each RSU may be converted		1
Stock Options
Restricted Shares
Restricted common stock units granted in period, shares			13,861
Options granted, shares					186,302
Award vesting period			3 years		3 years
Award vesting rights, percentage			33.30%		33.30%
Expiration period			10 years
Options granted, weighted-average exercise price (in USD per share) \| $ / shares			$ 46.58		$ 41.44
Granted, weighted-average grant-date fair value (in USD per share) \| $ / shares									$ 17.24	$ 15.95	$ 13.94
Stock Options \| Chief Financial Officer
Restricted Shares
Options granted, shares	8,079
Award vesting period	3 years
Award vesting rights, percentage	33.30%
Expiration period	10 years
Options granted, weighted-average exercise price (in USD per share) \| $ / shares	$ 50.42
Stock Options \| Minimum
Restricted Shares
Award vesting period									3 years
Stock Options \| Maximum
Restricted Shares
Award vesting period					10 years				5 years
Options
Award exercisability period, from date of grant (not greater than)									10 years
Restricted Shares
Restricted Shares
Restricted common stock units granted in period, shares									266,100	106,900	126,600
Granted, weighted-average grant-date fair value (in USD per share) \| $ / shares									$ 42.41	$ 33.33	$ 30.19
Restricted Shares \| Minimum
Restricted Shares
Award vesting period									3 years
Restricted Shares \| Maximum
Restricted Shares
Award vesting period									5 years
2005 Long-term Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for grant									5,000,000.0
Number of additional shares authorized under plan								1,800,000.0
Maximum number of shares awarded, per employee, annual							1,000,000	2,500,000.0
Increase to plan term								10 years
Options
Number of shares available for issuance under plan									2,600,000

Share-Based Compensation (Restricted Shares Activity) (Details) - Restricted Shares - $ / shares	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Shares
Outstanding, beginning of period (in shares)	362,300	437,500	421,300
Granted (in shares)	266,100	106,900	126,600
Vested and issued (in shares)	(155,600)	(154,400)	(104,800)
Forfeited (in shares)	(5,000)	(27,700)	(5,600)
Outstanding, end of period (in shares)	467,800	362,300	437,500
Vested, end of period (in shares)	69,800	76,600	69,600
Weighted-Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)	$ 22.74	$ 16.76	$ 11.01
Granted, weighted-average grant-date fair value (in USD per share)	42.41	33.33	30.19
Vested, weighted-average grant-date fair value (in USD per share)	18.31	13.37	9.98
Forfeited, weighted-average grant-date fair value (in USD per share)	39.61	21.45	15.11
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)	35.22	22.74	16.76
Vested, end of period, weighted-average grant-date fair value (in USD per share)	$ 14.76	$ 11.62	$ 9.34

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) - Stock Options - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	40.20%	47.30%	48.00%
Expected dividends	$ 0	$ 0	$ 0
Expected term in years	6 years	6 years	6 years
Risk-free rate	1.70%	2.20%	1.30%

Share-Based Compensation (Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Shares
Outstanding, beginning of period (in shares)	871,200	994,900	1,386,400
Granted (in shares)	208,200	317,900	227,700
Exercised (in shares)	(348,000)	(386,300)	(605,000)
Forfeited or expired (in shares)	(3,700)	(55,300)	(14,200)
Outstanding, end of period (in shares)	727,700	871,200	994,900
Exercisable, end of period (in shares)	308,400
Weighted-Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 23.40	$ 15.24	$ 10.43
Options, grant date fair value (in USD per share)	42.13	33.54	29.94
Exercised, weighted-average exercise price (in USD per share)	19.22	10.24	9.76
Forfeited or expired, weighted-average exercise price (in USD per share)	35.72	26.77	14.56
Outstanding, end of period, weighted-average exercise price (in USD per share)	30.70	$ 23.40	$ 15.24
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 21.75
Options
Outstanding, end of period, weighted-average remaining contractual term	7 years 7 months 6 days
Exercisable, end of period, weighted-average remaining contractual term	6 years 6 months
Outstanding, end of period, aggregate intrinsic value	$ 16,512
Exercisable, end of period, aggregate intrinsic value	$ 9,756

Accumulated Other Comprehensive Income (Loss) (Components of AOCI) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of Accumulated Other Comprehensive Loss	$ 744,336	$ 627,624	$ 563,360	$ 477,943
Cumulative Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of Accumulated Other Comprehensive Loss	(23,525)	(23,412)
Accumulated Other Comprehensive (Loss) Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Components of Accumulated Other Comprehensive Loss	$ (23,525)	$ (23,412)	$ 739	$ (104)

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 32,000
Net operating loss carryforwards, tax effected	12,350	$ 23,800
Operating loss carryforwards, limitation on use, annual amount	33,000
Unrecognized tax benefits	$ 4,084	$ 3,420	$ 1,236	$ 1,016
Effective income tax rate, change in enacted tax rate	2.60%	2.70%	1.20%
Earnings U.S income taxes not provided by	$ 27,800
Uncertain tax liability	2,200
Subsidiaries
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards, tax effected	$ 11,200

Income Taxes (Income Before Continuing Operations) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Income from Continuing Operations before Income Taxes:
United States									$ 142,253	$ 122,588	$ 98,786
Foreign									14,932	4,870	2,962
Income before income taxes	$ 24,603	$ 43,181	$ 49,231	$ 40,170	$ 37,449	$ 33,534	$ 28,325	$ 28,150	$ 157,185	$ 127,458	$ 101,748

Income Taxes (Components of Provision for Income Taxes) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Current
Federal									$ 6,080	$ 13,066	$ 7,801
State									1,171	760	625
Foreign									3,905	3,228	1,675
Deferred
Federal									44,787	31,012	27,045
State									1,678	1,162	(7,879)
Foreign									(343)	(30)	(134)
Total provision for income taxes	$ 10,667	$ 15,186	$ 17,428	$ 13,997	$ 13,677	$ 12,241	$ 11,862	$ 11,418	$ 57,278	$ 49,198	$ 29,133

Income Taxes (Components of Deferred Tax Balances) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
Deferred Tax Assets
Allowance for doubtful accounts and sales returns	$ 5,083	$ 4,106
Inventory capitalization	1,838	1,550
Inventory reserves	1,367	1,495
Net operating loss carryforwards	12,350	23,800
State income taxes	10,293	7,557
Accrued liabilities	2,162	619
Stock compensation	4,411	3,517
Other	300	834
Total deferred tax assets	37,804	43,478
Deferred Tax Liabilities
Property and equipment	(833)	(1,143)
Intangible assets	(496,485)	(385,807)
Total deferred tax liabilities	(497,318)	(386,950)
Net deferred tax liability	$ (459,514)	$ (343,472)

Income Taxes (Reconciliation of Effective Tax Rate) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Income Tax Disclosure [Abstract]
Income tax provision at statutory rate	$ 55,015	$ 44,610	$ 35,612
Income tax provision at statutory rate, percentage	35.00%	35.00%	35.00%
Foreign tax benefit	$ (2,894)	$ (2,019)	$ (918)
Foreign tax benefit provision, percentage	(1.80%)	(1.60%)	(0.90%)
State income taxes, net of federal income tax benefit	$ 3,284	$ 2,865	$ 2,004
State income taxes, net of federal income tax benefit, percentage	2.00%	2.30%	2.00%
Decrease in net deferred tax liability resulting from a change in the effective state tax rate	$ 0	$ 0	$ (8,892)
Decrease in net deferred tax liability resulting from a change in the effective state tax rate, percentage	0.00%	0.00%	(8.70%)
Goodwill adjustment for sale of asset	$ 0	$ 206	$ 0
Goodwill adjustment for sale of asset, percentage	0.00%	0.20%	0.00%
Nondeductible transaction costs	$ 1,071	$ 2,936	$ 0
Transaction costs, percentage	0.70%	2.30%	0.00%
Nondeductible compensation	$ 758	$ 566	$ 1,011
Nondeductible compensation, percentage	0.50%	0.40%	1.00%
Other	$ 44	$ 34	$ 316
Other, percentage	0.00%	0.00%	0.30%
Total provision for income taxes	$ 57,278	$ 49,198	$ 29,133
Total provision for income taxes, percentage	36.40%	38.60%	28.70%

Income Taxes (Uncertain Tax Liability Activity) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance – beginning of year	$ 3,420	$ 1,236	$ 1,016
Additions based on tax positions related to the current year	664	2,229	360
Reductions based on lapse of statute of limitations	0	(45)	(140)
Balance – end of year	$ 4,084	$ 3,420	$ 1,236

Commitments and Contingencies (Future Minimum Rental Payments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Operating Leased Assets [Line Items]
2017	$ 2,000
2018	1,934
2019	1,926
2020	1,757
2021	817
Total future minimum payments due	8,434	$ 9,957
Less: Sublease rentals	(1,165)	(1,401)
Minimum lease payments, net of sublease rentals	7,269	8,556
Operating leases, rent expense	1,800	$ 1,600	$ 1,500
Office Facilities
Operating Leased Assets [Line Items]
2017	1,923
2018	1,934
2019	1,926
2020	1,757
2021	817
Total future minimum payments due	8,357
Equipment
Operating Leased Assets [Line Items]
2017	77
2018	0
2019	0
2020	0
2021	0
Total future minimum payments due	$ 77

Commitments and Contingencies (Long-term Supply Agreement) (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2016 USD ($)
Long-term Purchase Commitment [Line Items]
2017	$ 1,044
2018	1,013
2019	982
2020	560
2021	0
Thereafter	0
Total purchase commitment	$ 3,599
Third-party Manufacturing
Long-term Purchase Commitment [Line Items]
Supply agreement, term	10 years

Concentrations of Risk (Details)	12 Months Ended
Concentrations of Risk (Details)	Mar. 31, 2016 brand manufacturer customer	Mar. 31, 2015 manufacturer customer	Mar. 31, 2014 customer
Concentration Risk [Line Items]
Number of third-party manufacturers \| manufacturer	119
Sales \| Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	41.90%	38.20%	38.30%
Number of highest selling brands comprising group against which concentration risk is measured \| brand	5
Sales \| Customer Concentration Risk
Concentration Risk [Line Items]
Number of customers exceeding concentration risk benchmark \| customer		1	1
Sales \| Customer Concentration Risk \| Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	20.20%	18.10%	19.50%
Number of customers exceeding concentration risk benchmark \| customer	1
Sales \| Customer Concentration Risk \| Next largest customer
Concentration Risk [Line Items]
Concentration risk, percentage	9.60%
Sales \| Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	79.90%	82.90%
Number of third-party manufacturers with long-term contracts \| manufacturer	55	44
Accounts Receivable \| Customer Concentration Risk \| Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	24.70%
Accounts Receivable \| Customer Concentration Risk \| Walgreens
Concentration Risk [Line Items]
Concentration risk, percentage	10.40%

Business Segments (Information on Operating and Reportable Segments) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information, Profit (Loss):
Revenues									$ 803,088	$ 710,070	$ 592,454
Other revenues									3,159	4,553	4,927
Total revenues	$ 207,855	$ 200,195	$ 206,065	$ 192,132	$ 190,046	$ 197,606	$ 181,269	$ 145,702	806,247	714,623	597,381
Cost of sales	89,604	83,411	86,125	79,896	79,976	85,861	78,727	63,836	339,036	308,400	261,830
Gross profit	118,251	116,784	119,940	112,236	110,070	111,745	102,542	81,866	467,211	406,223	335,551
Advertising and promotion	26,552	29,935	27,893	26,422	25,367	30,144	25,044	19,096	110,802	99,651	84,968
Contribution margin									356,409	306,572	250,583
Other operating expenses									96,094	99,013	61,967
Operating income	65,269	62,643	69,898	62,505	61,245	56,993	46,518	42,803	260,315	207,559	188,616
Other expense									103,130	80,101	86,868
Income before income taxes	24,603	43,181	49,231	40,170	37,449	33,534	28,325	28,150	157,185	127,458	101,748
Provision for income taxes	10,667	15,186	17,428	13,997	13,677	12,241	11,862	11,418	57,278	49,198	29,133
Net income	$ 13,936	$ 27,995	$ 31,803	$ 26,173	$ 23,772	$ 21,293	$ 16,463	$ 16,732	99,907	78,260	72,615
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Revenues									657,857	566,256	482,138
Other revenues									14	637	749
Total revenues									657,871	566,893	482,887
Cost of sales									250,018	216,781	184,796
Gross profit									407,853	350,112	298,091
Advertising and promotion									97,393	86,897	77,083
Contribution margin									310,460	263,215	221,008
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Revenues									57,670	57,729	26,687
Other revenues									43	64	42
Total revenues									57,713	57,793	26,729
Cost of sales									21,676	22,820	12,646
Gross profit									36,037	34,973	14,083
Advertising and promotion									11,114	10,922	5,264
Contribution margin									24,923	24,051	8,819
Household Cleaning
Segment Reporting Information, Profit (Loss):
Revenues									87,561	86,085	83,629
Other revenues									3,102	3,852	4,136
Total revenues									90,663	89,937	87,765
Cost of sales									67,342	68,799	64,388
Gross profit									23,321	21,138	23,377
Advertising and promotion									2,295	1,832	2,621
Contribution margin									21,026	19,306	20,756
Operating Segments
Segment Reporting Information, Profit (Loss):
Revenues									805,749	713,457	595,639
Operating Segments \| North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Revenues									660,518	569,643	485,323
Operating Segments \| International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Revenues									57,670	57,729	26,687
Operating Segments \| Household Cleaning
Segment Reporting Information, Profit (Loss):
Revenues									87,561	86,085	83,629
Intersegment Eliminations
Segment Reporting Information, Profit (Loss):
Revenues									(2,661)	(3,387)	(3,185)
Intersegment Eliminations \| North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Revenues									(2,661)	(3,387)	(3,185)
Intersegment Eliminations \| International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Revenues									0	0	0
Intersegment Eliminations \| Household Cleaning
Segment Reporting Information, Profit (Loss):
Revenues									$ 0	$ 0	$ 0

Business Segments (Revenue by Product) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Revenue from External Customer [Line Items]
Total revenues	$ 207,855	$ 200,195	$ 206,065	$ 192,132	$ 190,046	$ 197,606	$ 181,269	$ 145,702	$ 806,247	$ 714,623	$ 597,381
Analgesics
Revenue from External Customer [Line Items]
Total revenues									119,465	114,551	109,984
Cough & Cold
Revenue from External Customer [Line Items]
Total revenues									116,570	121,766	113,425
Women's Health
Revenue from External Customer [Line Items]
Total revenues									135,166	73,767	3,795
Gastrointestinal
Revenue from External Customer [Line Items]
Total revenues									94,587	96,968	82,307
Eye & Ear Care
Revenue from External Customer [Line Items]
Total revenues									107,498	97,925	85,491
Dermatologicals
Revenue from External Customer [Line Items]
Total revenues									85,074	67,095	58,091
Oral Care
Revenue from External Customer [Line Items]
Total revenues									51,125	46,399	48,313
Other OTC
Revenue from External Customer [Line Items]
Total revenues									6,099	6,215	8,210
Household Cleaning
Revenue from External Customer [Line Items]
Total revenues									90,663	89,937	87,765
North American OTC Healthcare
Revenue from External Customer [Line Items]
Total revenues									657,871	566,893	482,887
North American OTC Healthcare \| Analgesics
Revenue from External Customer [Line Items]
Total revenues									117,337	111,954	108,101
North American OTC Healthcare \| Cough & Cold
Revenue from External Customer [Line Items]
Total revenues									100,148	103,686	100,060
North American OTC Healthcare \| Women's Health
Revenue from External Customer [Line Items]
Total revenues									132,184	71,506	1,960
North American OTC Healthcare \| Gastrointestinal
Revenue from External Customer [Line Items]
Total revenues									74,568	77,596	81,469
North American OTC Healthcare \| Eye & Ear Care
Revenue from External Customer [Line Items]
Total revenues									95,515	85,236	78,753
North American OTC Healthcare \| Dermatologicals
Revenue from External Customer [Line Items]
Total revenues									82,941	64,806	56,436
North American OTC Healthcare \| Oral Care
Revenue from External Customer [Line Items]
Total revenues									49,099	45,916	47,900
North American OTC Healthcare \| Other OTC
Revenue from External Customer [Line Items]
Total revenues									6,079	6,193	8,208
North American OTC Healthcare \| Household Cleaning
Revenue from External Customer [Line Items]
Total revenues									0	0	0
International OTC Healthcare
Revenue from External Customer [Line Items]
Total revenues									57,713	57,793	26,729
International OTC Healthcare \| Analgesics
Revenue from External Customer [Line Items]
Total revenues									2,128	2,597	1,883
International OTC Healthcare \| Cough & Cold
Revenue from External Customer [Line Items]
Total revenues									16,422	18,080	13,365
International OTC Healthcare \| Women's Health
Revenue from External Customer [Line Items]
Total revenues									2,982	2,261	1,835
International OTC Healthcare \| Gastrointestinal
Revenue from External Customer [Line Items]
Total revenues									20,019	19,372	838
International OTC Healthcare \| Eye & Ear Care
Revenue from External Customer [Line Items]
Total revenues									11,983	12,689	6,738
International OTC Healthcare \| Dermatologicals
Revenue from External Customer [Line Items]
Total revenues									2,133	2,289	1,655
International OTC Healthcare \| Oral Care
Revenue from External Customer [Line Items]
Total revenues									2,026	483	413
International OTC Healthcare \| Other OTC
Revenue from External Customer [Line Items]
Total revenues									20	22	2
International OTC Healthcare \| Household Cleaning
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning
Revenue from External Customer [Line Items]
Total revenues									90,663	89,937	87,765
Household Cleaning \| Analgesics
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Cough & Cold
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Women's Health
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Gastrointestinal
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Eye & Ear Care
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Dermatologicals
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Oral Care
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Other OTC
Revenue from External Customer [Line Items]
Total revenues									0	0	0
Household Cleaning \| Household Cleaning
Revenue from External Customer [Line Items]
Total revenues									$ 90,663	$ 89,937	$ 87,765

Business Segments (Narrative) (Details) - Geographic Concentration Risk	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Sales \| UNITED STATES
Concentration Risk [Line Items]
Concentration risk, percentage	87.40%	85.20%	86.90%
Sales \| CANADA
Concentration Risk [Line Items]
Concentration risk, percentage	5.20%	5.90%	7.70%
Sales \| AUSTRALIA
Concentration Risk [Line Items]
Concentration risk, percentage	5.60%	6.90%	3.00%
Goodwill and Intangible Assets \| UNITED STATES
Concentration Risk [Line Items]
Concentration risk, percentage	95.90%	95.60%
Goodwill and Intangible Assets \| AUSTRALIA
Concentration Risk [Line Items]
Concentration risk, percentage	4.10%	4.40%

Business Segments (Assets by Segment) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 360,191	$ 290,651	$ 190,911	$ 167,546
Indefinite-lived intangible assets	2,020,046	1,873,404
Finite-lived intangible assets	302,677	261,296
Intangible assets, net (excluding goodwill)	2,322,723	2,134,700	1,394,817
Intangible assets, net (including goodwill)	2,682,914	2,425,351
North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	330,615	263,411	160,157	160,157
Indefinite-lived intangible assets	1,823,873	1,676,991
Finite-lived intangible assets	277,762	235,642
Intangible assets, net (excluding goodwill)	2,101,635	1,912,633	1,217,139
Intangible assets, net (including goodwill)	2,432,250	2,176,044
International OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	22,776	20,440	23,365	0
Indefinite-lived intangible assets	85,901	86,141
Finite-lived intangible assets	2,237	1,231
Intangible assets, net (excluding goodwill)	88,138	87,372	31,691
Intangible assets, net (including goodwill)	110,914	107,812
Household Cleaning
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	6,800	6,800	7,389	$ 7,389
Indefinite-lived intangible assets	110,272	110,272
Finite-lived intangible assets	22,678	24,423
Intangible assets, net (excluding goodwill)	132,950	134,695	$ 145,987
Intangible assets, net (including goodwill)	$ 139,750	$ 141,495

Unaudited Quarterly Financial Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Total revenues	$ 207,855	$ 200,195	$ 206,065	$ 192,132	$ 190,046	$ 197,606	$ 181,269	$ 145,702	$ 806,247	$ 714,623	$ 597,381
Cost of sales (exclusive of depreciation shown below)	89,604	83,411	86,125	79,896	79,976	85,861	78,727	63,836	339,036	308,400	261,830
Gross profit	118,251	116,784	119,940	112,236	110,070	111,745	102,542	81,866	467,211	406,223	335,551
Operating Expenses
Advertising and promotion	26,552	29,935	27,893	26,422	25,367	30,144	25,044	19,096	110,802	99,651	84,968
General and administrative	20,232	18,135	16,462	17,589	17,685	19,454	27,128	17,006	72,418	81,273	48,481
Depreciation and amortization	6,198	6,071	5,687	5,720	5,773	5,154	3,852	2,961	23,676	17,740	13,486
Total operating expenses	52,982	54,141	50,042	49,731	48,825	54,752	56,024	39,063	206,896	198,664	146,935
Operating income	65,269	62,643	69,898	62,505	61,245	56,993	46,518	42,803	260,315	207,559	188,616
Net interest expense	23,147	19,462	20,667	21,884	23,796	24,592	18,193	14,653
Gain on sale of asset					0	(1,133)	0	0	0	(1,133)	0
Loss on extinguishment of debt	17,519	0	0	451					17,970	0	18,286
Income before income taxes	24,603	43,181	49,231	40,170	37,449	33,534	28,325	28,150	157,185	127,458	101,748
Provision for income taxes	10,667	15,186	17,428	13,997	13,677	12,241	11,862	11,418	57,278	49,198	29,133
Net income	$ 13,936	$ 27,995	$ 31,803	$ 26,173	$ 23,772	$ 21,293	$ 16,463	$ 16,732	$ 99,907	$ 78,260	$ 72,615
Earnings per share:
Basic (in USD per share)	$ 0.26	$ 0.53	$ 0.60	$ 0.50	$ 0.45	$ 0.41	$ 0.32	$ 0.32	$ 1.89	$ 1.50	$ 1.41
Diluted (in USD per share)	$ 0.26	$ 0.53	$ 0.60	$ 0.49	$ 0.45	$ 0.40	$ 0.31	$ 0.32	$ 1.88	$ 1.49	$ 1.39
Weighted average shares outstanding:
Basic (in shares)	52,833	52,824	52,803	52,548	52,356	52,278	52,088	51,956	52,754	52,170	51,641
Diluted (in shares)	53,252	53,203	53,151	52,958	52,821	52,730	52,594	52,533	53,143	52,670	52,349
Comprehensive income, net of tax:
Currency translation adjustments	$ 6,449	$ 4,922	$ (11,079)	$ (405)	$ (7,268)	$ (8,779)	$ (10,830)	$ 2,726	$ (113)	$ (24,151)	$ 843
Total other comprehensive income (loss)	6,449	4,922	(11,079)	(405)	(7,268)	(8,779)	(10,830)	2,726	(113)	(24,151)	843
Comprehensive income	$ 20,385	$ 32,917	$ 20,724	$ 25,768	$ 16,504	$ 12,514	$ 5,633	$ 19,458	$ 99,794	$ 54,109	$ 73,458

Condensed Consolidating Financial Statements (Condensed Consolidating Statements of Income and Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Revenues
Net sales									$ 803,088	$ 710,070	$ 592,454
Other revenues									3,159	4,553	4,927
Total revenues	$ 207,855	$ 200,195	$ 206,065	$ 192,132	$ 190,046	$ 197,606	$ 181,269	$ 145,702	806,247	714,623	597,381
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	89,604	83,411	86,125	79,896	79,976	85,861	78,727	63,836	339,036	308,400	261,830
Gross profit	118,251	116,784	119,940	112,236	110,070	111,745	102,542	81,866	467,211	406,223	335,551
Operating Expenses
Advertising and promotion	26,552	29,935	27,893	26,422	25,367	30,144	25,044	19,096	110,802	99,651	84,968
General and administrative	20,232	18,135	16,462	17,589	17,685	19,454	27,128	17,006	72,418	81,273	48,481
Depreciation and amortization	6,198	6,071	5,687	5,720	5,773	5,154	3,852	2,961	23,676	17,740	13,486
Total operating expenses	52,982	54,141	50,042	49,731	48,825	54,752	56,024	39,063	206,896	198,664	146,935
Operating income	65,269	62,643	69,898	62,505	61,245	56,993	46,518	42,803	260,315	207,559	188,616
Other (income) expense
Interest income									(162)	(92)	(60)
Interest expense									85,322	81,326	68,642
Gain on sale of asset					0	1,133	0	0	0	1,133	0
Loss on extinguishment of debt	17,519	0	0	451					17,970	0	18,286
Equity in (income) loss of subsidiaries									0	0	0
Total other (income) expense									103,130	80,101	86,868
Income before income taxes	24,603	43,181	49,231	40,170	37,449	33,534	28,325	28,150	157,185	127,458	101,748
Provision for income taxes	10,667	15,186	17,428	13,997	13,677	12,241	11,862	11,418	57,278	49,198	29,133
Net income (loss)	13,936	27,995	31,803	26,173	23,772	21,293	16,463	16,732	99,907	78,260	72,615
Comprehensive income, net of tax:
Currency translation adjustments	6,449	4,922	(11,079)	(405)	(7,268)	(8,779)	(10,830)	2,726	(113)	(24,151)	843
Total other comprehensive income (loss)	6,449	4,922	(11,079)	(405)	(7,268)	(8,779)	(10,830)	2,726	(113)	(24,151)	843
Comprehensive income	$ 20,385	$ 32,917	$ 20,724	$ 25,768	$ 16,504	$ 12,514	$ 5,633	$ 19,458	99,794	54,109	73,458
Prestige Brands Holdings, Inc.
Revenues
Net sales									0	0	0
Other revenues									0	0	0
Total revenues									0	0	0
Cost of Sales
Cost of sales (exclusive of depreciation shown below)									0	0	0
Gross profit									0	0	0
Operating Expenses
Advertising and promotion									0	0	0
General and administrative									5,737	4,571	3,140
Depreciation and amortization									4,050	3,381	2,994
Total operating expenses									9,787	7,952	6,134
Operating income									(9,787)	(7,952)	(6,134)
Other (income) expense
Interest income									(48,342)	(48,543)	(48,730)
Interest expense									34,553	34,198	34,436
Gain on sale of asset										0
Loss on extinguishment of debt									0		0
Equity in (income) loss of subsidiaries									(98,803)	(76,383)	(66,739)
Total other (income) expense									(112,592)	(90,728)	(81,033)
Income before income taxes									102,805	82,776	74,899
Provision for income taxes									2,898	4,516	2,284
Net income (loss)									99,907	78,260	72,615
Comprehensive income, net of tax:
Currency translation adjustments									(113)	(24,151)	843
Total other comprehensive income (loss)									(113)	(24,151)	843
Comprehensive income									99,794	54,109	73,458
Prestige Brands, Inc., the issuer
Revenues
Net sales									111,747	106,439	97,509
Other revenues									347	385	295
Total revenues									112,094	106,824	97,804
Cost of Sales
Cost of sales (exclusive of depreciation shown below)									45,763	39,637	37,272
Gross profit									66,331	67,187	60,532
Operating Expenses
Advertising and promotion									9,465	8,828	10,223
General and administrative									9,098	9,090	8,026
Depreciation and amortization									594	592	577
Total operating expenses									19,157	18,510	18,826
Operating income									47,174	48,677	41,706
Other (income) expense
Interest income									(85,882)	(73,755)	(57,446)
Interest expense									84,822	81,326	68,642
Gain on sale of asset										0
Loss on extinguishment of debt									17,970		18,286
Equity in (income) loss of subsidiaries									(70,953)	(51,573)	(53,836)
Total other (income) expense									(54,043)	(44,002)	(24,354)
Income before income taxes									101,217	92,679	66,060
Provision for income taxes									11,016	14,798	3,500
Net income (loss)									90,201	77,881	62,560
Comprehensive income, net of tax:
Currency translation adjustments									(113)	(24,151)	843
Total other comprehensive income (loss)									(113)	(24,151)	843
Comprehensive income									90,088	53,730	63,403
Combined Subsidiary Guarantors
Revenues
Net sales									643,330	555,388	474,338
Other revenues									3,116	4,452	4,886
Total revenues									646,446	559,840	479,224
Cost of Sales
Cost of sales (exclusive of depreciation shown below)									280,169	254,670	218,692
Gross profit									366,277	305,170	260,532
Operating Expenses
Advertising and promotion									90,353	79,944	69,583
General and administrative									51,198	55,209	34,469
Depreciation and amortization									18,617	12,752	9,715
Total operating expenses									160,168	147,905	113,767
Operating income									206,109	157,265	146,765
Other (income) expense
Interest income									(5,087)	(5,373)	(2,327)
Interest expense									100,540	88,464	72,064
Gain on sale of asset										1,133
Loss on extinguishment of debt									0		0
Equity in (income) loss of subsidiaries									(8,564)	(2,013)	(4,052)
Total other (income) expense									86,889	79,945	65,685
Income before income taxes									119,220	77,320	81,080
Provision for income taxes									40,279	27,111	22,055
Net income (loss)									78,941	50,209	59,025
Comprehensive income, net of tax:
Currency translation adjustments									(113)	(24,151)	843
Total other comprehensive income (loss)									(113)	(24,151)	843
Comprehensive income									78,828	26,058	59,868
Combined Non-Guarantor Subsidiaries
Revenues
Net sales									50,672	51,630	23,286
Other revenues									1,776	1,497	1,639
Total revenues									52,448	53,127	24,925
Cost of Sales
Cost of sales (exclusive of depreciation shown below)									18,459	19,127	9,428
Gross profit									33,989	34,000	15,497
Operating Expenses
Advertising and promotion									10,984	10,879	5,162
General and administrative									6,385	12,403	2,846
Depreciation and amortization									415	1,015	200
Total operating expenses									17,784	24,297	8,208
Operating income									16,205	9,703	7,289
Other (income) expense
Interest income									(531)	(456)	(382)
Interest expense									5,087	5,373	2,325
Gain on sale of asset										0
Loss on extinguishment of debt									0		0
Equity in (income) loss of subsidiaries									0	0	0
Total other (income) expense									4,556	4,917	1,943
Income before income taxes									11,649	4,786	5,346
Provision for income taxes									3,085	2,773	1,294
Net income (loss)									8,564	2,013	4,052
Comprehensive income, net of tax:
Currency translation adjustments									(113)	(24,151)	843
Total other comprehensive income (loss)									(113)	(24,151)	843
Comprehensive income									8,451	(22,138)	4,895
Eliminations
Revenues
Net sales									(2,661)	(3,387)	(2,679)
Other revenues									(2,080)	(1,781)	(1,893)
Total revenues									(4,741)	(5,168)	(4,572)
Cost of Sales
Cost of sales (exclusive of depreciation shown below)									(5,355)	(5,034)	(3,562)
Gross profit									614	(134)	(1,010)
Operating Expenses
Advertising and promotion									0	0	0
General and administrative									0	0	0
Depreciation and amortization									0	0	0
Total operating expenses									0	0	0
Operating income									614	(134)	(1,010)
Other (income) expense
Interest income									139,680	128,035	108,825
Interest expense									(139,680)	(128,035)	(108,825)
Gain on sale of asset										0
Loss on extinguishment of debt									0		0
Equity in (income) loss of subsidiaries									178,320	129,969	124,627
Total other (income) expense									178,320	129,969	124,627
Income before income taxes									(177,706)	(130,103)	(125,637)
Provision for income taxes									0	0	0
Net income (loss)									(177,706)	(130,103)	(125,637)
Comprehensive income, net of tax:
Currency translation adjustments									339	72,453	(2,529)
Total other comprehensive income (loss)									339	72,453	(2,529)
Comprehensive income									$ (177,367)	$ (57,650)	$ (128,166)

Condensed Consolidating Financial Statements (Condensed Consolidating Balance Sheet) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Current assets
Cash and cash equivalents	$ 27,230	$ 21,318	$ 28,331	$ 15,670
Accounts receivable, net	95,247	87,858
Inventories	91,263	74,000
Deferred income tax assets	10,108	8,097
Prepaid expenses and other current assets	25,165	10,434
Total current assets	249,013	201,707
Property and equipment, net	15,540	13,744
Goodwill	360,191	290,651	190,911	167,546
Intangible assets, net	2,322,723	2,134,700	1,394,817
Other long-term assets	1,324	1,165
Intercompany receivables	0	0
Investment in subsidiary	0	0
Total Assets	2,948,791	2,641,967
Current liabilities
Accounts payable	38,296	46,115
Accrued interest payable	8,664	11,974
Other accrued liabilities	59,724	40,948
Total current liabilities	106,684	99,037
Long-term debt
Principal amount	1,652,500	1,593,600
Less unamortized debt costs	(27,191)	(32,327)
Long-term debt, net	1,625,309	1,561,273
Deferred income tax liabilities	469,622	351,569
Other long-term liabilities	2,840	2,464
Intercompany payables	0	0
Total Liabilities	2,204,455	2,014,343
Stockholders’ Equity
Common stock	530	525
Additional paid-in capital	445,182	426,584
Treasury stock, at cost	(5,163)	(3,478)
Accumulated other comprehensive income (loss), net of tax	(23,525)	(23,412)
Retained earnings (accumulated deficit)	327,312	227,405
Total Stockholders’ Equity	744,336	627,624	563,360	477,943
Total Liabilities and Stockholders’ Equity	2,948,791	2,641,967
Prestige Brands Holdings, Inc.
Current assets
Cash and cash equivalents	4,440	11,387	24,644	14,720
Accounts receivable, net	0	0
Inventories	0	0
Deferred income tax assets	316	452
Prepaid expenses and other current assets	15,311	5,731
Total current assets	20,067	17,570
Property and equipment, net	9,166	10,726
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivables	1,457,011	1,210,017
Investment in subsidiary	1,641,477	1,545,575
Total Assets	3,127,721	2,783,888
Current liabilities
Accounts payable	2,914	1,959
Accrued interest payable	0	0
Other accrued liabilities	12,285	10,378
Total current liabilities	15,199	12,337
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0	0
Intercompany payables	2,368,186	2,143,927
Total Liabilities	2,383,385	2,156,264
Stockholders’ Equity
Common stock	530	525
Additional paid-in capital	445,182	426,584
Treasury stock, at cost	(5,163)	(3,478)
Accumulated other comprehensive income (loss), net of tax	(23,525)	(23,412)
Retained earnings (accumulated deficit)	327,312	227,405
Total Stockholders’ Equity	744,336	627,624
Total Liabilities and Stockholders’ Equity	3,127,721	2,783,888
Prestige Brands, Inc., the issuer
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	12,025	14,539
Inventories	9,411	8,667
Deferred income tax assets	681	674
Prepaid expenses and other current assets	257	141
Total current assets	22,374	24,021
Property and equipment, net	210	175
Goodwill	66,007	66,007
Intangible assets, net	191,789	192,325
Other long-term assets	1,324	1,165
Intercompany receivables	2,703,192	2,607,054
Investment in subsidiary	1,527,718	1,228,535
Total Assets	4,512,614	4,119,282
Current liabilities
Accounts payable	7,643	6,829
Accrued interest payable	8,664	11,974
Other accrued liabilities	1,714	1,153
Total current liabilities	18,021	19,956
Long-term debt
Principal amount	1,652,500	1,593,600
Less unamortized debt costs	(27,191)	(32,327)
Long-term debt, net	1,625,309	1,561,273
Deferred income tax liabilities	60,317	59,038
Other long-term liabilities	0	0
Intercompany payables	1,241,084	1,001,219
Total Liabilities	2,944,731	2,641,486
Stockholders’ Equity
Common stock	0	0
Additional paid-in capital	1,280,947	1,280,948
Treasury stock, at cost	0	0
Accumulated other comprehensive income (loss), net of tax	(23,525)	(23,412)
Retained earnings (accumulated deficit)	310,461	220,260
Total Stockholders’ Equity	1,567,883	1,477,796
Total Liabilities and Stockholders’ Equity	4,512,614	4,119,282
Combined Subsidiary Guarantors
Current assets
Cash and cash equivalents	2,899	0	0	0
Accounts receivable, net	74,446	66,523
Inventories	72,296	60,297
Deferred income tax assets	8,293	6,497
Prepaid expenses and other current assets	8,379	3,804
Total current assets	166,313	137,121
Property and equipment, net	5,528	2,207
Goodwill	271,409	204,205
Intangible assets, net	2,042,640	1,854,798
Other long-term assets	0	0
Intercompany receivables	1,083,488	668,169
Investment in subsidiary	81,545	65,564
Total Assets	3,650,923	2,932,064
Current liabilities
Accounts payable	24,437	32,898
Accrued interest payable	0	0
Other accrued liabilities	38,734	25,795
Total current liabilities	63,171	58,693
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	408,893	292,504
Other long-term liabilities	2,682	2,293
Intercompany payables	1,570,265	1,279,833
Total Liabilities	2,045,011	1,633,323
Stockholders’ Equity
Common stock	0	0
Additional paid-in capital	1,359,921	1,131,578
Treasury stock, at cost	0	0
Accumulated other comprehensive income (loss), net of tax	(23,525)	(23,412)
Retained earnings (accumulated deficit)	269,516	190,575
Total Stockholders’ Equity	1,605,912	1,298,741
Total Liabilities and Stockholders’ Equity	3,650,923	2,932,064
Combined Non-Guarantor Subsidiaries
Current assets
Cash and cash equivalents	19,891	9,931	3,687	950
Accounts receivable, net	8,776	6,796
Inventories	10,088	6,182
Deferred income tax assets	818	474
Prepaid expenses and other current assets	1,218	758
Total current assets	40,791	24,141
Property and equipment, net	636	636
Goodwill	22,775	20,439
Intangible assets, net	88,294	87,577
Other long-term assets	0	0
Intercompany receivables	$ 10,738	8,764
Investment in subsidiary		0
Total Assets	$ 163,234	141,557
Current liabilities
Accounts payable	3,302	4,429
Accrued interest payable	0	0
Other accrued liabilities	6,991	3,622
Total current liabilities	10,293	8,051
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	412	27
Other long-term liabilities	158	171
Intercompany payables	74,894	69,025
Total Liabilities	85,757	77,274
Stockholders’ Equity
Common stock	0	0
Additional paid-in capital	78,774	74,031
Treasury stock, at cost	0	0
Accumulated other comprehensive income (loss), net of tax	(23,525)	(23,412)
Retained earnings (accumulated deficit)	22,228	13,664
Total Stockholders’ Equity	77,477	64,283
Total Liabilities and Stockholders’ Equity	163,234	141,557
Eliminations
Current assets
Cash and cash equivalents	0	0	$ 0	$ 0
Accounts receivable, net	0	0
Inventories	(532)	(1,146)
Deferred income tax assets	0	0
Prepaid expenses and other current assets	0	0
Total current assets	(532)	(1,146)
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivables	(5,254,429)	(4,494,004)
Investment in subsidiary	(3,250,740)	(2,839,674)
Total Assets	(8,505,701)	(7,334,824)
Current liabilities
Accounts payable	0	0
Accrued interest payable	0	0
Other accrued liabilities	0	0
Total current liabilities	0	0
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0	0
Intercompany payables	(5,254,429)	(4,494,004)
Total Liabilities	(5,254,429)	(4,494,004)
Stockholders’ Equity
Common stock	0	0
Additional paid-in capital	(2,719,642)	(2,486,557)
Treasury stock, at cost	0	0
Accumulated other comprehensive income (loss), net of tax	70,575	70,236
Retained earnings (accumulated deficit)	(602,205)	(424,499)
Total Stockholders’ Equity	(3,251,272)	(2,840,820)
Total Liabilities and Stockholders’ Equity	$ (8,505,701)	$ (7,334,824)

Condensed Consolidating Financial Statements (Condensed Consolidating Statement of Cash Flows) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Operating Activities
Net income (loss)	$ 13,936	$ 27,995	$ 31,803	$ 26,173	$ 23,772	$ 21,293	$ 16,463	$ 16,732	$ 99,907	$ 78,260	$ 72,615
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization									23,676	17,740	13,486
Gain on sale of asset					0	$ (1,133)	$ 0	0	0	(1,133)	0
Deferred income taxes									46,152	28,922	19,012
Long term income taxes payable									(332)	2,294	0
Amortization of debt origination costs									8,994	8,821	10,512
Stock-based compensation costs									9,954	6,918	5,146
Lease termination costs									0	785	0
Loss on extinguishment of debt									17,970	0	18,286
Premium payment on Senior Notes											(15,527)
(Gain) loss on sale or disposal of property and equipment									(35)	321	(3)
Equity in income of subsidiaries									0	0	0
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable									1,824	1,608	9,735
Inventories									(3,005)	15,360	(2,850)
Prepaid expenses and other current assets									(7,921)	4,664	(2,130)
Accounts payable									(11,348)	(17,637)	(4,641)
Accrued liabilities									(1,328)	9,332	(12,059)
Net cash provided by operating activities									174,350	156,255	111,582
Investing Activities
Purchases of property and equipment									(3,568)	(6,101)	(2,764)
Proceeds from the sale of property and equipment									344	0	3
Proceeds from sale of business									0	18,500	0
Proceeds from sale of asset										10,000
Proceeds from Insight Pharmaceuticals working capital arbitration settlement									7,237	0	0
Intercompany activity, net									0	0	0
Net cash used in investing activities									(222,971)	(805,258)	(57,976)
Financing Activities
Borrowings under Bridge term loans									80,000	0	0
Repayments under Bridge term loans									(80,000)	0	0
Term loan borrowings									0	720,000	0
Term loan repayments									(60,000)	(130,000)	(157,500)
Borrowings under revolving credit agreement									115,000	124,600	50,000
Repayments under revolving credit agreement									(96,100)	(58,500)	(83,000)
Payments of debt origination costs									(11,828)	(16,072)	(7,466)
Proceeds from exercise of stock options									6,689	3,954	5,907
Proceeds from restricted stock exercises									544	57	0
Excess tax benefits from share-based awards									1,960	1,330	1,650
Fair value of shares surrendered as payment of tax withholding									(2,229)	(2,104)	(744)
Intercompany activity, net									0	0	0
Net cash (used in) provided by financing activities									54,036	643,265	(41,153)
Effects of exchange rate changes on cash and cash equivalents									497	(1,275)	208
Increase (decrease) in cash and cash equivalents									5,912	(7,013)	12,661
Cash and cash equivalents - beginning of year				21,318				28,331	21,318	28,331	15,670
Cash and cash equivalents - end of year	27,230				21,318				27,230	21,318	28,331
Prestige Brands Holdings, Inc.
Operating Activities
Net income (loss)									99,907	78,260	72,615
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization									4,050	3,381	2,994
Gain on sale of asset										0
Deferred income taxes									136	(192)	(42)
Long term income taxes payable									0	0
Amortization of debt origination costs									0	0	0
Stock-based compensation costs									9,794	6,918	5,146
Lease termination costs										0
Loss on extinguishment of debt									0		0
Premium payment on Senior Notes											0
(Gain) loss on sale or disposal of property and equipment									0	0	0
Equity in income of subsidiaries									(98,803)	(76,383)	(66,739)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable									0	473	(452)
Inventories									0	0	0
Prepaid expenses and other current assets									(9,580)	2,273	(3,062)
Accounts payable									929	(2,457)	1,815
Accrued liabilities									1,907	2,650	(4,966)
Net cash provided by operating activities									8,340	14,923	7,309
Investing Activities
Purchases of property and equipment									(2,460)	(5,029)	(2,351)
Proceeds from the sale of property and equipment									0		0
Proceeds from sale of business										0
Proceeds from sale of asset										0
Intercompany activity, net									0	0	0
Net cash used in investing activities									(2,460)	(5,029)	(2,351)
Financing Activities
Borrowings under Bridge term loans									0
Repayments under Bridge term loans									0
Term loan borrowings										0
Term loan repayments									0	0	0
Borrowings under revolving credit agreement									0	0	0
Repayments under revolving credit agreement									0	0	0
Payments of debt origination costs									0	0	0
Proceeds from exercise of stock options									6,689	3,954	5,907
Proceeds from restricted stock exercises									544	57
Excess tax benefits from share-based awards									1,960	1,330	1,650
Fair value of shares surrendered as payment of tax withholding									(2,229)	(2,104)	(744)
Intercompany activity, net									(19,791)	(26,388)	(1,847)
Net cash (used in) provided by financing activities									(12,827)	(23,151)	4,966
Effects of exchange rate changes on cash and cash equivalents									0	0	0
Increase (decrease) in cash and cash equivalents									(6,947)	(13,257)	9,924
Cash and cash equivalents - beginning of year				11,387				24,644	11,387	24,644	14,720
Cash and cash equivalents - end of year	4,440				11,387				4,440	11,387	24,644
Prestige Brands, Inc., the issuer
Operating Activities
Net income (loss)									90,201	77,881	62,560
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization									594	592	577
Gain on sale of asset										0
Deferred income taxes									1,272	2,462	1,466
Long term income taxes payable									0	0
Amortization of debt origination costs									8,994	8,821	10,512
Stock-based compensation costs									0	0	0
Lease termination costs										0
Loss on extinguishment of debt									17,970		18,286
Premium payment on Senior Notes											(15,527)
(Gain) loss on sale or disposal of property and equipment									0	0	0
Equity in income of subsidiaries									(70,953)	(51,573)	(53,836)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable									2,514	(294)	(370)
Inventories									(744)	5,690	(3,193)
Prepaid expenses and other current assets									(116)	(28)	(20)
Accounts payable									814	(829)	(2,942)
Accrued liabilities									(2,749)	1,384	(3,835)
Net cash provided by operating activities									37,639	44,106	13,678
Investing Activities
Purchases of property and equipment									(93)	(119)	(119)
Proceeds from the sale of property and equipment									0		0
Proceeds from sale of business										0
Proceeds from sale of asset										0
Intercompany activity, net									(228,343)	(809,157)	(55,215)
Net cash used in investing activities									(228,436)	(809,276)	(55,334)
Financing Activities
Borrowings under Bridge term loans									80,000
Repayments under Bridge term loans									(80,000)
Term loan borrowings										720,000
Term loan repayments									(60,000)	(130,000)	(157,500)
Borrowings under revolving credit agreement									115,000	124,600	50,000
Repayments under revolving credit agreement									(96,100)	(58,500)	(83,000)
Payments of debt origination costs									(11,828)	(16,072)	(7,466)
Proceeds from exercise of stock options									0	0	0
Proceeds from restricted stock exercises									0	0
Excess tax benefits from share-based awards									0	0	0
Fair value of shares surrendered as payment of tax withholding									0	0	0
Intercompany activity, net									143,725	125,142	89,622
Net cash (used in) provided by financing activities									190,797	765,170	41,656
Effects of exchange rate changes on cash and cash equivalents									0	0	0
Increase (decrease) in cash and cash equivalents									0	0	0
Cash and cash equivalents - beginning of year				0				0	0	0	0
Cash and cash equivalents - end of year	0				0				0	0	0
Combined Subsidiary Guarantors
Operating Activities
Net income (loss)									78,941	50,209	59,025
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization									18,617	12,752	9,715
Gain on sale of asset										(1,133)
Deferred income taxes									45,070	26,795	17,765
Long term income taxes payable									(332)	2,294
Amortization of debt origination costs									0	0	0
Stock-based compensation costs									0	0	0
Lease termination costs										785
Loss on extinguishment of debt									0		0
Premium payment on Senior Notes											0
(Gain) loss on sale or disposal of property and equipment									1	0	(3)
Equity in income of subsidiaries									(8,564)	(2,013)	(4,052)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable									(388)	5,146	12,460
Inventories									213	8,981	2,165
Prepaid expenses and other current assets									1,977	2,631	711
Accounts payable									(11,284)	(16,734)	(4,142)
Accrued liabilities									(1,943)	3,560	(2,664)
Net cash provided by operating activities									122,308	93,273	90,980
Investing Activities
Purchases of property and equipment									(521)	(739)	(108)
Proceeds from the sale of property and equipment									0		3
Proceeds from sale of business										18,500
Proceeds from sale of asset										10,000
Intercompany activity, net									228,343	731,166	0
Net cash used in investing activities									8,075	9,261	(105)
Financing Activities
Borrowings under Bridge term loans									0
Repayments under Bridge term loans									0
Term loan borrowings										0
Term loan repayments									0	0	0
Borrowings under revolving credit agreement									0	0	0
Repayments under revolving credit agreement									0	0	0
Payments of debt origination costs									0	0	0
Proceeds from exercise of stock options									0	0	0
Proceeds from restricted stock exercises									0	0
Excess tax benefits from share-based awards									0	0	0
Fair value of shares surrendered as payment of tax withholding									0	0	0
Intercompany activity, net									(127,484)	(102,534)	(90,875)
Net cash (used in) provided by financing activities									(127,484)	(102,534)	(90,875)
Effects of exchange rate changes on cash and cash equivalents									0	0	0
Increase (decrease) in cash and cash equivalents									2,899	0	0
Cash and cash equivalents - beginning of year				0				0	0	0	0
Cash and cash equivalents - end of year	2,899				0				2,899	0	0
Combined Non-Guarantor Subsidiaries
Operating Activities
Net income (loss)									8,564	2,013	4,052
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization									415	1,015	200
Gain on sale of asset										0
Deferred income taxes									(326)	(143)	(177)
Long term income taxes payable									0	0
Amortization of debt origination costs									0	0	0
Stock-based compensation costs									160	0	0
Lease termination costs										0
Loss on extinguishment of debt									0		0
Premium payment on Senior Notes											0
(Gain) loss on sale or disposal of property and equipment									(36)	321	0
Equity in income of subsidiaries									0	0	0
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable									(302)	(3,717)	(1,903)
Inventories									(1,860)	555	(2,832)
Prepaid expenses and other current assets									(202)	(212)	241
Accounts payable									(1,807)	2,383	628
Accrued liabilities									1,457	1,738	(594)
Net cash provided by operating activities									6,063	3,953	(385)
Investing Activities
Purchases of property and equipment									(494)	(214)	(186)
Proceeds from the sale of property and equipment									344		0
Proceeds from sale of business										0
Proceeds from sale of asset										0
Intercompany activity, net									0	77,991	55,215
Net cash used in investing activities									(150)	(214)	(186)
Financing Activities
Borrowings under Bridge term loans									0
Repayments under Bridge term loans									0
Term loan borrowings										0
Term loan repayments									0	0	0
Borrowings under revolving credit agreement									0	0	0
Repayments under revolving credit agreement									0	0	0
Payments of debt origination costs									0	0	0
Proceeds from exercise of stock options									0	0	0
Proceeds from restricted stock exercises									0	0
Excess tax benefits from share-based awards									0	0	0
Fair value of shares surrendered as payment of tax withholding									0	0	0
Intercompany activity, net									3,550	3,780	3,100
Net cash (used in) provided by financing activities									3,550	3,780	3,100
Effects of exchange rate changes on cash and cash equivalents									497	(1,275)	208
Increase (decrease) in cash and cash equivalents									9,960	6,244	2,737
Cash and cash equivalents - beginning of year				9,931				3,687	9,931	3,687	950
Cash and cash equivalents - end of year	19,891				9,931				19,891	9,931	3,687
Eliminations
Operating Activities
Net income (loss)									(177,706)	(130,103)	(125,637)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization									0	0	0
Gain on sale of asset										0
Deferred income taxes									0	0	0
Long term income taxes payable									0	0
Amortization of debt origination costs									0	0	0
Stock-based compensation costs									0	0	0
Lease termination costs										0
Loss on extinguishment of debt									0		0
Premium payment on Senior Notes											0
(Gain) loss on sale or disposal of property and equipment									0	0	0
Equity in income of subsidiaries									178,320	129,969	124,627
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable									0	0	0
Inventories									(614)	134	1,010
Prepaid expenses and other current assets									0	0	0
Accounts payable									0	0	0
Accrued liabilities									0	0	0
Net cash provided by operating activities									0	0	0
Investing Activities
Purchases of property and equipment									0	0	0
Proceeds from the sale of property and equipment									0		0
Proceeds from sale of business										0
Proceeds from sale of asset										0
Intercompany activity, net									0	0	0
Net cash used in investing activities									0	0	0
Financing Activities
Borrowings under Bridge term loans									0
Repayments under Bridge term loans									0
Term loan borrowings										0
Term loan repayments									0	0	0
Borrowings under revolving credit agreement									0	0	0
Repayments under revolving credit agreement									0	0	0
Payments of debt origination costs									0	0	0
Proceeds from exercise of stock options									0	0	0
Proceeds from restricted stock exercises									0	0
Excess tax benefits from share-based awards									0	0	0
Fair value of shares surrendered as payment of tax withholding									0	0	0
Intercompany activity, net									0	0	0
Net cash (used in) provided by financing activities									0	0	0
Effects of exchange rate changes on cash and cash equivalents									0	0	0
Increase (decrease) in cash and cash equivalents									0	0	0
Cash and cash equivalents - beginning of year				$ 0				$ 0	0	0	0
Cash and cash equivalents - end of year	$ 0				$ 0				0	0	0
Care Pharma
Investing Activities
Acquisitions, less cash acquired									0	0	(55,215)
Care Pharma \| Prestige Brands Holdings, Inc.
Investing Activities
Acquisitions, less cash acquired											0
Care Pharma \| Prestige Brands, Inc., the issuer
Investing Activities
Acquisitions, less cash acquired											0
Care Pharma \| Combined Subsidiary Guarantors
Investing Activities
Acquisitions, less cash acquired											0
Care Pharma \| Combined Non-Guarantor Subsidiaries
Investing Activities
Acquisitions, less cash acquired											(55,215)
Care Pharma \| Eliminations
Investing Activities
Acquisitions, less cash acquired											0
Insight Pharmaceuticals
Investing Activities
Proceeds from Insight Pharmaceuticals working capital arbitration settlement									7,237
Acquisitions, less cash acquired									0	(749,666)	0
Insight Pharmaceuticals \| Prestige Brands Holdings, Inc.
Investing Activities
Proceeds from Insight Pharmaceuticals working capital arbitration settlement									0
Acquisitions, less cash acquired										0
Insight Pharmaceuticals \| Prestige Brands, Inc., the issuer
Investing Activities
Proceeds from Insight Pharmaceuticals working capital arbitration settlement									0
Acquisitions, less cash acquired										0
Insight Pharmaceuticals \| Combined Subsidiary Guarantors
Investing Activities
Proceeds from Insight Pharmaceuticals working capital arbitration settlement									7,237
Acquisitions, less cash acquired										(749,666)
Insight Pharmaceuticals \| Combined Non-Guarantor Subsidiaries
Investing Activities
Proceeds from Insight Pharmaceuticals working capital arbitration settlement									0
Acquisitions, less cash acquired										0
Insight Pharmaceuticals \| Eliminations
Investing Activities
Proceeds from Insight Pharmaceuticals working capital arbitration settlement									0
Acquisitions, less cash acquired										0
Hydralyte
Investing Activities
Acquisitions, less cash acquired									0	(77,991)	0
Hydralyte \| Prestige Brands Holdings, Inc.
Investing Activities
Acquisitions, less cash acquired										0
Hydralyte \| Prestige Brands, Inc., the issuer
Investing Activities
Acquisitions, less cash acquired										0
Hydralyte \| Combined Subsidiary Guarantors
Investing Activities
Acquisitions, less cash acquired										0
Hydralyte \| Combined Non-Guarantor Subsidiaries
Investing Activities
Acquisitions, less cash acquired										(77,991)
Hydralyte \| Eliminations
Investing Activities
Acquisitions, less cash acquired										0
DenTek Oral Care, Inc.
Investing Activities
Acquisitions, less cash acquired									(226,984)	0	0
DenTek Oral Care, Inc. \| Prestige Brands Holdings, Inc.
Investing Activities
Acquisitions, less cash acquired									0
DenTek Oral Care, Inc. \| Prestige Brands, Inc., the issuer
Investing Activities
Acquisitions, less cash acquired									0
DenTek Oral Care, Inc. \| Combined Subsidiary Guarantors
Investing Activities
Acquisitions, less cash acquired									(226,984)
DenTek Oral Care, Inc. \| Combined Non-Guarantor Subsidiaries
Investing Activities
Acquisitions, less cash acquired									0
DenTek Oral Care, Inc. \| Eliminations
Investing Activities
Acquisitions, less cash acquired									0
2013 Senior Notes
Financing Activities
Proceeds from issuance of Senior Notes									0	0	400,000
2013 Senior Notes \| Prestige Brands Holdings, Inc.
Financing Activities
Proceeds from issuance of Senior Notes											0
2013 Senior Notes \| Prestige Brands, Inc., the issuer
Financing Activities
Proceeds from issuance of Senior Notes											400,000
2013 Senior Notes \| Combined Subsidiary Guarantors
Financing Activities
Proceeds from issuance of Senior Notes											0
2013 Senior Notes \| Combined Non-Guarantor Subsidiaries
Financing Activities
Proceeds from issuance of Senior Notes											0
2013 Senior Notes \| Eliminations
Financing Activities
Proceeds from issuance of Senior Notes											0
2016 Senior Notes
Financing Activities
Proceeds from issuance of Senior Notes									350,000	0	0
2016 Senior Notes \| Prestige Brands Holdings, Inc.
Financing Activities
Proceeds from issuance of Senior Notes									0
2016 Senior Notes \| Prestige Brands, Inc., the issuer
Financing Activities
Proceeds from issuance of Senior Notes									350,000
2016 Senior Notes \| Combined Subsidiary Guarantors
Financing Activities
Proceeds from issuance of Senior Notes									0
2016 Senior Notes \| Combined Non-Guarantor Subsidiaries
Financing Activities
Proceeds from issuance of Senior Notes									0
2016 Senior Notes \| Eliminations
Financing Activities
Proceeds from issuance of Senior Notes									0
2012 Senior Notes
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Premium payment on Senior Notes									(10,158)	0	0
Financing Activities
Repayment of Senior Notes									(250,000)	0	0
2012 Senior Notes \| Prestige Brands Holdings, Inc.
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Premium payment on Senior Notes									0
Financing Activities
Repayment of Senior Notes									0
2012 Senior Notes \| Prestige Brands, Inc., the issuer
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Premium payment on Senior Notes									(10,158)
Financing Activities
Repayment of Senior Notes									(250,000)
2012 Senior Notes \| Combined Subsidiary Guarantors
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Premium payment on Senior Notes									0
Financing Activities
Repayment of Senior Notes									0
2012 Senior Notes \| Combined Non-Guarantor Subsidiaries
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Premium payment on Senior Notes									0
Financing Activities
Repayment of Senior Notes									0
2012 Senior Notes \| Eliminations
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Premium payment on Senior Notes									0
Financing Activities
Repayment of Senior Notes									0
2010 Senior Notes
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Premium payment on Senior Notes									0	0	(15,527)
Financing Activities
Repayment of Senior Notes									$ 0	$ 0	(250,000)
2010 Senior Notes \| Prestige Brands Holdings, Inc.
Financing Activities
Repayment of Senior Notes											0
2010 Senior Notes \| Prestige Brands, Inc., the issuer
Financing Activities
Repayment of Senior Notes											(250,000)
2010 Senior Notes \| Combined Subsidiary Guarantors
Financing Activities
Repayment of Senior Notes											0
2010 Senior Notes \| Combined Non-Guarantor Subsidiaries
Financing Activities
Repayment of Senior Notes											0
2010 Senior Notes \| Eliminations
Financing Activities
Repayment of Senior Notes											$ 0

Subsequent Events (Details) - $ / shares					12 Months Ended
Subsequent Events (Details) - $ / shares	May. 09, 2016	Aug. 04, 2015	Jul. 01, 2015	May. 11, 2015	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Subsequent Event [Line Items]
Options granted, shares					208,200	317,900	227,700
Options granted, weighted-average exercise price (in USD per share)					$ 42.13	$ 33.54	$ 29.94
Subsequent Event
Subsequent Event [Line Items]
Options granted, shares	236,116
Restricted Stock Units (RSUs)
Subsequent Event [Line Items]
Restricted common stock units granted in period, shares		2,075	2,841	185,904
Award vesting period		1 year	3 years
Restricted Stock Units (RSUs) \| Subsequent Event
Subsequent Event [Line Items]
Restricted common stock units granted in period, shares	51,266
Award vesting period	3 years
Stock Options
Subsequent Event [Line Items]
Restricted common stock units granted in period, shares			13,861
Options granted, shares				186,302
Award vesting period			3 years	3 years
Award vesting rights, percentage			33.30%	33.30%
Expiration period			10 years
Options granted, weighted-average exercise price (in USD per share)			$ 46.58	$ 41.44
Stock Options \| Subsequent Event
Subsequent Event [Line Items]
Award vesting period	3 years
Award vesting rights, percentage	33.30%
Expiration period	10 years
Options granted, weighted-average exercise price (in USD per share)	$ 57.18

Schedule II Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Reserves for Sales Returns and Allowances
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	$ 6,716	$ 7,395	$ 6,446
Amounts charged to expense	41,217	34,598	38,314
Deductions	(40,085)	(35,277)	(37,365)
Other	975	0	0
Valuation allowances and reserves, balance at end of year	8,823	6,716	7,395
Reserves for Trade Promotions
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	9,932	6,101	8,523
Amounts charged to expense	62,331	60,499	39,967
Deductions	(62,409)	(56,668)	(42,389)
Other	2,787	0	0
Valuation allowances and reserves, balance at end of year	12,641	9,932	6,101
Reserves for Consumer Coupon Redemptions
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	1,672	1,742	4,249
Amounts charged to expense	6,235	5,089	2,755
Deductions	(5,637)	(5,159)	(5,262)
Other	2,053	0	0
Valuation allowances and reserves, balance at end of year	4,323	1,672	1,742
Allowance for Doubtful Accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowances and reserves, balance at beginning of year	1,277	1,035	863
Amounts charged to expense	(276)	340	134
Deductions	(186)	(98)	(6)
Other	0	0	44
Valuation allowances and reserves, balance at end of year	$ 815	$ 1,277	$ 1,035

Business and Basis of Presentation (Details)	12 Months Ended
Business and Basis of Presentation (Details)	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash equivalents, original maturities, eligibility, period	3 months

Business and Basis of Presentation (Intangible Assets) (Details)	12 Months Ended
	Mar. 31, 2016
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	30 years